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trends in cancer care
Cancer is still one of the leading causes of morbidity and mortality worldwide. In the 
Netherlands, the number of cancer deaths remains high mainly due to population 
growth and aging. In 2017, over 150.000 people died in the Netherlands, with cancer 
being the most common cause of death (31%), followed by cardiovascular disease 
(25%) [1].
Fortunately, cancer can increasingly be seen as a chronic disease. Recent advances in 
the understanding of the molecular profile of tumour cells have led to the promise of 
precision medicine for treatment of cancer [2]. Novel therapies target key molecules 
that allow cancer to survive, such as the immune checkpoint inhibitors that inactivate 
proteins that cancer cells use to evade the immune system, and the targeted therapy 
that block specific molecules needed for tumour growth and spread. These major 
advancements have resulted in new promising therapies for patients with advanced 
cancers of the lung, breast, skin, and kidney previously considered refractory.
trends in multidisciplinary cancer care
Although surgery is still considered the cornerstone of many cancer treatments, the 
field of oncologic care becomes more complex with an increase in multimodality 
therapies. This has motivated the development of multidisciplinary teams, which 
have been widely adopted in many countries and form an important component in 
guidelines [3].
In order to assure high-quality multidisciplinary cancer care in The Netherlands, the 
Dutch federation of oncological societies (SONCOS) has set up multidisciplinary 
standards listing general and tumour-specific requirements a cancer centre must 
meet [4]. They include requirements for infrastructure, specialisms that should be 
available, participation in registration projects and maximum waiting times.
The first SONCOS standardisation report was published in December 2012. 
Multidisciplinary cancer care continues to expand to other interventions, such as 
psychosocial support, genetics and frailty aspects. This is evidenced by the 24 parties 
that contributed to the development of the last SONCOS report published in 2018, 
which contains multidisciplinary standards for 25 tumour types [5].
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essence of population-based quality registry
The question whether cancer care can be reorganized in order to keep our healthcare 
system sustainable, has been subject of investigation for several years. The Quality of 
Cancer Care working group of the Dutch Cancer Society has addressed this question 
since April 2007 [6]. For the first time, considerable hospital variation was shown in 
the treatment and outcomes of colorectal, breast, bladder and lung cancer. One of the 
most important recommendations was that more reliable data on hospital variation 
and targets for improvement should be made available and fed back to clinicians in 
order to reduce variation and improve outcomes. This has led to a growing interest 
amongst medical professionals to define and understand their own outcomes. In 
2009, the Association of Surgeons of the Netherlands (ASN) proceeded to develop 
the first national outcomes registry in the Netherlands: the Dutch Surgical Colorectal 
Audit (DSCA) [7].
This nationwide clinical audit aims to evaluate and improve outcomes of surgical 
care for colorectal cancer patients. Clinical auditing is known to be a powerful tool 
to initiate and assess quality improvement programmes. Within an audit cycle, col-
lected data are compared with pre-defined quality indicators and continuously fed 
back to participating centres [8]. Numerous studies with DSCA data have revealed 
important areas for improvement [9] [10], but have also shown remarkable improve-
ments in processes and outcomes in colorectal cancer surgery [11] [12].
After the successful initiation of the DSCA, the Dutch Institute for Clinical Auditing 
(DICA) was founded in 2011, aiming to facilitate the initiation of nationwide audits 
in a uniform format. Today, DICA facilitates 22 nationwide audits covering a wide 
range of medical conditions, from breast cancer to Parkinson’s disease and obesity 
[13]. Unique features of DICA audits are the leading role of clinicians in defining the 
data set, the nation-wide coverage, the secured web-based data collection system, 
and the rapid online feedback of benchmarked data to participating hospitals for 
improvement initiatives [7].
In the early years of DICA, the main focus was on evaluating and improving the 
quality of the surgical treatment of cancer patients. Nowadays, some DICA audits 
have been expanded to non-surgical treatments, such as radiotherapy and medical 




The advancements in precision medicine together with the continuous expansion of 
multidisciplinary cancer care and the growing group of (long-term) cancer survivors 
poses some major challenges in assuring quality. This thesis aims to investigate how 
quality could be assured facing these trends in cancer care.
part i: Assuring quality in multidisciplinary cancer care
In gastric cancer surgery, surgery still has a central role in potentially curative treat-
ment. Despite surgical advancements, overall survival remains poor with five-year 
survival rates of 19% in The Netherlands [14]. The high relapse rate has led to the 
utilization of perioperative chemotherapy for patients with resectable gastric cancer 
[15]. This multimodal approach is challenging for assessing quality indicators, as 
different treatment modalities can influence each other. As gastric cancer is associ-
ated with high perioperative morbidity rates [16], it is essential to understand to 
what extent surgically related adverse events influence the multimodal aspects of the 
treatment process. In Chapter 2, factors associated with the utilization of adjuvant 
chemotherapy in patients with resectable gastric cancer are described with a special 
attention to postoperative complications. The study is conducted with data from 
the Upper GI Cancer Audit (DUCA). The DUCA was one of the first nationwide 
registries facilitated by DICA and registers all patients with oesophageal or gastric 
cancer who underwent surgery with the intent of a resection.
part ii: Assuring quality in precision medicine
For a long time, chemotherapy dominated the field of medical oncology. Patient 
selection, treatment schedules and toxicities were mainly universal for common 
chemotherapeutic agents [17]. The wide adoption of precision medicine has changed 
the field of medical oncology dramatically with major benefits for patient outcomes, 
but also poses new challenges. Random screening is being replaced by screening 
against specific critical molecular targets. While standard chemotherapeutic agents 
are mainly associated with immunosuppression and infections, the new targeted 
and immunotherapies can induce overwhelming inflammation and autoimmunity 
[18][19]. Nationwide quality registries could be a valuable mechanism to safely and 
effectively introduce these new drugs in daily practice.
12
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The first registry of DICA aiming to give insight in the quality of precision medicine 
in cancer care was set-up in July 2013: the Dutch Melanoma Treatment Registry 
(DMTR).
For many years, the standard of care for patients with metastatic melanoma was the 
chemotherapeutic agent dacarbazine, resulting in low response rates and a poor sur-
vival of less than six months [20]. The introduction of targeted therapies, such as the 
BRAF inhibitor vemurafenib [21], and immune checkpoint inhibitors, such as the 
CTLA-4 antibody ipilimumab [18], marked the first treatments that could prolong 
life for metastatic melanoma patients. The DMTR documents detailed information 
on all Dutch patients with unresectable or advanced melanoma since the introduc-
tion of the new drugs.
The DMTR unites multiple objectives: I) clinical auditing, II) optimizing transpar-
ency of melanoma care, III) providing an insight into real-world outcomes on effects 
and costs and IV) creating a platform for research. The initiation of the DMTR and 
an overview of the first results are described in Chapter 3.
Prognostic factors in metastatic melanoma
The approval by the European Medicine Agency (EMA) of new melanoma drugs 
relies on the results of clinical trials. However, clinical trial populations differ in 
important ways from patients in daily practice. A recent nationwide study of the 
Danish Metastatic Melanoma Database showed that 55% of melanoma patients in 
daily practice would not be eligible for participation in phase III immunotherapy 
trials [22]. Given the high costs and considerable side effect of the new melanoma 
drugs, it is of utmost importance to be able to determine who is likely to benefit the 
most.
Moreover, data from the DMTR shows that over 60% of patients receive two or more 
lines of therapies [23], but the pivotal trials on which the EMA based their conclu-
sion on drug approval have not yet addressed this issue.
The following chapters show the added value of research with data from the DMTR, 
complementing the information from pivotal trials.
Chapter 4 describes prognostic factors associated with clinical outcomes in BRAF-
mutant metastatic melanoma patients treated with vemurafenib in real-world clinical 
practice. Secondly, it gives an insight in the differences in clinical outcomes across 
subgroups of patients with different risk profiles.
13
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Although long-term survival may be achieved in a subgroup of patients, there is still 
an unmet medical need for patients with aggressive disease, in particular for patients 
with baseline serum LDH of ≥2x upper limit of normal (ULN). Clinicians and re-
searchers worldwide are searching for treatment strategies to improve the very poor 
prognosis of these patients Chapter 5 investigates whether BRAF inhibitor induction 
treatment preceding immunotherapy in patients with a baseline serum LDH of ≥2x 
ULN can be beneficial.
part iii: Assuring quality focusing on patient centred outcomes
With the emerging group of cancer survivors, monitoring functional and QoL 
outcomes becomes more important, while standardized data on these outcomes 
are lacking [24]. Doctors typically ask patients about their symptoms only during 
outpatient visits without collecting this information in a standardized manner.
Secondly, patients today take an active role in their care, from the moment of diag-
nosis to follow-up. Currently, the information given to support treatment choices is 
mostly based on clinical outcomes, such as overall survival or disease free survival, 
whereas many studies showed that the impact on quality of life (QoL) is just as 
important [25] [26]. This suggests that reliable and valid patient-reported outcomes 
in addition to clinical outcomes are needed as a basis for constructive treatment 
discussions between doctors and patients.
Fortunately, there is a growing recognition of the importance of collecting patient-
centered outcomes systematically. In 2012, a joint taskforce of the Karolinska Institute 
in Sweden, the Harvard Busines School and the Boston Consulting group, initiated 
the International Consortium for Health Outcomes Measurement (ICHOM). The 
mission of ICHOM is to develop global standard sets of outcomes measures that 
matter most to patients.
Chapter 6 and chapter 7 describe the process facilitated by ICHOM by which com-
prehensive standard sets for two of the most common cancer diagnoses (colorectal 
and breast cancer) were developed. The development process involved a combination 
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Part I
Assuring quality in multidisciplinary 
cancer care

2 Hospital variation and the impact of postoperative complications on the use 
of perioperative chemo(radio)therapy 
in resectable gastric cancer. Results 
from the Dutch Upper GI Cancer 
Audit
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Amodio S, van Berge Henegouwen MI, Cats A, van Hillegersberg R, 
van Sandick JW, Wijnhoven BPL, Wouters MWJ, 
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Background: Dutch national guidelines on the diagnosis and treatment of gastric 
cancer recommend the use of perioperative chemotherapy in patients with resectable 
gastric cancer. However, adjuvant chemotherapy is often not administered. The aim 
of this study was to evaluate hospital variation on the probability to receive adjuvant 
chemotherapy and to identify associated factors with special attention to postopera-
tive complications.
Methods: All patients who received neoadjuvant chemotherapy and underwent an 
elective surgical resection for stage IB-IVa (M0) gastric adenocarcinoma between 
2011 and 2015 were identified from a national database (Dutch Upper GI Cancer 
Audit). A multivariable linear mixed model was used to evaluate case-mix adjusted 
hospital variation and to identify factors associated with adjuvant therapy. Results: Of 
all surgically treated gastric cancer patients who received neoadjuvant chemotherapy 
(n ¼ 882), 68% received adjuvant chemo(radio)therapy. After adjusting for case-mix 
and random variation, a large hospital variation in the administration rates for adju-
vant was observed (OR range 0.31 e7.1). In multivariable analysis, weight loss, a poor 
health status and failure of neoadjuvant chemo-therapy completion were strongly 
associated with an increased likelihood of adjuvant therapy omission. Patients with 
severe postoperative complications had a threefold increased likelihood of adjuvant 
therapy omission (OR 3.07 95% CI 2.04e4.65).
Conclusion: Despite national guidelines, considerable hospital variation was ob-
served in the probability of receiving adjuvant chemo(radio)therapy. Postoperative 
complications were strongly associated with adjuvant chemo(radio)therapy omis-





Surgery is the cornerstone of curative treatment for patients with gastric cancer.
However, optimal surgical treatment provides long-term survival in only 20e30% 
of the patients [1,2] The high relapse rate has led to the utilization of perioperative 
treatment modalities, with adjuvant chemoradiotherapy being the preferred treat-
ment in the United States [3] and perioperative chemotherapy in Europe [4,5]. 
Adjuvant chemotherapy is presumed to be an important component of perioperative 
chemotherapy, since several Asian studies showed a survival benefit with adjuvant 
chemotherapy regimens alone [6,7].
Dutch guidelines recommend perioperative chemotherapy containing the ECF 
(epirubicin, cisplatin and 5-fluorouracil) regimen for patients with resectable gastric 
cancer who are eligible in terms of physical condition and comorbidity [8]. Despite 
national guidelines, only half of the patients receive perioperative chemotherapy in 
Dutch clinical practice [9]. It remains to be elucidated whether this relates to low 
compliance with national guidelines or to the variation in frailty and comorbidities 
of the unselected patient population. Previous population-based studies confirmed 
that both patient and tumour characteristics influence the probability of receiving 
perioperative treatment, including a higher age, more comorbidity and a lower clini-
cal tumour stage [9-12].
However, it is not well understood to what extent perioperative complications in-
fluence the probability of receiving adjuvant chemo(radio)therapy in patients who 
are considered eligible for multimodal treatment. Gastric surgery is associated with 
relatively high perioperative complication rates [13], which, by decreasing patient’s 
condition, could have a major influence on the probability of receiving the adjuvant 
component of perioperative chemo(radio) therapy.
Furthermore, to what extent the use of guideline-recommended adjuvant chemo-
(radio)therapy varies between hospitals is not fully elucidated.
The aim of this study was to evaluate hospital, patient, tumour and treatment fac-
tors that influence the utilization of the adjuvant component of the perioperative 
22
Chapter 2
chemo(radio)therapy regimen for surgically treated gastric cancer patients in the 
Netherlands.
methods
Since 2011, all patients with the intent of a resection for oesophageal or gastric cancer 
in the Netherlands are registered in the Dutch Upper Gastrointestinal Cancer Audit 
(DUCA) [14]. The DUCA was set up as a nationwide surgical quality improvement 
programme. The main objective of the audit is to report risk-adjusted process and 
outcome information to participating hospitals for internal quality improvement 
purposes.
Detailed information on patient- and disease-specific characteristics as well as infor-
mation on the diagnostic process, treatment and perioperative outcome is collected 
prospectively. Data are compared with an external data registration, the Netherlands 
Cancer Registry (NCR), on completeness and accuracy. The NCR registers all newly 
diagnosed malignancies in the Netherlands [2]. The concordance of the DUCA reg-
istration with the data set of the NCR on a national level is very high, and has been 
estimated to be 98% of all gastric cancer resections in 2013 [14].
patient selection
All patients who were planned to receive the standard perioperative chemo (radio)
therapy and received neoadjuvant chemo-therapy and underwent a curative resec-
tion for primary gastric cancer between 2011 and 2015 were selected. A curative 
resection was defined as a curative macroscopically complete resection and no signs 
of metastatic disease at time of diagnosis and at surgery. Tumour stage was defined 
according to the seventh edition of the International Union Against Cancer tumour 
node metastasis (TNM) classification [15]. According to the 7th TNM classification, 
gastro-oesophageal junction (GEJ) tumours were classified as oesophageal tumours 
in the DUCA database and were therefore excluded from this study. Patients were 
considered not eligible for analyses when information was missing regarding the 
location of the tumour, date of birth, date of surgery, intent of surgery, treatment 
modalities received and the patient’s vital status 30 days post-operatively and/or 
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at time of discharge. Patients with other treatment regimens, such as neoadjuvant 
chemo (radio)therapy alone or adjuvant chemo(radio)therapy alone, were excluded.
In order to investigate current hospital variation, hospitals that stopped performing 
gastric cancer surgery during the study period were excluded.
Patients were classified to the hospital of surgical treatment, since the hospital of 
diagnosis or the hospital of chemo(radio) therapy is not registered in the DUCA.
For this study, no ethical approval or informed consent was required under Dutch 
law.
variables
The studied variables included patient characteristics (age, sex, weight loss before 
surgery, American Society of Anesthesiologists (ASA) classification, comorbidity 
according to the Charlson Co-morbidity Index (CCI) [16]), tumour characteristics 
(tumour site, clinical and pathological tumour stage, differentiation grade) and 
treatment characteristics (histologic regression after neoadjuvant therapy, radicality 
of resection, completion of neoadjuvant therapy, intraoperative complications and 
severe postoperative complications). Hospital stay was defined as days between date 
of surgery and date of discharge. Postoperative mortality was defined as death within 
30 days from the date of surgery or during the initial hospital admission.
A severe postoperative complication was defined as a complication within 30 days 
with a Clavien-Dindo classification of grade III (requiring surgical, endoscopic or 
radiological intervention), grade IV (requiring intensive care (IC) management) 
or grade V (leading to death) [17] Complications were classified into non-surgical 
complications (e.g. pulmonary, cardiac, thromboembolic, neurologic, urologic 
complications) or surgical complications (e.g. anastomotic leakage, chylous leakage, 
haemorrhage, wound and intra-abdominal abscess, pancreatitis).
treatment groups
Patients were grouped into two treatment categories: receipt of neoadjuvant 
chemotherapy component alone or receipt of the complete perioperative regimen. 
Perioperative therapy was defined as neoadjuvant chemotherapy (three cycles of 
ECF, ECC or EOX) and either adjuvant chemotherapy (three cycles of ECF/ECC or 
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EOX) or adjuvant chemoradiotherapy with cisplatin and capecitabine according to 
the CRITICS trial; a large randomized phase III trial evaluating the added value of 
adjuvant chemoradiotherapy after neoadjuvant chemotherapy that ran during the 
study period [18].
statistical analysis
Patient, tumour and treatment characteristics between both treatment groups were 
compared using the chi-square test for categorical variables and the independent 
two-sample t-test for continuous variables.
To quantify the true hospital variation for the use of adjuvant chemo(radio)therapy, 
adjusting for case-mix factors (non-modifiable patient and tumour-specific risk fac-
tors that can influence the outcome) was required [19]. Available case-mix factors that 
can influence the use of adjuvant chemo(radio)therapy were entered in a multivari-
able linear mixed model: age, sex, weight loss before surgery, ASA classification, CCI, 
pathologic tumour and nodal stage, tumour location, histologic tumour regression 
and tumour differentiation. Missing items were included in the analysis as a separate 
category if exceeding 5%. To account for the hierarchical nature of patients nested 
within hospitals, the hospital was included as a random effect [19]. The case-mix and 
random effect adjusted log odds of adjuvant chemo(radio)therapy per hospital were 
individually presented with the hospital-specific 95% confidence intervals (CIs). The 
log odds could then be converted into an odds ratio (OR) by taking the exponential. 
The variation in use of adjuvant chemo(radio)therapy between hospitals was tested 
for statistical significance with the likelihood ratio test.
Secondly, a univariable and multivariable linear mixed model were used to quantify 
the association of patient, tumour and treatment factors with the omission of adju-
vant chemo(radio) therapy. The multivariable analysis for adjuvant therapy omission 
was repeated to evaluate the association of surgical and non-surgical complications 
separately. As a sensitivity analysis, we also assessed the association of severe compli-
cations on adjuvant therapy in a younger (<70 years) and healthier (ASA classifica-
tion I-II, minor weight loss of <5 kg) cohort of patients. Statistical significance was 
defined as a two-sided p value < .05. All analyses were performed in PASW Statistics 




use of perioperative chemo(radio)therapy
Between January 1st, 2011 and December 31st, 2015, 882 patients who received 
neo-adjuvant chemotherapy and underwent a curative resection for gastric cancer 
were registered in 24 hospitals (Figure 1). In total, 167 patients (18%) started with 
the neoadjuvant therapy but did not complete the regimen due to toxicity. Of the 
remaining, 280 patients only completed the neoadjuvant component (32%) and 
Patients with gastric cancer with the 
intent of a resection registered in  
DUCA 2011-2015 
N=2076 
Excluded patients not eligible for 
analysis (N=59)  
Eligible for analysis 
N=2017 
Primary tumor with  
cT1b-4a, cN0-3, M0 
N=1891 
Excluded patients with: 
-  Recurrent disease (N=42)   
-  cT1a tumour (N=32)  
-  Distant metastasis (cM1; N=52) 
Excluded patients with: 
-  Emergency/urgent procedure 
(N=90) 
-  Palliative resection (N=60)  
-  Irresectable (N=175) 
-  R2 resection (N=27) 
-  pM1 (N=51) Elective surgery,  




Excluded patients with: 
-  Other treatment regimens (N=61)   
-  No neoadjuvant CT (N=545) 
figure 1. Study population. DUCA = Dutch Upper Gastro-Intestinal Cancer Audit, CT = chemotherapy.
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602 patients (68%) received the whole perioperative chemo(radio)therapy regimen 
(Table 1). Patients with perioperative chemo (radio)therapy were younger, with less 
weight loss, less comorbidities, completed neoadjuvant chemotherapy more often, 
had a better tumour response to chemotherapy and experienced postoperative 
complications less frequently compared to patients with neoadjuvant chemotherapy 
alone. Sixteen patients (2%) died within the hospitalization or 30 days after surgery, 
all due to severe postoperative complications.







Age, mean [range], years 67 [31-83] 63 [22-83] <.001b
Age, years
<60 56 (20) 206 (34) <.001
60-69 109 (39) 225 (37)
≥70 115 (41) 171 (28)
Sex
Male 175 (63) 395 (66) .368
Female 105 (38) 207 (34)
Weight loss
0kg 62 (22) 172 (29) .001
1-5kg 51 (18) 154 (26)
6-10kg 75 (27) 134 (22)
>10kg 45 (16) 52 (9)
Unknown 47 (17) 90 (15)
ASA classification
ASA I 20 (7) 145 (24) <.001
ASA II 178 (64) 353 (59)
ASA III+ 79 (28) 103 (17)
Unknown 3 (1) 1 (0)
Charlson Comorbidity Index
Charlson 0 128 (46) 348 (58) .001
Charlson 1 62 (22) 128 (21)
Charlson 2+ 90 (32) 126 (21)
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I 41 (15) 99 (16) .062
II 117 (42) 271 (45)
III 35 (13) 52 (9)
Unknown 87 (31) 180 (30)
Pathological tumour stagec
I 69 (25) 151 (25) 0.003
II 73 (26) 200 (33)
III 90 (32) 207 (34)
Unknown 48 (18) 44 (7)
Site of tumour .346
Fundus 31 (11) 52 (9)
Corpus 93 (33) 214 (36)
Antrum / pylorus 116 (41) 260 (43)
Whole stomach 19 (7) 40 (7)
Other 4 (1) 15 (3)
Unknown 17 (6) 21 (4)
Histologic regression
None 88 (31) 146 (24) <.001
Partial/complete 107 (38) 351 (58)
Unknown 85 (30) 105 (17)
Differentiation grade
Well/moderately 89 (32) 162 (27) .034
Poorly/Undifferentiated 157 (56) 327 (54)
Unknown 34 (12) 113 (19)
Radical resection
R0 246 (88) 545 (91) .282
R1 32 (11) 50 (8)
Unknown 2 (1) 7 (1)
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hospital variation in the use of adjuvant chemo(radio)therapy
Unadjusted hospital variation in the administration of adjuvant chemo(radio)therapy 
ranged from 9% to 94%. A likelihood ratio test showed that the variability between 
hospitals for use of adjuvant chemo(radio)therapy was statistically significant (p 
value < .01). After adjustment for case-mix variables and fitting a random effect 
model, still considerable variation remained (Figure 2). Three hospitals administered 








No 111 (40) 56 (9) <.001
Yes 166 (59) 543 (90)
Unknown 3 (1) 3 (1)
Intraoperative complications
No 263 (94) 581 (97) .079
Yes 17 (6) 21 (4)
Postoperative complicationse
No 151 (54) 428 (71) <.001
Yes, grade I-II 24 (9) 62 (10)
Yes, grade III-V 105 (38) 112 (19)
Surgical 35 (7) 34 (6)
Non-surgical 28 (13) 43 (7)
Surgical and non-surgical 33 (16) 19 (3)
Unknown 9 (4) 16 (3)
Postoperative mortality
No 264 (94) 602 (100) <.001
Yes 16 (6) 0 (0)
Hospital stay (median), days 10 8 <.001b
ASA=American Society of Anesthesiologists; CT=chemotherapy.
aNeoadjuvant chemotherapy combined with adjuvant chemo(radio)therapy
bAnalysis performed independent two-sample t-test
c Tumour Node Metastasis system (7th edition)
d More than 80% of cycles were completed
e Classified according to Clavien-Dindo classification. Postoperative complications of grade III or 
higher are considered severe.
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significantly less neoadjuvant chemotherapy (negative outliers) and three hospitals 
administered significantly more chemotherapy (positive outliers) compared to the 
national average (range on log odds scale is -1.37-1.36, meaning a range on the odds 
scale of 0.31-7.2). Hence, in the hospital with the highest administration rate, patients 
were seven times more likely to receive adjuvant chemo(radio)therapy compared 
to the national average, irrespective of patient- and tumour-specific risk factors. In 
the hospital with the lowest administration rate, adjuvant chemo(radio)therapy was 
three times more likely to be omitted compared to the national average.
effect of patient, tumour and treatment risk factors on adjuvant 
chemo(radio)therapy omission
Multivariable analysis showed that women, patients with severe weight loss, a higher 
ASA classification, failure of neoadjuvant chemotherapy completion and postopera-
tive severe complications were most strongly associated with an increased likelihood 






























figure 2. Hospital variation on the administration adjuvant chemo(radio)therapy on the log odds 
scale. Every hospital is presented as a dot with hospital specific 95% confidence interval, adjusted 
for case-mix with random-effects models. The zero-line represents the national average. Hospitals 
with an outcome less than 0 and marked with a dash (-) are negative outliers and have administered 
significantly less than average. Hospitals with an outcome above 0 and marked with a dash (-) are 
positive outliers and have administered significantly more than average.
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table 2. Univariable and multivariable linear mixed model of patient, tumour and treatment factors 
associated with the omission of adjuvant chemo(radio)therapy.
Factor Univariable OR (95% CI) P Multivariable OR (95% CI) P
Age
<60 ref ref
60-69 2.78 (1.23-2.69) <.001 1.42 (0.87-2.30) .208
>/= 70 2.47 (1.70-3.61) <.001 1.80 (1.10-3.01) .036
Sex
Male ref ref
Female 1.15 (0.85-1.54) .368 1.50 (1.02-2.22) .036
Weight loss
0kg ref ref
1-5kg 0.92 (0.60-1.41) .699 1.06 (0.62-1.82) .967
6-10kg 1.56 (1.04-2.32) .33 1.57 (0.93-2.65) .125
>10kg 2.40 (1.47-3.93) .001 2.31 (1.22-4.38) .030
Unknown 1.45 (0.92-2.29) .112 1.47 (0.81-2.67) .338
ASA classification
ASA I ref ref
ASA II 3.66 (2.22-6.03) <.001 2.04 (1.12-3.72) .021
ASA III+ 5.56 (3.20-9.66) <.001 2.82 (1.41-5.66) .005
Charlson score
Charlson 0 ref ref
Charlson 1 1.31 (0.91-1.90) .139 1.01 (0.63-1.61) .838
Charlson 2+ 1.94 (1.39-2.72) <.001 1.39 (0.88-2.19) .101
Pathological tumour stagea
I ref ref
II 0.80 (0.54-1.18) .260 0.53 (0.32-0.87) .012
III 0.95 (0.65-1.39) .796 0.48 (0.28-0.83) .008
Unknown 2.39 (1.45-3.93) .001 0.70 (0.34-1.43) .322
Site of tumour
Corpus ref ref
Fundus 1.37 (0.83-2.28) .222 1.73 (0.89-3.35) .115
Antrum/pylorus 1.02 (0.74-1.42) .875 0.90 (0.58-1.38) .898
Whole stomach 1.09 (0.601-1.99) .771 1.21 (0.54-2.71) .545
Unknown 1.34 (0.74-2.42) .329 1.23 (0.56-2.67) .661
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Severe postoperative complications increased the likelihood of adjuvant treatment 
omission more than threefold (OR 3.07; 95% CI2.04-4.65). Additional multivariable 
analysis showed that severe surgical complications displayed a greater effect on the 
probability of the omission of adjuvant chemo(radio)therapy than severe non-surgi-
cal complications (OR 3.42 95% CI 1.93-6.04 vs 1.85 95% CI 1.02-3.37). Patients with 
a combination of both severe surgical and severe non-surgical complications had 
table 2. Univariable and multivariable linear mixed model of patient, tumour and treatment factors 
associated with the omission of adjuvant chemo(radio)therapy (continued)
Factor Univariable OR (95% CI) P Multivariable OR (95% CI) P
Differentiation
Good/medium ref ref
Bad/none 1.14 (0.83-1.58) .411 0.92 (0.60-1.42) .980
Unknown 0.63 (0.41-0.96) .032 0.69 (0.38-1.27) .367
Histologic regression
Partial/complete ref ref
None 1.98 (1.41-2.78) <.001 1.68 (1.05-2.69) .023
Unknown 2.66 (1.96-3.8) <.001 2.13 (1.26-3.58) .003
Radical resection
R0 ref ref
R1 1.42 (0.89-2.27) 1.44 1.36 (0.70-2.66) .481
Neoadjuvant therapy completedb
Yes ref ref
No 6.48 (4.5-9.34) <.001 6.55 (4.14-10.35) <.001
Intraoperative complications
No ref ref
Yes 1.79 (0.93-3.45) .082 1.82 (0.77-4.30) .179
Severe postoperative complications
No ref ref
Grade I-II 1.1 (0.67-1.82) .72 1.36 (0.73-2.53) .439
Grade >III 2.66 (1.92-3.68) <.001 3.07 (2.04-4.65) <.001
Bold printed numbers are statistically significant (p<0.05).
ASA=American Society of Anesthesiologists, CI=confidence interval.
e Tumour Node Metastasis system (7th edition)
b More than 80% of cycles were completed
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the highest likelihood of adjuvant chemo(radio)therapy omission (OR5.54 95%CI 
2.77- 11.07).
After further selecting a younger cohort of patients with less comorbidities and 
weight loss (<70 years, ASA I-II, weight loss <5 kg; N = 267), 81% received adjuvant 
chemotherapy and 20% experienced a severe postoperative complication. After 
adjustment, an increase in the likelihood of adjuvant treatment omission following 
severe postoperative complications was also found in this subgroup (OR 2.45 95% 
CI 1.15-5.25).
discussion
This population-based study shows that after completing the neoadjuvant 
therapy, only 68% of surgically treated gastric cancer patients receive the adjuvant 
chemo(radio)therapy component of the perioperative chemo(radio)therapy regi-
men. Furthermore, a significant hospital variation is observed in the probability of 
receiving adjuvant treatment, with postoperative severe surgical complications hav-
ing a major impact.
Similar compliance rates of adjuvant chemo(radio)therapy were observed in this 
study as those shown in the MAGIC trial (68% vs 65%, respectively) [4]. The ACTS-
GC and CLASSIC trial evaluated the effect on survival of adjuvant chemotherapy 
alone and reported comparable compliance rates of 67% [6,7]. This indicates the 
difficulty of delivering the adjuvant component following gastric surgery, even in 
selected patient populations. Apparently, the treating physicians and/or patients are 
reluctant to administer the adjuvant component in older and frail patients because 
of perceived toxicity of the regimen in the trials and uncertainty on long-term harms 
and benefits. These results show the need for specific guidelines that are more tailored 
to individual patients and subgroups.
Considerable hospital variation was observed with regard to the use of adjuvant 
chemo(radio)therapy, even after adjustment for case-mix factors and random 
variation. In hospitals with the lowest administration rates, adjuvant chemo(radio)
therapy was three times more likely to be omitted compared to the national average, 
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suggesting that underuse of adjuvant chemotherapy is not merely a reflection of the 
age or comorbidity burden, but it may also reflect other (hospital specific) factors. 
Previous studies demonstrated that consultation of a medical oncologist [10] and a 
dedicated multi-disciplinary team meeting [11] are independently associated with 
higher rates of adjuvant chemo(radio)therapy receipt, which underlines the impor-
tance of the decisional process.
The effect of hospital variation in adjuvant chemotherapy use on overall survival has 
not been studied yet. A recent Dutch study on gastric cancer patients demonstrated 
significant hospital variation in the probability to receive potential curative surgical 
treatment [20]. Patients diagnosed in hospitals with a lower probability of undergo-
ing surgical treatment had a worse overall survival [20]. Future studies are needed to 
explore whether a lower hospital probability of chemotherapy use is also associated 
with poorer survival.
A very strong effect of severe postoperative complications on the probability to omit 
adjuvant chemo(radio)therapy was demonstrated, which increased more than three-
fold compared to patients who had no complications. This has also been reported 
for other oncologic procedures with high perioperative morbidity rates, including 
procedures for colorectal and pancreatic cancer [21e24]. A recent retrospective mul-
ticentre US study in resectable gastric cancer patients showed that the combination of 
experiencing postoperative complications and not subsequently receiving adjuvant 
chemo(radio)therapy increased the long-term overall mortality twofold [25].
Optimal treatment comprises not merely the administration, but also a timely start 
after surgery and completion of all planned cycles of chemotherapy. Two recent Asian 
studies on timing of adjuvant chemotherapy in resectable gastric cancer showed that 
delayed treatment after 8 weeks was associated with worse survival outcomes [26,27]. 
They also demonstrated that the occurrence of postoperative surgical complications 
was the strongest factor related to this delay. Like our study, this indicates that com-
plications following gastric cancer surgery not only affect short-term outcomes, but 
also influence long-term survival. This phenomenon might be related to the omis-
sion or delay of adjuvant treatment.
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Gastric cancer surgery is complex and has a relatively high incidence of postopera-
tive complications. This study showed that the effect of surgical complications on 
the omission of adjuvant chemotherapy is much stronger than that of non-surgical 
complications (OR 3.4 vs 1.9, respectively). Even among the healthier and younger 
patient cohort, severe complications were common (20%) with an over twofold 
increased likelihood of adjuvant chemo(-radio)therapy omission. Many efforts 
aimed to improve the outcome of gastric cancer surgery have been made, such as the 
centralization and the initiation of clinical audits [28]. Despite these efforts, severe 
complication rates remain high, ranging from 20% to 35% in Western countries 
[13,29].
This study has several strengths and limitations. The strength of this study is the 
population-based and prospective nature of the audit, including all Dutch hospitals 
with a 98% national coverage of all gastric cancer resections. It therefore reflects daily 
practice and is highly representative of the Dutch population. However, the DUCA 
has its focus on the quality of surgical treatment and short-term outcomes of care. 
Therefore, detailed information on the chemotherapy regimen, the number of re-
ceived cycles, dosage, toxicity, reasons for not receiving chemotherapy and long-term 
follow-up is not registered. A multidisciplinary extension of the audit, including 
participation of medical oncologists, pathologists, gastroenterologists and radiation 
oncologists and merging DUCA data with survival data of the National Cancer Reg-
istry may offer a better understanding of the decision-making process and treatment 
patterns for multimodal therapy and ultimately the impact on long-term survival.
Furthermore, the DUCA does not register the hospital of diagnosis, and actual refer-
ral patterns could therefore not be revealed. Since centralization of surgical treatment 
of gastric cancer in the Netherlands has been introduced in 2013 with a minimum 
requirement of 20 resections per hospital annually, an increasing number of patients 
are referred for surgery from another hospital. However, perioperative treatment is 
not centralized and the hospital variation as shown in this study might thus also be 




These findings broaden our understanding of decision-making in the use of adjuvant 
chemotherapy for gastric cancer in daily clinical practice. In addition to the well-
known patient and tumour factors associated with its use, the occurrence of post-
operative surgical complications also has a major effect on adjuvant chemo(radio)
therapy omission and might eventually affect long-term survival. Further efforts 
should therefore be made to decrease the incidence of complications and to improve 
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Background: In recent years, the treatment of metastatic melanoma has changed 
dramatically due to the development of immune checkpoint and mitogen-activated 
protein (MAP) kinase inhibitors. A population-based registry, the Dutch Melanoma 
Treatment Registry (DMTR), was set up in July 2013 to assure the safety and quality 
of melanoma care in the Netherlands. This article describes the design and objectives 
of the DMTR and presents some results of the first 2 years of registration.
Methods: The DMTR documents detailed information on all Dutch patients with 
unresectable stage IIIc or IV melanoma. This includes tumour and patient charac-
teristics, treatment patterns, clinical outcomes, quality of life, healthcare utilisation, 
informal care and productivity losses. These data are used for clinical auditing, 
increasing the transparency of melanoma care, providing insights into real-world 
cost-effectiveness and creating a platform for research. Results: Within 1 year, all 
melanoma centres were participating in the DMTR. The quality performance indica-
tors demonstrated that the BRAF inhibitors and ipilimumab have been safely intro-
duced in the Netherlands with toxicity rates that were consistent with the phase trials 
conducted. The median overall survival of patients treated with systemic therapy was 
10.1 months (95% confidence interval [CI] 9.1e11.1) in the first registration year and 
12.7 months (95% CI 11.6e13.7) in the second year.
Conclusion: The DMTR is the first comprehensive multipurpose nationwide registry 
and its collaboration with all stakeholders involved in melanoma care reflects an 
integrative view of cancer management. In future, the DMTR will provide insights 
into challenging questions regarding the definition of possible subsets of patients 




Malignant melanoma is one of the most aggressive types of skin cancer. The incidence 
of melanoma has increased in Europe over the past few decades [1,2]. In the Nether-
lands, the number of new cases of invasive melanoma (all stages) more than doubled 
between 2000 and 2014 and it accounts for approximately 90% of skin-cancer-related 
mortality in 2014 [3]. The increased incidence accompanied by the high mortality 
rates made it one of the worst performing tumours in the Netherlands over recent 
years, especially for males [4].
The treatment of unresectable and metastatic melanoma has changed dramatically 
in recent years due to the development of immune checkpoint inhibitors (e.g. ipi-
limumab, nivolumab and pembrolizumab) and inhibitors of the mitogen-activated 
protein (MAP) kinase pathway (e.g. the BRAF inhibitors vemurafenib and dabrafenib 
and the MAP kinase (MEK) inhibitors trametinib and cobimetinib) [5-8]. These 
drugs create new opportunities to prolong progression-free and overall survival (OS) 
for patients with metastatic melanoma. However, the introduction of the new drugs 
poses several challenges. First, adequate selection of subsets of patients who may 
benefit from immune checkpoint inhibitors or MAP kinase inhibitors and sequenc-
ing these new drugs present a challenge. Second, experience in recognising and 
treating the potentially life-threatening side effects of immune checkpoint inhibitors 
is essential. Finally, the high costs of these new drugs raise questions about their 
cost-effectiveness in daily clinical practice.
The introduction of the new drugs to treat metastatic melanoma was approved by 
the Dutch Minister of Health subject to two firm conditions: I) the concentration of 
metastatic melanoma treatment in a limited number of designated centres and II) 
the recording of all patients with unresectable or metastatic melanoma (stage IIIc or 
stage IV melanoma) in a nationwide registry.
To achieve centralisation, the Dutch Society of Medical Oncologists (NVMO) se-
lected 14 hospitals as melanoma centres in 2012. These centres were chosen on the 
basis of their expertise in the systemic treatment of melanoma, their infrastructure 
and their geographic distribution. At the same time, a set of multidisciplinary quality 
standards was established by the professional organisations involved in melanoma 
treatment, including a minimum volume standard of 20 new patients annually 
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receiving systemic treatment for meta-static melanoma [9]. This number of patients 
is based on safety reports in clinical trials [5,6]. In addition, it was assumed that this 
would allow the centres to have sufficient experience in treating patients with severe 
toxicity.
The Dutch Melanoma Treatment Registry (DMTR) was set up in July 2013. A unique 
consortium of organisations, including medical specialists, policymakers, healthcare 
researchers, patient advocates and pharmaceutical companies, was involved in estab-
lishing the registry.
This article describes the design and the objectives of the DMTR and presents some 
results of the first 2 years of registration.
mAteriAls And methods
objectives of the dmtr
The DMTR was designed to serve multiple objectives: I) clinical auditing, II) im-
proving transparency concerning the quality of melanoma care, III) providing an 
insight into real-world outcomes on effects and costs and IV) to create a platform 
for research.
Clinical auditing: improving melanoma care
Clinical auditing has been recognised as an important tool for quality assessment and 
improvement [10,11]. The DMTR is used to provide melanoma treatment centres 
with benchmarked feedback on the number of patients treated, treatment patterns, 
toxicity rates and survival data on a weekly basis in relation to the national average 
and in relation to the results of other anonymised melanoma centres. All results are 
discussed at the quarterly meetings of the Medical Committee in which all centres 
participate to increase awareness of the quality of care delivered and to stimulate 
quality improvement initiatives.
Improving transparency of melanoma care: a set of quality standards
Healthcare professionals increasingly need to provide evidence of the quality of the 
care they deliver [12,13]. A set of well-defined, uniformly collected quality indicators 
evaluating melanoma care can be derived from data in the DMTR. These quality 
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indicators are established by the joint efforts of clinical professionals, patient advo-
cates and the National Health Care Institute. These quality indicators at the level 
of melanoma centre will gradually be made publicly available to all stakeholders 
involved in melanoma care.
Real-world outcomes: cost-effectiveness of the new drugs
It is of great importance to assess the quality of life and cost-effectiveness of the new 
drugs in clinical practice. The DMTR, therefore, not only collects clinical data, but 
also data on quality of life, healthcare utilisation, informal care and productivity 
losses. These data will be used to develop a health economic disease model to evalu-
ate the real-world cost-effectiveness of treatment for metastatic melanoma.
Platform for research
A population-based registry is a valuable resource for research as it provides real-
world data, including information on patients often not eligible for clinical trials. 
Exploratory comparative effectiveness studies may be conducted with DMTR data if 
randomised controlled trials are not yet available.
main structures of the dmtr
Funding
The initial costs of developing the DMTR database were funded through a grant from 
the Netherlands Organisation for Health Research and Development (ZonMw). The 
pharmaceutical companies (Roche Nederland B.V., Bristol-Myers Squibb, and Glax-
oSmithKline/Novartis, participating from the establishment of the registry, and MSD, 
participating since 1 July 2015), which produce the newly approved drugs, funded 
the first 4 years of registration. Future funding will be created in collaboration with 
the pharmaceutical companies, health insurance companies and melanoma centres.
Organisational structure
The DMTR is a collaboration of multiple stakeholders involved in the treatment of 
metastatic melanoma. The NVMO is the official representative of all medical oncolo-




(Stichting Melanoom) and the Working Group on Immunotherapy and Oncology 
(WIN-O), they form the Board of Directors.
The Dutch Institute for Clinical Auditing (DICA) facilitates the implementation of 
the DMTR and supervises data collection and management. The DICA is specialised 
in the uniform collection of data and in making appropriate adjustments to case-mix 
variations between hospitals to provide benchmarked feedback. The methods for 
case-mix adjustment are described in more detail elsewhere [14].
The Institute for Medical Technology Assessment (iMTA) cooperates with DICA and 
is responsible for reporting on the cost-effectiveness of the new drugs for advanced 
melanoma. The iMTA is a scientific institute for research in health economics [15].
Trained data managers at the Netherlands Comprehensive Cancer Organisation 
(IKNL) coordinate and perform data collection in the melanoma centres. IKNL is 
responsible for the Dutch Cancer Registry, which collects data concerning incidence, 
prevalence, survival and mortality of all malignancies in the Netherlands [16].
A diagram of the DMTR’s organisational structure can be found in Figure 1.
Governance 
Medical committee 



















Board of directors 
NVMO, WIN-O, 
Stichting Melanoom 
figure 1. Organisational structure of the Dutch Melanoma Treatment Registry (DMTR). NVMO, 
Dutch Society of Medical Oncologists; WIN-O, the Working Group on Immunotherapy and Oncol-
ogy; Stichting Melanoom, patient association; iMTA, Institute for Medical Technology Assessment; 
ZonMW, Netherlands Organisation for Health Research and Development; ZiNL, National Health 






Data collection started in September 2013, retrospectively registering data from 
patients with metastatic melanoma newly diagnosed (metastatic at first diagnosis) 
and metastatic upon progression or recurrence who were treated with ipilimumab 
and/or a BRAF inhibitor from July 2012 to June 2013. During this period, patients 
not receiving treatment with one of these drugs were not yet registered in the DMTR. 
From July 2013, all patients diagnosed with metastatic melanoma were prospectively 
registered irrespective of treatment modality.
An extensive entry in the register was performed for all patients who were referred 
to a melanoma centre. A concise entry in the register was carried out for patients for 
whom a melanoma centre was only consulted.
For all extensively monitored patients, the DMTR contains detailed clinical informa-
tion on patient and tumour characteristics, diagnostics, treatment strategies, adverse 
events, time to progression and survival. In addition, data are collected on healthcare 
resource utilisation, informal care, productivity losses and patient-reported outcome 
measures (PROMs) (i.e. melanoma-specific and overall quality of life).
No ethical approval or informed consent was required under Dutch law to register 
this information. The clinical dataset is presented as a diagram in Appendix 1.
Web-based environment: data collection, processing and benchmarked feedback
The DMTR uses a web-based environment for data collection and data manage-
ment including continuous benchmarked feedback to the participating healthcare 
professionals through a secure website. Pharmaceutical companies are provided with 
aggregated information regarding the use and performance of their drugs in clinical 
practice.
Internal and external data verification
Data quality is verified at several key time points along the registration process. Miss-
ing or potentially incorrect data are fed back directly to the data managers within the 
web-based environment. Furthermore, the IKNL data managers verify 10% of the 
registered data annually. Oncologists supervise the registration process and check 
all results at patient level. The administrative burden for participating physicians is 




Descriptive statistics were used to assess patient, tumour and treatment characteris-
tics. The OS was defined as the time from date of diagnosis of metastatic melanoma 
to death from any cause. Patients alive at time of analysis were censored. The OS 
with corresponding two-sided 95% confidence interval [CI] was analysed using the 
Kaplan Meier method. Follow-up time was calculated from first visit to a melanoma 
centre using the inverse Kaplan Meier method [17]. Performance on the quality in-
dicators is presented in funnel plots using 99% confidence limits that vary in relation 
to the volume of patients per hospital [18]. All statistical analyses were performed in 
PASW Statistics version 20 (SPSS Inc., Chicago, IL).
results
patient characteristics
From 1st July 2012 to 1st July 2014, 1472 patients with metastatic melanoma were 
registered in the DMTR. A total of 60 patients were not referred to a melanoma 
centre and therefore received only a concise entry mainly due to poor performance 
status or limited prognosis. Of all the patients referred to a melanoma centre (n 
=1412), 23 patients (1.6%) were excluded because of missing data on date of birth, 
date of first visit to a melanoma centre, date of diagnosis of disseminated disease and 
the type of treatment. These items of in-formation were considered to be the minimal 
requirements for analysis. Complete data was available for 1389 patients. Median 
follow-up was 18.8 months (95% CI 18.0-19.5) (data cut-off 14th September, 2015).
Baseline patient and tumour characteristics at the first visit to a melanoma centre are 
shown in Table 1 per registration year. Most patients had a World Health Organiza-
tion performance score of 0e1 (83% first year and 77% second year), the median age 
was 59 and 62 years and over half of the patients were male (59% and 54%). Most of 
the patients had stage M1c disease (78% and 69%) and over a quarter had elevated 
serum lactate dehydrogenase (LDH) levels (35% and 26%). Furthermore, 23% of 
patients had brain metastases on radiographic imaging, with more than 10% of these 
patients having symptomatic brain metastases at first visit.
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table 1. Patient, tumour and treatment characteristics at first presentation in a melanoma centre
Characteristic July 2012-July 2013
N=401
N (%)




Age, median (range), yrs 59 (20-90) 63 (18-92)
Age group
< 50 108 (27) 191 (19)
50-59 97 (24) 210 (21)
60-69 118 (29) 291 (30)
=>70 78 (20) 296 (30)
Gender
Female 163 (41) 453 (46)
Male 238 (59) 535 (54)
Median (range) time since
primary diagnosis, yrs
2 (0-28) 2 (0-43)
ECOG performance score
0 199 (50) 475 (48)
1 132 (33) 251 (25)
>/=2 44 (11) 102 (10)
Unknown 26 (7) 160 (16)
Elevated serum LDH level (>250 U/L)
No 250 (62) 619 (63)
Yes 139 (35) 252 (26)
Unknown 12 (3) 117 (12)
Brain metastases
No 290 (72) 664 (67)
Yes 92 (23) 224 (23)
Symptomatic brain metastasis 48 (12) 155 (16)
Unknown 19 (5) 100 (10)
tumour characteristics
Disease stage
Unresectable stage IIIc 8 (2) 55 (6)
M1a 30 (8) 58 (6)
M1b 35 (9) 88 (9)
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table 1. Patient, tumour and treatment characteristics at first presentation in a melanoma centre 
(continued)
Characteristic July 2012-July 2013
N=401
N (%)
July 2013- July 2014
N=988
N (%)
M1c 314 (78) 679 (69)
Unknown M stage 12 (3) 85 (9)
Unknown 2 (1) 23 (2)
Location of primary tumour
Trunk 169 (42) 330 (33)
Extremities 106 (26) 292 (30)
Head and/or neck 50 (13) 119 (12)
Uveal 5 (1) 69 (7)
Acral 10 (3) 28 (3)
Mucosal 5 (1) 22 (2)
Primary unknown 50 (13) 121 (12)
Missing 6 (2) 7 (1)
Histology of primary tumoura
Superficial spreading 171 (51) 374 (49)
Nodular 86 (26) 207 (27)
Acral lentiginous 5 (2) 16 (2)
Desmoplastic 4 (1) 5 (1)
Lentigo maligna 4 (1) 12 (2)
Other 19 (6) 55 (7)
Unknown 46 (14) 100 (13)
Mutation status
No mutation status analysed 6 (2) 107 (11)
Mutation status analysed 395 (99) 879 (89)
Unknown 0 (0) 2 (0)
Type of mutation
BRAF mutation 306 (76) 475 (48)
No BRAF mutation 89 (22) 404 (41)
NRAS mutationb 17 146
KIT mutationb 2 7




Figure 2 demonstrates the type of drug administered to patients by line of treatment 
and by year of registration in the DMTR. In the first registration year, a BRAF inhibi-
tor was most frequently administered in the first line of therapy (66%). Ipilimumab 
was mostly administered as second-line therapy (39%), but a shift towards first-line 
table 1. Patient, tumour and treatment characteristics at first presentation in a melanoma centre 
(continued)
Characteristic July 2012-July 2013
N=401
N (%)
July 2013- July 2014
N=988
N (%)
GN-11 mutationb 0 1
Wild typeb 58 209
Type of mutation unknownb 12 34
treatment characteristics
Previous systemic treatment for metastatic 
disease
Chemotherapy 78 (20) 41 (4)
BRAF inhibitor 13 (3) 13 (1)
Ipilimumab 0 (0) 2 (0)
Trial 26 (6) 30 (3)
Treatment in melanoma centre
Systemic treatment 401 (100) 717 (73)
Only local treatment N/A 151 (15)
RFA N/A 2 (0)
Surgery N/A 60 (6)
Radiotherapy N/A 68 (7)
Surgery and radiotherapy N/A 19 (2)
Other N/A 2 (0)
No therapy N/A 120 (12)
Yrs=years; ECOG = Eastern Cooperative Oncology Group; LDH= lactate dehydrogenase; RFA = 
radiofrequency ablation; N/A = not applicable.
a Histology is presented for patients with cutaneous melanoma (first registration year, N=335; second 
registration year, N=769).
b Type of mutation is presented for patients with BRAF, wild-type (first registration year, N=89; sec-
ond registration year, N=404).
54
Chapter 3
therapy (16%) was observed in the second registration year. This was probably due to 
the approval of ipilimumab as a first-line therapy at the beginning of 2014. More than 
one-third of the patients (36%) participated in a clinical trial or compassionate-use 
programme as first-line therapy in the second year.
performance indicators of quality of metastatic melanoma care
Table 2 shows the indicators for quality of care in the first 2 registration years at 
national level.
Structure
Participation in the DMTR is obligatory for all 14 melanoma treatment centres and 
the full participation of all centres was achieved within the first registration year. Of 
all patients referred to a melanoma centre, 98-100% had sufficient quality of data to 
include for further analysis.
Outcome
Of all the patients treated with a BRAF inhibitor, almost 30% experienced at least 
































Systemically treated patients registered in the DMTR 
1 July 2012 - 30 June 2013 
N=401 
Systemically treated patients registered in the DMTR 













figure 2. Treatment patterns of all systemically treated patients with metastatic melanoma, present-




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ipilimumab were 20% and 23% in year 1 and 2, respectively. No deaths were related 
to the toxicity of treatment with a BRAF inhibitor. One death was associated with 
ipilimumab toxicity. The median OS of patients treated with systemic therapy was 
10.1 months (95% CI 9.1- 11.1) in the first year and 12.7 months (95% CI 11.6- 13.7) 
in the second year. Figure 3 shows the hospital variation in percentage of patients 
with grade 3/4 adverse events during treatment with a BRAF inhibitor (3a) and 
ipilimumab (3b) in the first 2 years of registration. The funnel plots demonstrate that 
no melanoma centre performed significantly worse than average on toxicity rates 
for both ipilimumab and BRAF inhibitors. One melanoma centre performed sig-

































































Patients treated with ipilimumab per melanoma centre  
(N=494)  
 
Grade III-IV AE 
Mean 
99% CI  
figure 3. Variation between melanoma centres in the percentage of patients with grade III-IV AEs 
caused by a BRAF inhibitor (A) and/or ipilimumab (B). The dotted line presents the average percent-




This article reports on the start-up and key elements of the DMTR. The DMTR is 
unique in its collaboration between all stakeholders involved in treating metastatic 
melanoma, and its multipurpose design. The active participation of the 14 dedicated 
melanoma centres led to the nationwide coverage of all patients with meta-static 
melanoma in the registry within the first year.
The results of the DMTR demonstrate that treatment with BRAF inhibitors and 
ipilimumab has been implemented as standard of care in the Netherlands. Moni-
toring these drugs in population-based registries is therefore highly relevant to the 
assessment of the extent to which results from clinical trials are achieved in clinical 
practice [19].
The first Dutch population-based registry in outcome research for cancer patients 
was PHAROS. This haematological registry started in 2010 and was created to serve 
multiple purposes, including evaluating the quality of care of three haematologic 
malignancies in daily practice and determining the clinical and cost-effectiveness of 
treatments used [20].
However, population-based registries are scarce in the field of metastatic melanoma. 
Existing registries generally have a retrospective design and do not have a nationwide 
coverage [21]. More importantly, these registries do not include information on 
patients treated with the new drugs; the reported results are, therefore, not applicable 
to current management of advanced melanoma [22].
Data from the DMTR demonstrates that BRAF inhibitors and ipilimumab have been 
safely introduced in the Netherlands. The toxicity rates were comparable with the 
results in clinical trials [5-8], although a relatively great number of patients registered 
in the DMTR have brain metastases and/or a poor performance status. These patients 
would have been ineligible for trial inclusion. Only one death was reported, due to an 
adverse event contributed to ipilimumab. This may indicate that adequate manage-
ment of adverse events in specialised melanoma centres with experience in the treat-
ment of patients with advanced melanoma can prevent life-threatening situations in 
daily practice. BRAF inhibitors and ipilimumab show a survival benefit compared 
with classic cytotoxic treatment [23,24]. In this study, the 12-month survival rate 
already improved during the second year of registration. This could be the effect 
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of the approval of ipilimumab as a first-line therapy and a large number of patients 
participating in clinical trials with an anti-PD1 antibody. With the rapid develop-
ment of new drugs and the combination of drugs [25,26], we expect the survival of 
metastatic melanoma patients to improve.
Real-time feedback and transparency are essential to evaluating and anticipating the 
rapid advances in met-astatic melanoma treatment, but existing quality initiatives 
concerning melanoma care have mainly focused on surgical treatment [11,27]. The 
DMTR provides clinicians with benchmarked feedback with detailed information on 
both systemically and non-systemically treated patients. It has further agreed to make 
the results gradually publicly available to provide transparency to all stakeholders 
concerned. For instance, the funnel plots on toxicity rates of the new drugs increase 
awareness regarding safety issues in clinical practice. Although no melanoma centre 
performed significantly worse, the positive outlier (best practice) indicates areas for 
improvement.
Furthermore, the DMTR may provide information on optimal sequencing of various 
types of treatment in a real-world setting compared with phase III trials that only 
report on the investigational drug. This knowledge in combination with data on clini-
cal effectiveness, quality of life, healthcare utilisation, informal care and productivity 
losses will be used to develop an advanced melanoma disease model. This may pro-
vide insight into real-world cost-effectiveness of treatments and treatment patterns, 
which is increasingly important to ensure the sustainability of the healthcare system. 
Effectiveness studies are important to both patients and healthcare providers as they 
determine whether interventions work in the real world, and therefore inform both 
clinical decision-making and health policy [20].
The DMTR also has its limitations. Population-based registers are generally more 
prone to registration bias because data are often self-reported and no standardised 
and uniform criteria are formulated as in clinical trials. This may have led unin-
tentionally to adverse events being less strictly categorised. However, because of the 
prospective nature of the DMTR’s long-term follow-up, patient records are updated 
every 3 months. To ensure high-quality data, data managers were extensively trained 
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and oncologists supervise the registration process and validate all data at patient 
level.
The multipurpose design makes the DMTR an extensive registry raising concerns 
on the financial and administrative burden and its sustainability in the future. The 
rough cost per patient in the DMTR is approximately V500, based on an average 
of 8 hours of registration per patient record, including data-entry (majority of the 
costs), validation, data-analyses, reporting and training of the data managers. This 
is a considerable amount; however, in comparison with the price of the drugs per 
patient, it is not more than 0.5e1% of the total costs per treated patient. Probably, 
this is an overestimation because costs of hospital resource use and informal care 
are not even included. It will be important to decision-makers whether securing a 
small percentage of the total treatment budget for obtaining quality information is 
acceptable.
Of course it is important to try to reduce the costs of the data registration. In the 
near future, the DMTR needs to discuss which items are essential to be collected 
on every patient and which items should be additional; for example, for evaluating 
cost-effectiveness.
Furthermore, integration with the electronic health record as well as data-linkage 
with existing sources and registries could reduce the administrative and financial 
burden even further.
To our knowledge, the DMTR is the first comprehensive population-based registry in 
advanced melanoma, since BRAF inhibitors and immune checkpoint inhibitors were 
introduced. The quality performance indicators demonstrated the safe introduction 
of the new drugs in the Netherlands with toxicity rates that were consistent with 
the phase III trials conducted. Bearing in mind the increasing number of expensive 
drugs for cancer coming on to the market, the unique design of the DMTR and the 
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The aim of this population-based study was to identify the factors associated with 
clinical outcomes in vemurafenib-treated patients and to evaluate outcomes across 
subgroups of patients with different risk profiles. Data were retrieved from the Dutch 
Melanoma Treatment Registry. Time to next treatment (TTNT) and overall survival 
(OS) of all metastatic melanoma patients who received vemurafenib between 2012 
and 2015 were assessed using Kaplan–Meier estimates. A risk score was developed 
on the basis of all prognostic factors associated with TTNT and OS derived from 
multivariable Cox regression analyses. Patients were stratified according to the pres-
ence of prognostic risk factors by counting the number of factors, ranging from 0 
to 6. A total of 626 patients received vemurafenib with a median follow-up of 35.8 
months. The median TTNT and OS were 4.7 months [95% confidence intervals (CI): 
4.4–5.1] and 7.3 months (95%CI: 6.6–8.0). The strongest prognostic factors were 
serum lactate dehydrogenase (LDH) level, Eastern Cooperative Oncology Group 
performance score, number of organ sites involved and brain metastases. Patients 
with a favourable risk profile (no risk factors) had a median TTNT and OS of 7.1 
(95%CI: 5.8–8.5) and 15.4 months (95%CI: 10.0–20.9). The median OS more than 
halved for patients with greater than or equal to 2 risk factors compared with patients 
with no risk factors. The clinical outcomes of vemurafenib in metastatic melanoma 
patients with a favourable risk profile are comparable with the results of the trials. 
Combining prognostic factors into a risk score could be valuable to stratify patients 




With the introduction of targeted therapies and immune checkpoint inhibitors, the 
treatment of metastatic melanoma has been revolutionized [1–6]. The BRIM-3 study 
showed an improved progression-free and overall survival (OS) of the BRAF inhibi-
tor vemurafenib compared with standard chemotherapy in BRAF-mutant metastatic 
melanoma [1]. Vemurafenib was the first targeted therapy for metastatic melanoma 
to be approved by the European Medicines Agency in 2012 [7]. Since then, vemu-
rafenib has increasingly been used in patients with poor prognostic factors as it can 
induce rapid antitumour response and symptom relief [8].
Patients with poor prognostic factors, such as an Eastern Cooperative Oncology 
Group (ECOG) performance status (PS) of greater than or equal to 2 and/or symp-
tomatic brain metastases, represent a significant group in real-world clinical practice 
[9,10], but were excluded from the pivotal trial [1]. Several open-label studies of ve-
murafenib in metastatic melanoma showed that an ECOG PS greater than or equal to 
2, presence of brain metastases and an elevated lactate dehydrogenase (LDH) serum 
level are among the strongest predictors of impaired outcomes [11,12]. However, 
there is little evidence on the association of these factors on clinical outcomes in real-
world daily practice. Most open-label studies excluded patients with symptomatic 
brain metastases [11,12] representing over 10% of systemically treated metastatic 
melanoma patients [13]. Second, the prognostic relevance of combining risk factors 
has not yet been studied. It is therefore very important to know to what extent the 
results achieved in the pivotal trials and open-label studies can be extrapolated to 
real-world melanoma patients treated with vemurafenib.
Furthermore, reliable real-world outcome data of vemurafenib could function as a 
valuable benchmark for future population-based outcome studies of metastatic mela-
noma patients treated with the more recently registered drugs, such as concurrent 
treatment with a MEK and BRAF inhibitor [5], monotherapy or combination therapy 
with immune checkpoint inhibitors targeting anti-PD1 and/or anti-CTLA-4 [3,6,14].
Therefore, the aim of this population-based study is to identify the prognostic factors 
associated with clinical out-comes in BRAF-mutant metastatic melanoma patients 
in real-world clinical practice in The Netherlands. Second, we assessed differences 





data: the dutch melanoma treatment registry
Data were retrieved from the Dutch Melanoma Treatment Registry (DMTR), a 
population-based registry that was set up to monitor the safety and effectiveness of 
the new drugs in real-world clinical practice and to assess the quality of melanoma 
care in The Netherlands. The DMTR registers information on baseline patient and 
tumour characteristics, treatments, treatment-related adverse events (grade 3 or 4 
according to the common terminology criteria for adverse events, version 4) and 
clinical outcomes of all Dutch patients with unresectable stage IIIc or IV melanoma. 
A detailed description of the set-up of the DMTR has been published previously [13].
In compliance with Dutch regulations, the DMTR was approved by the medical 
ethical committee and was not subject to the Medical Research Involving Human 
Subjects Act.
patients
All patients with BRAF-mutant unresectable or meta-static (stage IIIc or stage IV) 
cutaneous melanoma or with a BRAF-mutant melanoma of unknown primary in 
The Netherlands who received vemurafenib (monotherapy) between 1 July 2012 and 
30 June 2015 were included (follow-up data cut-off was 20 November 2016).
statistical analysis
Descriptive statistics were used to describe the baseline characteristics at the start 
of vemurafenib treatment. The median time to next treatment (TTNT) and OS with 
the corresponding two-sided 95% confidence intervals (CI) were analyzed using 
the Kaplan–Meier method. TTNT is a commonly used measure to assess treat-
ment effectiveness in real-world studies [15] and was determined from the start of 
vemurafenib to the start of subsequent systemic therapy or death from any cause. 
The median OS was defined as the time from the start of vemurafenib to the date of 
death from any cause. Follow-up time was calculated using the inverse Kaplan–Meier 
method [16]. TTNT and OS were compared between subgroups using log-rank tests 
for categorical variables and a univariate Cox proportional hazard regression for 
continuous variables. Subgroups of patients were stratified according to sex, baseline 
ECOG PS (0, 1, and ≥ 2), baseline LDH level [ < 1 × above the upper limit of normal 
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(ULN) range of 250 U/l, 1–2 × ULN, ≥ 2 × ULN], metastatic stage at baseline (M1a, 
M1b, and M1c), type of BRAF mutation (V600E, V600K or other), number of organ 
sites involved at baseline counted as any organ with at least one metastasis (< 3 vs. ≥ 
3) and brain metastases at baseline (absent, asymptomatic, or symptomatic). Age was 
analyzed as a continuous variable.
A backward stepwise multivariable Cox regression analysis was used to identify the 
baseline prognostic factors associated significantly with OS and TTNT. All factors of 
the above-mentioned subgroups were entered in the model. Variables with a P value 
greater than 0.05 were removed from the stepwise model.
A clinical risk score was developed by counting the four prognostic factors of the 
Cox regression analysis: ECOG PS 0, LDH less than 1 × ULN, no brain metastases 
and less than 3 organ sites involved counted as 0; ECOG PS 1, LDH 1–2 × ULN and 
brain metastases counted as 1; and ECOG PS 2 and LDH greater than or equal to 2 
× ULN counted as 2. Patients were stratified according to the presence of prognostic 
risk factors, ranging from 0 to 6.
Missing data were imputed for the Cox regression analyses using multiple impu-
tations by chained equations. To stabilize the results, 10 imputed data sets were 
produced [17].
All statistical analyses were carried out in PASW Statistics version 20 (SPSS Inc., 
Chicago, Illinois, USA).
results
patient and treatment characteristics
A total of 626 patients with unresectable stage IIIc or IV BRAF-mutant melanoma 
received vemurafenib from 1 July 2012 until 30 June 2015. The median follow-up 
was 35.8 months (95%CI: 32–39.5). Most patients had M1c disease (83%), almost 
one-fifth of patients had an ECOG PS of greater than or equal to 2 (19%) and 19% 
had symptomatic brain metastases (Table 1). In total, 42% of patients had an elevated 
serum LDH level. The imputed baseline characteristics were comparable with the 
observed baseline characteristics (Supplementary Table S1).
Most patients (n = 506; 81%) were treatment naïve. Almost one-fifth received 
previous systemic therapy (19%), including ipilimumab (6%), chemotherapy (3%), 
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table 1. Baseline characteristics of all consecutive patients diagnosed with irresectable melanoma in 
The Netherlands between July 2012- and July 2015 (n=626) at start of treatment with vemurafenib.
N (%)
Median age (range), years 59 (23-90)
Age group














≥1 to <2 x ULN 125 (20)
≥2 x ULN 138 (22)
Unknown 20 (3)
Disease stage
















dabrafenib (2%), vemurafenib (1%), therapy within a trial (1%) or multiple regimens 
(7%) (Table 1). At the time of analysis, 95% patients discontinued treatment with 
vemurafenib, mostly because of disease progression (n = 362; 58%). Other reasons 
were adverse events (17%), death (8%), preference of the patient (4%), planned in 
advance (4%) and unknown (10%). Of those who discontinued treatment, 254 (41%) 
patients received subsequent therapy, including ipilimumab (20%), dabrafenib (9%), 
anti-PD1 (7%), combination therapy of BRAF and MEK inhibitor (2%), chemo-
therapy (2%) and retreatment with vemurafenib (1%).
survival outcomes
The median TTNT and OS were 4.7 months (95%CI: 4.4–5.1) and 7.3 months 
(95%CI: 6.6–8.0), respectively. Survival rates at 1 and 2 years were 32% (95%CI: 
28–35) and 15% (95%CI: 12–18), respectively (Figure 1a and b, Table 2). Table 2 
shows the median TTNT, OS and 1-year and 2-year survival rates of the subgroup 
analyses. Patients with an ECOG PS of greater than or equal to 2 had the lowest 
table 1. Baseline characteristics of all consecutive patients diagnosed with irresectable melanoma in 









Treatment naive 506 (81)
Previously treated 120 (19)
Median time from advanced melanoma diagnosis to start of 
vemurafenib (IQR), months
1.4 (0.8-2.8)
Treatment naive 1.2 (0.7-2.1)
Previously treatedc 6.8 (3.1-12.4)
ECOG PS = Eastern Cooperative Oncology Group performance status; IQR = interquartile range; 
LDH= lactate dehydrogenase, ULN=upper limit of normal.
a ULN is defined at 250 U/L
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































median TTNT and OS (3.5 and 4.1 months, respectively) as well as patients with 
LDH level greater than or equal to 2 × ULN (3.7 and 4.4 months, respectively). The 
1-year survival rates were also the lowest in these subgroups of patients. The 1-year 
survival rate of patients with asymptomatic brain metastases was comparable with 
that of patients without brain metastases, but decreased considerably to a 2-year 
survival rate of 5% compared with a 2-year survival rate of 18% for patients without 
brain metastases. The median OS of patients with previous systemic therapy was not 
significantly different compared with treatment-naive patients (6.6 months 95%CI: 
4.8–8.4 vs. 7.4 months 95%CI: 6.6–8.2, respectively).
Multivariable Cox regression shows that ECOG PS, LDH level and the number of 
organ sites involved were associated significantly with TTNT and survival (Table 
3). The presence of brain metastases was only significantly associated with survival.
table 3. Multivariable Cox regression analysis of baseline factors associated with overall survival and 
time to next treatment in patients treated with of vemurafenib
Covariate
OS TTNT
HR (95% CI)a P HR (95% CI)a P
ECOG PS
0 reference reference
1 1.5 (1.2-1.8) <0.001 1.1 (0.9-1.3) 0.304
≥2 2.0 (1.5-2.6) <0.001 1.7 (1.3-2.1) <0.001
LDH category
<ULN reference reference
≥1 to <2 x ULN 1.6 (1.3-2.0) <0.001 1.7 (1.3-2.1) <0.001
≥2 x ULN 2.2 (1.8-2.8) <0.001 1.8 (1.4-2.2) <0.001
Brain metastases
No reference -
Asymptomatic 1.2 (0.9-1.6) 0.27 - -
Symptomatic 1.5 (1.2-1.8) <0.001 - -
Number of organ sites
< 3 reference reference
≥3 1.5 (1.2-1.8) <0.001 1.4 (1.2-1.6) <0.001
ECOG PS = Eastern Cooperative Oncology Group performance status; HR = hazard ratio; LDH = 
lactate dehydrogenase; OS = overall survival; TTNT= time to next treatment







figure 2. Kaplan-Meier curves of time to next treatment (a) and overall survival (b) according to the 
number of risk factors at baseline. CI = confidence interval; TTNT = time to next treatment .
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A risk score was created with all factors from the multi-variable cox regression, 
ranging from 0 to 6 factors. Patients with five or six risk factors were merged as only 
seven patients had six risk factors. Patients with a favourable risk profile (no risk 
factors; n = 50) had a median TTNT and OS of 7.1 and 15.4 months, respectively 
(Figure 2a and b). The median TTNT almost halved for patients with four risk factors 
compared with patients with no risk factors. The median OS decreased considerably 
for patients with three risk factors compared with patients without any risk factors 
(5.1 vs. 17.0 months). Patients with five or six risk factors (n = 56) had the lowest 
median TTNT and OS of 3.4 and 4.1 months, respectively.
discussion
This study shows that ECOG PS, LDH level and number of organ sites involved were 
the prognostic factors associated most strongly with TTNT and OS in BRAF-mutant 
metastatic melanoma patients treated with vemurafenib in real-world clinical prac-
tice. We also showed that combining prognostic factors into a clinical risk score 
could be useful to stratify patients into favourable or poor-prognosis groups.
The median OS in Dutch clinical practice was lower than that reported in the phase 
III BRIM-3 trial of vemurafenib (7.3 vs. 13.6 months, respectively) [1]. This is most 
likely because of the relatively large number of patients with less favourable prognos-
tic factors in our population-based study. Over one-third of our study population 
would have been ineligible for phase III trial enrolment because of symptomatic 
brain metastases and/or an ECOG PS greater than or equal to 2. Even in the safety 
study of vemurafenib [11], a lower rate of ECOG PS of greater than or equal to 2 was 
reported (10 vs. 19% in our study) and patients with symptomatic brain metastases 
were excluded. The multivariable Cox regression analysis confirmed that both factors 
impaired survival significantly.
On the basis of the results of our subgroup analyses, the median OS for patients with 
an ECOG PS greater than or equal to 2 appears to be comparable with survival data 
reported in the safety study (4.1 vs. 4.9 months, respectively [18]). Similar results 
were observed for patients with symptomatic brain metastases (5.4 months in our 
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study vs. 5.1 months in the open-label pilot study of patients with symptomatic brain 
metastases treated with vemurafenib [19]). Compared with the historic series with 
an estimated median OS of 2.1 months for patients with brain metastases [20], our 
study may indicate a benefit of targeted therapy in this subgroup.
Consistent with previous results [11,12], a baseline LDH level of greater than or equal 
to 2 ULN was an important independent predictor of inferior survival (hazard ratio: 
2.2). Although long-term outcomes remain poor, it is known that targeted therapies 
are capable of inducing rapid antitumour responses and might be more effective in 
this subgroup compared with immunotherapy [21]. Previous studies on immuno-
therapies in metastatic melanoma confirmed that benefit was unlikely, reporting a 
median OS of 2.3 after ipilimumab therapy for patients with an LDH level of greater 
than or equal to 2 ULN [21] and 2.9 months after anti-PD1 therapy for patients with 
an LDH level of greater than or equal to 2.5 ULN [22]. Although a direct comparison 
of outcomes is not possible between studies, our results may indicate more activity 
of targeted therapy in this patient group. Findings from a pooled analysis of trials of 
concurrent treatment with a MEK and BRAF inhibitor showed even more promising 
results for this subgroup of patients with a median OS of 8.8 months [23].
Combining the risk factors instead of assessing them separately could be useful to 
stratify patients into favourable or poor-prognosis groups and may support clinical-
decision making. The median TTNT and OS of 7.1 and 15.4 months in patients 
with a favourable risk profile (no risk factors) could indicate that durable benefit is 
possible with vemurafenib in well-defined patient subgroups. However, the majority 
of patients had one or more risk factors, with almost 70% of patients having multiple 
risk factors (≥2). The poor outcomes in patients with an unfavourable risk profile (≥3 
risk factors; median OS of <5 months) underline the unmet medical need for patients 
with multiple risk factors treated with vemurafenib monotherapy. In recent years, 
concurrent treatment with a MEK and BRAF inhibitor has become the standard of 
care for BRAF-mutant metastatic melanoma patients, including for patients with 
poor prognostic factors. It will be important to assess whether the superior efficacy 
achieved in the trials of combined targeted therapies [5,24] may also be achieved in 
these high-risk groups in daily practice.
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This population-based study has some limitations. Registries are generally more 
prone to missing data compared with clinical trials. The clinical risk score could not 
be calculated for 23% of patients because data were missing on one or more of the 
selected risk factors. However, reliable survival data could still be analyzed because of 
the large sample size and long follow-up. Furthermore, data managers were trained 
extensively and medical oncologists supervise the registration process to ensure 
high-quality data [13]. This study only focused on the clinical outcomes TTNT and 
OS. As vemurafenib is commonly used for symptom relief in unfit patients with a 
high disease load, the emphasis is predominantly on improving the quality of life. 
The DMTR is currently collecting quality of life data and we are planning to as-
sess the overall benefit of vemurafenib treatment, especially in patients with poor 
prognostic factors.
conclusion
In conclusion, our results show that the clinical outcomes of vemurafenib in BRAF-
mutant metastatic melanoma patients with a favourable risk profile are comparable 
with the pivotal trials. However, our results also emphasize that trial results are not 
generalizable to a more heterogeneous patient population in daily practice as the 
majority of patients have a less favourable risk profile. Real-world data from clinical 
practice complement the knowledge on clinical outcomes in high-risk metastatic 
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supplementary table 1. Imputed baseline characteristics of patients treated with vemurafenib
Real-world data N= 626
N (%)
Imputed data N= 626
N (%)
Median age (range), years 59 (23-90) 59 (23-90)
Age group
< 50 159 (25) 159 (25)
50-59 157 (25) 157 (25)
60-69 177 (28) 177 (28)
≥70 133 (21) 133 (21)
Sex
Male 349 (56) 349 (56)
Female 277 (44) 277 (44)
ECOG PS
0 223 (40) 248 (40)
1 218 (39) 244 (39)
≥2 118 (21) 134 (21)
Unknown 67 (11)
LDH categorya
<ULN 343 (57) 347 (55)
≥ULN 263 (43) 279 (45)
≥1 to <2 x ULN 125 (21) 130 (21)
≥2 x ULN 138 (23) 149 (24)
Unknown 20 (3)
Disease stage
Stage IIIc 12 (2) 12 (2)
M1a 34 (6) 35 (6)
M1b 36 (6) 37 (6)
M1c 522 (86) 542 (87)
Unknown M stage 22 (3)
Number of organ sitesb
<3 215 (39) 238 (37)




supplementary table 1. Imputed baseline characteristics of patients treated with vemurafenib 
(continued)
Real-world data N= 626
N (%)
Imputed data N= 626
N (%)
Brain metastases
No 406 (70) 437 (70)
Asymptomatic 58 (10) 62 (10)
Symptomatic 119 (20) 127 (20)
Unknown 43 (7)
Previous systemic therapy
Treatment naive 506 (81) 506 (81)
Previously treated 120 (19) 120 (19)
yrs=years; PS = performance score; LDH= lactate dehydrogenase, ULN=upper limit of normal.
a ULN is defined at 250 U/L
b Patients with stage IV disease (N=614)

5 Early switching of targeted therapy to immunotherapy; the road to long-term 
survival in LDH elevated advanced 
melanoma patients?
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Background: The clinical outcomes of advanced BRAF-mutant melanoma patients 
with elevated serum lactate dehydrogenase (LDH) remain very poor. The aim was to 
explore whether patients with normalized LDH after targeted therapy could benefit 
from subsequent immunotherapy.
Methods: Data from all BRAF-mutant metastatic melanoma patients with an initial 
elevated serum LDH (≥ 2x above the upper limit of normal) receiving first-line 
targeted therapy between 2012 and 2017 in The Netherlands were prospectively col-
lected. Patients were stratified according to response status to targeted therapy and 
change of LDH at start of subsequent immunotherapy. Differences in overall survival 
(OS) between the subgroups were compared using log-rank tests.
Results: After a median follow-up of 22.1 months, median OS of the total study 
population (N=270) was 4.7 months (95% CI 4.3– 5.1). Of all patients receiving sub-
sequent immunotherapy (N=65), survival from start of subsequent immunotherapy 
was significantly longer in patients who had normalized LDH and were still respond-
ing to targeted therapy compared to those with LDH that remained elevated (median 
OS not reached vs 0.9 months).
Conclusions: Introducing immunotherapy upon response to targeted therapy with 
normalization of LDH could be an effective strategy in obtaining long-term survival 




Multiple effective systemic treatment options have emerged for patients with 
advanced BRAF-mutant melanoma over the last decade. Since the approval of the 
BRAF inhibitor vemurafenib [1] and the CTLA-4 antibody ipilimumab [2], combi-
nation therapy with a BRAF and MEK inhibitor [3] and treatment with anti-PD-1 
antibodies as monotherapy [4] [5] or combined with a CTLA-4 antibody [6] have 
broadened the therapeutic arsenal for these patients. Combination therapy with a 
BRAF and MEK inhibitor has resulted in a median overall survival of over 2 years 
[7], while treatment with anti-PD-1 also concurrently showed significant improve-
ments with 2-year survival rates of 55-58% [8]. Although long-term survival may be 
achieved in a subgroup of patients, there is still an unmet medical need for patients 
with unfavourable prognostic factors [9][7]. Elevated serum lactate dehydrogenase 
(LDH) level is a well-known marker for poor outcome and a strong negative predic-
tor for response to immunotherapy and targeted therapy [7][8]. In previous reports 
substantially less activity was demonstrated in patients with elevated serum LDH of 
≥2x upper limit of normal (ULN), with a median OS of 2.9 months after ipilimumab 
therapy [9] and 2.3 months after anti-PD1 therapy [10] compared to 14.7 months 
and 16.1 months for patients with normal LDH, respectively. Similarly, LDH has 
been shown to be one of the key predictors of survival for patients receiving targeted 
therapy [11]. Although the majority of BRAF mutant patients with elevated serum 
LDH respond to targeted therapy, responses are usually short-lived, with median 
progression-free survival shorter than 6 months for patients with LDH ≥2xULN 
compared to 17 months for the patients with normal LDH [7].
Targeted therapies are capable of inducing rapid anti-tumour responses associated 
with a decrease in LDH [7], which might enable immunotherapy to work more 
efficiently in patients with initial elevated serum LDH. Furthermore, BRAF and 
MEK-inhibition could facilitate immune responses in multiple ways. Preclinical data 
showed an increase in CD8+ T-cell recognition of tumour cells by inducing rapid up-
regulation of MHC class I surface expression in BRAF-mutant melanoma cells [12] 
[13]. These data support the potential of BRAF-inhibition to increase response rates 
to immunotherapy. Although this concept seems promising, clinical data supporting 
the approach of BRAF inhibitor induction treatment preceding immunotherapy in 
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patients with aggressive disease are lacking and little is known about which patients 
could benefit from induction treatment.
This prospective population-based study focuses on the clinical outcomes of BRAF 
mutant metastatic melanoma patients with baseline serum LDH of ≥2x ULN treated 
with first-line targeted therapy. The main objective of the study was to investigate 
whether the level of LDH and response status at the switch to immunotherapy was 
associated with survival.
methods
data: the dutch melanoma treatment registry (dmtr)
Data was retrieved from the Dutch Melanoma Treatment Registry (DMTR), a 
prospective population-based registry that was set-up to monitor the safety and 
effectiveness of the new drugs in real-world clinical practice and to assess the 
quality of melanoma care in the Netherlands. The DMTR contains information on 
baseline patient and tumour characteristics, local and systemic treatment modalities, 
treatment-related adverse events (grade 3 or 4 according to common terminology 
criteria for adverse events (CTCAE) version 4) and clinical outcomes of all patients 
with unresectable stage IIIc or IV melanoma. A detailed description of the DMTR 
was published previously [14].
In compliance with Dutch regulations, the DMTR was approved by the medical 
ethical committee and was not subject to the Medical Research Involving Human 
Subjects Act. Patients were offered an opt-out option.
patients
All patients with BRAF-mutant unresectable or metastatic (stage IIIC or stage IV) 
cutaneous melanoma or with a BRAF-mutant melanoma of unknown primary with 
a baseline serum LDH of ≥2x above the upper limit of normal (ULN) who received 
targeted therapy (either monotherapy with a BRAF inhibitor or combination therapy 
with BRAF and MEK inhibitors) between July 1st 2012 and June 30th 2017 were in-
cluded (follow-up data cut-off was November 5th 2017). The ULN was defined at 250 
U/L. Patients with prior systemic treatment for metastasized disease were excluded 




Time to next treatment (TTNT) and overall survival (OS) with corresponding two-
sided 95% confidence intervals (CI) for medians were analysed using the Kaplan-
Meier method. For the overall study population, TTNT was determined from the 
start of targeted therapy to the start of subsequent systemic therapy or death from 
any cause. Patients who were still on treatment were censored at time of analysis. OS 
was defined as the time from start of targeted therapy to the date of death from any 
cause. Patients alive at time of analysis were censored. Follow-up time was calculated 
from start date of targeted therapy using the inverse Kaplan-Meier method [15].
The main objective of the study was to investigate whether the response to targeted 
therapy and level of serum LDH at start of subsequent immunotherapy affects sur-
vival. For this analysis, OS was defined from start of subsequent immunotherapy to 
the date of death from any cause. Patients were stratified according to LDH at start 
of subsequent immunotherapy (< ULN, >1 to < 2x ULN, ≥2x ULN) and tumour 
response after treatment of targeted therapy according to Response Evaluation 
Criteria in Solid Tumors (RECIST). OS was compared between the subgroups using 
log-rank tests. Multivariable Cox proportional hazard model was applied to iden-
tify prognostic factors at start of subsequent immunotherapy associated with OS. 
Backward stepwise selection was performed to eliminate non-influential variables 
from the multivariable model. The following factors at start of immunotherapy were 
entered in the model: gender, age, ECOG PS (0,1 and ≥2), serum LDH (<1x ULN, 
1-2x ULN, ≥2x ULN), number of organ sites involved counted as any organ with at 
least one metastasis (<3 vs ≥ 3), brain metastases (no brain metastases, asymptom-
atic, symptomatic), RECIST response on targeted therapy. Statistical significance was 
defined as a two-sided p value <0.05.




A total of 4043 unresectable stage IIIC or IV melanoma patients were registered in 
the DMTR between July 1st 2012 and June 30th 2017 (Supplemental Figure 1). Of 
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table 1. Patient and treatment characteristics of study population
N=270
(%)














Median baseline LDH (IQR) 815 (613-1396)









Type of targeted therapy
BRAFi monotherapy 205 (76)
BRAFi + MEKi 65 (24)
Type of subsequent immunotherapy
Ipilimumab 23 (9)
Anti-PD1 29 (11)
Ipilimumab & nivolumab 14 (5)
IQR = interquartile range; ECOG PS = Eastern Cooperative Oncology Group performance status; 
BRAFi = BRAF-inhibitor; MEKi= MEK inhibitor
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these, 270 BRAF-mutant advanced melanoma patients with a baseline serum LDH of 
≥2x ULN received first-line targeted therapy and were included for analyses. Baseline 
characteristics are shown in Table 1. The median age was 60 years and the majority of 
patients were male (60%). Median serum LDH was 815 U/L (IQR 613-1396). Thirty 
seven percent of patients had an ECOG PS of ≥2 and most patients had ≥3 organ 
sites involved (72%). The majority of patients received BRAF monotherapy (76%). 
BRAF monotherapy was administered up to August 2016. Combination therapy with 
a BRAF- and MEK inhibitor was increasingly being used since October 2015 and was 
the only administered therapy in 2017. Median follow-up was 22.1 months (95% CI 
14.8- 29.5) and 228 patients (84%) died during follow-up. At time of analysis, 93% 
of patients discontinued treatment with targeted therapy, due to disease progression 
(63%), toxicity (10%) and death (10%), planned in advance (7%), patient’s choice 
(2%), other (4%) and unknown (4%).
Median OS was 4.7 months (95% CI 4.3– 5.1) (Figure 1). Survival rates at 6 months 
and 1 year were 37% (95%CI 31-43) and 12% (95% CI 8-16), respectively.
figure 1. Overall survival of study population.
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table 2. Patient and treatment characteristics at start of subsequent immunotherapy
N=65 (%)























Type of targeted therapy
BRAFi monotherapy 41 (63)
BRAFi + MEKi 24 (37)
Serum LDH
<ULN 19 (29)
≥1 to <2 x ULN 27 (42)
≥2 x ULN 19 (29)
Response on targeted therapy
Partial response 7 (11)
Stable disease 6 (9)
Progressive disease 52 (80)
ECOG PS = Eastern Cooperative Oncology Group performance status; BRAFi = BRAF-inhibitor; 
MEKi= MEK inhibitor. LDH= lactate dehydrogenase, ULN=upper limit of normal.
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patients with subsequent immunotherapy
A total of 65 patients (24%) received subsequent immunotherapy. Anti-PD1 (44%) 
was most often administered, followed by ipilimumab (35%) and a combination 
of ipilimumab & nivolumab (21%). Baseline characteristics at start of subsequent 
immunotherapy are shown in Table 2. Median follow up from start of subsequent 
immunotherapy was 15.0 months (95% CI 5.7- 24.4).
Outcomes were stratified according to LDH at start of subsequent immunotherapy 
and tumour response after targeted therapy. Table 3 shows the median OS and 
6-months survival rates, calculated from start of subsequent immunotherapy.
Patients with a normalized LDH who had a partial response to targeted therapy 
(BRAF monotherapy: n=5, combination therapy with BRAF and MEK inhibitor: 
n=1) had the best survival from start of immunotherapy (median OS and 6-months 
survival rate not reached). These patients had an original LDH level at start of tar-
geted therapy between 541- 690 U/L. Median duration of targeted therapy before 
switching to immunotherapy was 2.4 months (95%CI 2.2-2.7).
All patients who had an elevated LDH at start of immunotherapy had progressed on 
targeted therapy (n=44). Median duration of targeted therapy before switching to 
table 3. Kaplan-Meier estimates of time to next treatment, median overall survival, and 6 months 
survival rates at start of subsequent immunotherapy, according to serum LDH at start of subsequent 









6 mo survival rate
(95% CI), %
<ULN
PR 0/6 NR NR
SD 4/5 8.8 (0-20.9) 60 (17-100)
PD 7/8 4.4 (2.4-6.3) 29 (0-62)
≥1 to <2x LNa
PD 19/25 2.7 (1.9-3.6) 22 (5-39)
≥2 x ULN
PD 16/19 0.9 (0.3-1.7) 17 (0-34)
LDH= lactate dehydrogenase, ULN=upper limit of normal, IT = immunotherapy, TTNT = time to 
next treatment, OS = overall survival, mo = months, NR = not reached, PR = partial response, SD = 
stable disease, PD = progressive disease.
a Due to low numbers of patients with stable disease (N=1) and partial response (N=1) in this sub-
group, these patients were excluded from analyses
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immunotherapy was 5.8 months (95%CI 4.7-6.9). Patients who started second-line 
immunotherapy with LDH ≥2x ULN had the worst outcomes with a median OS of 
0.9 months (95%CI 0.3-1.7) and 6-months survival rate of 17% (95%CI 0-34). The 
survival curves demonstrate significant survival differences between the normalized 
LDH group with partial response compared to the other subgroups (Figure 2).
After backward multivariable selection, only LDH at start of second-line immuno-
therapy and response to targeted therapy retained in the final model (Table 4). In 
particular, normal LDH was significantly associated with survival (HR 0.38 95%CI 
0.16-0.94). No significant differences were found between characteristics at start of 
second-line immunotherapy according to response status to immunotherapy (data 
not shown).
figure 2. Kaplan Meier curves of overall survival at start of subsequent immunotherapy, according 




These real-world data support previous reports of the poor prognosis of advanced 
melanoma patients with elevated serum LDH. At the same time, these data provide 
a potential strategy to improve clinical outcomes. In our cohort of metastatic mela-
noma patients with baseline serum LDH of ≥ 2x ULN treated with first-line BRAF(/
MEK) inhibitors, median OS was significantly longer in patients who started second-
line immunotherapy with normalized LDH and still responding to initial targeted 
therapy compared to those with elevated LDH at start of immunotherapy. Our data 
suggest that introducing immunotherapy upon response to targeted therapy with 
normalization of LDH could be an effective strategy in obtaining long-term survival 
in patients with initial elevated serum LDH.
The median OS of 4.7 months of the overall study population confirms previous 
data that clinical outcomes remain poor in this subgroup of patients [9] [10] [16]. 
Patients who received subsequent immunotherapy with LDH ≥ 2x ULN at start of 
immunotherapy are unlikely to benefit from immunotherapy with a median OS of 
0.9 months and a 6-months survival rate of 17%.
The exact role of LDH is not completely elucidated. It could simply be a marker of 
more aggressive disease that requires rapid anti-tumour responses [9]. The delayed 
table 4. Multivariable Cox regression analysis after backward stepwise selection associated with 
overall survival using baseline characteristics at start of immunotherapy.
OS
HR (95% CI) P
Response on targeted therapy
PR 0.24 (0.05-1.07) 0.061
SD 0.64 (0.23-1.77) 0.391
PD reference
LDH level at start of immunotherapy
<ULN 0.38 (0.16-0.94) 0.036
≥1 to <2 x ULN 0.50 (0.25-1.02) 0.058
≥2 x ULN reference
LDH= lactate dehydrogenase, ULN=upper limit of normal, IT = immunotherapy, OS = overall sur-
vival, HR = hazard ratio, PR = partial response, SD = stable disease, PD = progressive disease.
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tumour responses generally observed with immunotherapies might therefore take 
too long for these patients to benefit. Moreover, tumour metabolism is characterized 
by the conversion of pyruvate into lactate, even in the presence of sufficient oxygen. 
Preclinical data demonstrated that tumour cells producing high levels of lactic acid 
disturb the function of cytotoxic T lymphocytes, thereby negatively influencing the 
potency of an immune response [17] [18].
Interestingly, our data showed that patients who switch to immunotherapy with 
normalized LDH while still responding to targeted therapy have a real chance of 
long-term survival. After a median follow-up of 15 months, median OS was not 
reached and survival was significantly longer compared to the other subgroups. 
Moreover, targeted therapy was given as an ‘induction’ therapy with a median dura-
tion of only 2.4 months, suggesting that sequential treatment with an early switch 
to immunotherapy in this subgroup could result in durable outcomes. Although 
promising, baseline LDH values of these patients did not exceed 690 U/L (<3x ULN). 
Patients with extremely high LDH values of >3x ULN at baseline might not be good 
candidates for this strategy. It should also be noted that only a small proportion of 
patients received this treatment strategy (n=6; 2%). However, the majority of our 
study population received BRAF monotherapy as first-line targeted therapy. The 
emergence of combination therapy with a BRAF and MEK inhibitor for this subgroup 
of patients might lead to a greater proportion of patients with response to targeted 
therapy and normalisation of LDH. A 3-year follow-up pooled analysis of phase III 
trials with BRAF and MEK inhibitor combination therapy showed promising results 
with 50% partial response in patients with initial LDH ≥ 2x ULN [19].
The value of sequencing targeted therapy prior to immunotherapy in patients with 
initial elevated LDH has not been investigated thus far. Previous retrospective re-
ports revealed that normalization of LDH while on targeted therapy was a strong 
feature of ipilimumab cycle completion [20] [21]. Another report on 101 advanced 
melanoma patients with decreased serum LDH after BRAF inhibitor treatment who 
were fit enough to complete all courses of ipilimumab had a significantly longer OS 
compared to those who did not (median OS 12.7 months vs 1.2 months) [22].
The real benefit of induction treatment with combined BRAF- and MEK-inhibition 
in patients with elevated LDH is currently investigated in multiple prospective ran-
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domized trials. In the Netherlands, the phase II COWBOY study (NCT02968303) 
comparing BRAF- and MEK-inhibitor induction treatment with vemurafenib and 
cobimetinib followed by ipilimumab and nivolumab or upfront immunotherapy in 
advanced melanoma patients with elevated serum LDH is currently recruiting. An-
other trial, the EORTC EBIN study (NCT03235245), will compare ipilimumab and 
nivolumab upfront versus the same treatment preceded by induction therapy with 
encorafenib and binimetinib in advanced melanoma patients, irrespective of LDH 
level. One of the arms of the three-arm phase II SECOMBIT study (NCT02631447) 
will assess whether an induction treatment with encorafenib plus binimetinib of 8 
weeks before combination immunotherapy might help potentiate an immunothera-
peutic response. Guidelines are not conclusive on this issue and the abovementioned 
trials are currently recruiting. Our results may therefore be of added value to medical 
oncologists while awaiting these trial results.
It would be interesting to investigate survival differences between patients who 
started second-line immunotherapy with normalized LDH and response to initial 
targeted therapy vs responders who stayed on targeted therapy. The 3-year follow-
up pooled analysis of phase III trials with BRAF and MEK inhibitor combination 
therapy showed that patients with initial elevated LDH levels that normalized at 6 
months could have long-term benefit with a 3-years survival rate of 41% [19]. Unfor-
tunately, this could not be assessed with our data, as we have no information of LDH 
level during follow-up of patients who stayed on targeted therapy.
Given the observational design of this analysis, we cannot rule out confounding by 
indication or selection bias. However, its multicentre design attenuates this potential 
selection bias. Furthermore, observational studies are more susceptible to registra-
tion bias. To ensure high-quality data, data managers were extensively trained and 
supervised by oncologists [14]. Another limitation is the small number of patients 
of the subgroup analyses. The conclusions drawn need validation in prospective ran-
domized trials. Lastly, other clinical parameters such as lymphocyte counts and CRP 
level that have also been associated with patient outcome after immunotherapy were 
not registered in our database and could therefore not be included in this study [18].
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In conclusion, our population-based study suggests immunotherapy upon response 
to targeted therapy with normalization of LDH may be beneficial in this group of 
patients with generally a poor prognosis. Nevertheless, randomized trials are needed 
to assess the real benefit of sequential treatment of targeted therapy and immuno-
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Importance: Global health systems are shifting toward value-based care in an effort 
to drive better outcomes in the setting of rising health care costs. This shift requires a 
common definition of value, starting with the outcomes that matter most to patients.
Objective: The International Consortium for Health Outcomes Measurement 
(ICHOM), a non-profit initiative, was formed to define standard sets of outcomes by 
medical condition. In this article, we report the efforts of ICHOM’s working group 
in colorectal cancer.
Evidence review: The working group was composed of multidisciplinary oncol-
ogy specialists in medicine, surgery, radiation therapy, palliative care, nursing, and 
pathology, along with patient representatives. Through a modified Delphi process 
during 8 months (July 8, 2015 to February 29, 2016), ICHOM led the working group 
to a consensus on a final recommended standard set. The process was supported by a 
systematic PubMed literature review (1042 randomized clinical trials and guidelines 
from June 3, 2005, to June 3, 2015), a patient focus group (11 patients with early 
and metastatic colorectal cancer convened during a teleconference in August 2015), 
and a patient validation survey (among 276 patients with and survivors of colorectal 
cancer between October 15, 2015, and November 4, 2015).
Findings: After consolidating findings of the literature review and focus group meet-
ing, a list of 40 outcomes was presented to the WG and underwent voting. The final 
recommendation includes outcomes in the following categories: survival and disease 
control, disutility of care, degree of health, and quality of death. Selected case-mix 
factors were recommended to be collected at baseline to facilitate comparison of 
results across treatments and health care professionals.
Conclusions: A standardized set of patient-centered outcome measures to inform 
value-based health care in colorectal cancer was developed. Pilot efforts are under 




Colorectal cancer (CRC) is the third leading cancer in men and the second leading 
cancer in women globally, with 1.2 million new cases and 600 000 deaths per year [1]. 
Existing treatment options include surgery, radiation therapy, and chemotherapy, 
each with trade-offs between disease treatment and quality of life (QOL). Within 
each treatment modality, significant variation exists in the quality of care delivered 
across institutions, suggesting that there is opportunity for standardization to ensure 
high-value health care for all patients [2].
Value-based health care is a conceptual framework that is guiding global health 
system reform and will grow in importance with re-cent health care policy 
changes [3]. It is founded on the principle of mea-suringandmakingdecisionson-
theoutcomesofcarerelativetothetotal cost of care [4]. In this instance, outcomes are 
patient-centered outcomes that include not only survival but also the ability to lead 
productive lives free of the symptoms of disease or treatment. Value-based health 
care is a framework that guides internal improvement efforts and system-level poli-
cies, such as reimbursement, market transparency, and comparative effectiveness 
research [5-7]. The foundation for these efforts is a common definition of value, 
starting with outcomes.
Outcomes measurement efforts in CRC exist [8,9]. However, to our knowledge, no 
measurement initiative includes patient-reported out-comes and is accepted interna-
tionally. This lack of standardized measurement impedes a widespread attainment of 
value-based care for patients with CRC. To inform the development of value-based 
initiatives [10], the International Consortium for Health Outcomes Measurement 
(ICHOM) secured funding to develop a comprehensive patient-centered outcomes 
measurement set for this patient group.
methods
The development of a standard set was initiated by ICHOM (http: //www.ichom.org). 
ICHOM is a non-profit organization that has developed standardized sets of perti-
nent outcomes for multiple medical conditions, including cancers of the prostate 
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[11,12] and lung [13]. No institutional review board approval or informed consent 
was required for this study.
working group
ICHOM assembled a diverse team of experts (all authors except J. Lippa) and for-
mulated a working group (WG), including representatives from patient advocacy 
groups, palliative care, oncology nursing, pathology, epidemiology, and radiation, 
surgical, and medical oncology from Europe, Australia, Asia, and the United States. 
A smaller project team (PT) (J.A.Z., M.G.S., A.C.M.V., C.S., C.J.V., and R.T.) guided 
the efforts of the larger group.
development of the crc cancer standard set
The WG convened via 8 teleconferences between July 8, 2015, and February 29, 
2016, and proceeded through a structured process similar to that described for prior 
cancer standard sets [11,12,14-16]. The development of the standard set involved 
several phases, shown in detail in the eFigure in the Supplement.
development of potential outcomes list
The PT performed a structured PubMed (June 3, 2005, to June 3, 2015) literature re-
view to identify clinical and patient-reported outcomes and measures of health-related 
QOL in men and women with CRC (eTable 1). The literature review identified 1042 
randomized clinical trials and guidelines. Three individuals (including J.A.Z.) reviewed 
citations until a saturation of outcomes was observed at 310 citations. Existing CRC 
registries were also reviewed, and the WG was asked to identify pertinent sources.
An international focus group of 11 patients (including authors D.B., J. Lloyd, P.K.M., 
and K.R.) with early and metastatic CRC was convened during a teleconference in 
August 2015. Through a semi-structured interview, participants provided their input 
on patient-centered outcomes for CRC, including which outcomes mattered most 
to them or other patients with CRC, what affected them most in day-to-day activi-
ties, and during what period. They were asked about outcomes in the categories of 
survival and disease control, complications, and degree of health. Findings from the 
literature review and the focus group were used to guide and inform the content of 
the WG teleconference discussions.
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modified 2-round delphi method to prioritize outcomes and case-mix 
variables
After each teleconference, each WG member voted anonymously for inclusion or 
exclusion of each outcome or case-mix variable. A similar process was used to agree 
on outcome definitions or, in the case of patient-reported outcomes measurements 
(PROMs), the measurement tool to be recommended.
Two rounds of a modified Delphi process were conducted. As per prior outcome 
development [17-19], inclusion for all proposed out-comes and case-mix variables 
required consensus by at least 70% of the WG members rating the item as very 
important (score of 7-9 on a 9-point Likert-type scale) in either round (eTable 2 
and eTable 3). The items had to score between 7 and 9 by at least 50% to 70% in the 
second voting round to be brought to a final vote. The items were included in the 
standard set when at least 70% of WG members voted for inclusion in this final vote. 
Members of ICHOM maintained the data and conducted the surveys, but neither 
ICHOM nor its funders influenced voting.
validation of outcomes
The final list of outcomes as defined by the WG was validated in a larger group of 
patients with and survivors of CRC. Patients were recruited via several CRC patient 
organizations (Bowel Cancer Australia, Colon Cancer Alliance, Fight Colorectal 
Cancer, and the Association of Cancer Online Resources Colon Discussion List) to 
complete an anonymous online survey. Through social media recruitment, partici-
pants were asked to rate the importance of out-comes on a 9-point Likert-type scale. 
Participants had the option of including additional missing outcomes in a free-text 
box (eTables 4, 5, and 6).
prom tools selection
After finalizing the list of outcomes, the corresponding PROMs were identified. The 
PROMs’ psychometric qualities were evaluated by the PT according to the Inter-
national Society for Quality of Life Research Standards (eTable 7) [20]. A mapping 





The final standard set was presented to key stakeholders and others with an inter-
est in outcomes measurement to review the set and provide feedback via an online 
survey. They were asked to rate their confidence on a 9-point Likert-type scale on 
several elements of the set (eg, completeness of the outcomes list and implementa-
tion feasibility), with an open field for comments (eTable 9).
results
project scope
The PT defined the scope of the project as all patients with invasive, American Joint 
Committee of Cancer stage I to IV colon or rectal cancer regardless of type or intent 
of treatment received, including those who did not receive therapy. Patients undergo-
ing treatment with investigational agents were excluded because such studies have 
their own specific outcome assessments.
outcomes
After consolidating findings of the literature review and focus group meeting, a list of 
40 outcomes was presented to the WG and underwent voting (eTable 2). Outcomes 
were grouped into the following 4 categories: survival and disease control, disutility 
of care (short-term treatment complications), degree of health (QOL, functioning, 
and long-term adverse effects), and quality of death. The final 31 outcomes are listed 
in Table 1 and are discussed below. Of the 276 patients participating in the patient 
validation survey between October 15, 2015 and November 4, 2015, 223 (80.8%) 
believed that this list captured the most important outcomes and that no additional 
outcomes had to be included (eTable 6). Some respondents suggested additional 
outcomes, which are discussed below. The timeline for outcome assessment was de-
termined by the WG to achieve a balance between the clinically relevant times when 
outcomes may be expected to change and the pragmatic concerns that institutions 
and practices face in data collection (Figure 1).
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table 1 – Summary of outcomes for the ICHOM Colorectal Cancer Standard Set
Patient Population Measure Details Data Sourcesa
Survival and Disease Control




Cause of death Death attributed to 
colorectal cancer













Patients with rectal 
cancer receiving neo-
adjuvant therapy
Pathologic or clinical 
complete response
No sign of residual invasive 
cancer of resected specimen 
or on diagnostic evaluation
Patients with rectal 
cancer receiving 
surgery
Margin status Evidence of circumferential 
margin involvement
Disutility of Care

































table 1 – Summary of outcomes for the ICHOM Colorectal Cancer Standard Set (continued)
Patient Population Measure Details Data Sourcesa




Dietary issues Tracked via MSKCC Bowel 
Function - Dietary Subscale






Patients with systemic 
therapy
Neuropathy Tracked via EORTC QLQ-
LMC21- one item
Patients with surgery Presence of stoma 
(colostomy/ileostomy
If yes, report ostomy 
functioning as well via 
EORTC-QLQ-CR29




Patients with advanced 
disease
Hospital admission at 
the end of life
Admission to the hospital 
> 1 time in last 30 days of life
Clinical 
abstraction
Hospice care Hospice care at time of death Administrative 
or clinical 
abstraction
Place of death Where patient died (home, 






Preference for place 
of death
Where patient preferred 
to die




EORTC= European Organization for Research and Treatment of Cancer, MSKCC = Memorial Sloan 
Kettering Cancer Center, CTCAE= US National Cancer Institute Common Terminology Criteria for 
Adverse Events, N/A = not applicable
a The data source reflects the way outcomes are collected and was determined as clinical (e.g. physi-
cian report), patient-reported (e.g. EORTC QLQ C-30) or administrative (with a combination of 
ways in some cases)
b Collection of short-term complications is recommended whilst the patient is undergoing treatment 
or within 90 days after initiation of treatment. The type of acute complication is also to be recorded, 
specific to treatment type (surgery: leakage, breakdown of anastomosis, wound infection, thrombo-
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embolic, hematoma, stoma-related complication, incontinence; radiotherapy: skin desquamation, 
dysuria, dehydration, weight loss, neurotoxicity; chemotherapy: febrile neutropenia, neutropenic 
sepsis, mucositis; targeted therapy: skin toxicity). Full details of definitions may be found in the on-
line reference guide available at www.ichom.org/medical-conditions/colorectal-cancer
c Self care activities of daily living (ADL) refer to bathing, dressing and undressing, feeding self, using 
the toilet, taking medications, and not bedridden
figure 1. Sample timelines showing when outcomes and baseline factors should be collected for 
patients with colorectal cancer. These timelines are intended to represent the outcome data collection 
points for possible treatment paths a patient could take and do not advocate a particular treatment 
approach. Most baseline factors should be collected at the time of initiation of the colorectal cancer 
standard set, although several
(eg, pathological stage) are collected after treatment.
CT = chemotherapy; PROMs = patient-reported outcomes measurements.
aAt first physician visit.
bDistinction for long-term follow-up: patients with local disease should receive follow-up for up to 10 
years, and patients with advanced disease should receive follow-up annually for life.
cAll PROMs will be collected at baseline, 6 months after treatment, and then annually.
dCollection of short-term complications is recommended when the patient is undergoing treatment 
or within 90 days after initiation of treatment.
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survival and disease control
The following measures were included for survival and disease control: overall 
survival, disease-specific survival, recurrence, and progression-free survival. For 
patients with rectal cancer receiving neo-adjuvant therapy or surgery, pathological 
complete response and margin status, respectively, were included because they may 
serve as intermediary outcomes, proxies of survival, and short-term indicators of 
surgical quality [21]. The recommended time frame for col-lection of data was 1 year 
after treatment and, if possible, annually up to 10 years.
disutility of care
Care disutility measures focused on short-term complications of treatment, includ-
ing type and severity. An algorithm to determine severity was developed based on 
the grading systems of the Clavien-Dindo classification for surgical complications22 
and the Common Terminology Criteria for Adverse Events, version 4.0 for radiation 
therapy and chemotherapy [23].
degree of health (qol, functioning, and symptoms)
The final QOL, functioning, and symptoms measures are listed in Table 1. Although 
social functioning, dietary restrictions, and vaginal symptoms were excluded after 
the second Delphi round (eTable 2), they were reconsidered in the final voting 
because of their high rating of importance by focus group patients, on the patient 
validation survey, and by the WG.
PROMs were used to assess the degree of health outcomes. After relevant outcomes 
were selected, corresponding reliable and valid measurement tools were reviewed 
(eTables 7 and 8). PROM tools were researched based on the outcome cover-age, 
psychometric quality, clinical interpretability, and feasibility to assess and implement 
the PROMs in daily practice. After extensive evaluation and discussion, the WG 
recommended the European Organisation for Research and Treatment of Cancer 
(EORTC) Quality of Life C30 tool [24] to capture overall QOL and the EORTC 
Quality of Life CR29 tool [25] to capture CRC-specific outcomes. To capture out-
comes not directly assessed in the EORTC measurement tools, the Memorial Sloan 
Kettering Cancer Center Bowel Function dietary subscale [26] and a single item of 
the EORTC Quality of Life LM21 tool [27] were selected to assess dietary issues and 
neuropathy, respectively, for patients who received chemotherapy. All PROMs were 
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recommended for collection at baseline, 6 months and 1 year after treatment, and an-
nually up to 10 years, if possible. The use of recommended PROMs is encouraged at 
more frequent time points during the treatment process to support communication 
and clinical decision-making.
quality of death
Several reports have outlined outcomes related to the quality of end-of-life (EOL) 
care [28,29]. Because research suggests that EOL hospitalization may be preventable 
and may indicate poor quality of care [28], the WG decided to include the outcome of 
more than 1 hospital ad-mission in the last 30 days of life for patients with advanced 
dis-ease. Place of death was included, with response options that are internationally 
comparable and easy to obtain [30]. The patient’s preference for place of death was 
also included because patients often have individualized EOL care preferences and 
needs that necessitate assessment and documentation [29]. A measure on hospice use 
was included given evidence showing its benefit at the EOL, in part due to providing 
less aggressive care [28]. We recommend re-viewing the records of deceased patients 
on an annual basis for EOL outcomes.
case-mix variables
Case-mix variables were included for baseline collection to allow for cross-treatment 
and cross-center comparison (Table 2). These variables included demographic fac-
tors, baseline clinical factors, and baseline tumor factors.
Demographic factors included age, sex, race/ethnicity, educational level, and relation-
ship status. Because racial/ethnic disparities have been demonstrated in CRC treat-
ment and outcomes [31], the WG determined that race/ethnicity was also important 
to include. However, because there is no standardized method to assess racial/ ethnic 
subgroups internationally, we recommend using national or regional classification 
systems instead. While socioeconomic status is predictive of health outcomes in 
patients with CRC [32], it is difficult to accurately assess. Educational level, defined 
as the highest level of schooling attained, is reported to serve as a good surrogate for 
socioeconomic status and is easily obtainable and internationally comparable [33]. 
Relationship status was included because it is considered to be an important aspect of 
social support, which is independently associated with survival [34].
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Baseline clinical factors prioritized for inclusion were Eastern Cooperative Oncology 
Group performance status, comorbidities, cognitive status, and disorders with pre-
disposed CRC risk. The patient-reported, modified Self-Administered Comorbidity 
Questionnaire [35] was selected for comorbidity reporting because it has been shown 
to predict functional outcomes equally as well as the Charlson Comorbidity Index [36].
Several baseline tumor factors were included, such as tumor location, clinical and 
pathological TNM stage, and treatment intent (Table 2). If there is more than 1 pri-
mary tumor, tumor factors of the tumor with the highest clinical TNM stage should 
be collected. Urgency of procedure was also included according to the United King-
dom’s National Confidential Enquiry Into Peri-operative Deaths classification [37].
treatment variables
To provide a standardized terminology of treatment options among heterogeneous 
health care delivery institutions, the most commonly used treatment types in daily 
practice were included for local and systemic therapy, with free-text options for other 
treatment delivered. These variables are listed in Table 2.
reference guide
A reference guide, which includes sample questionnaires and time-lines, is freely avail-
able on the ICHOM website (http://www.ichom.org/medical-conditions/colorectal-
cancer). The website also contains a data dictionary for all variables in the standard set.
external input
A total of 28 health care professionals from different specialties participated in an 
open review period and shared feedback via an on-line survey. The respondents were 
confident (mean score, 6.8 on a 9-point Likert-type scale) about the comprehen-
siveness of the standard set and the feasibility of data collection in clinical practice 
(eTable 9). Main concerns raised were related to the duration of follow-up and the 
number of PROMs questions and data items, which could influence feasibility. One 
additional case-mix variable related to the tumor distance from the anal verge was 
included based on the feedback survey.
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table 2 – Summary of case-mix factors and treatment approaches for the ICHOM Colorectal Cancer 
Standard Set
Patient Population Measure Details Data Sourcesa
Demographic Factors
All patients Date of birth N/A Patient-reported 
sourcesGender
Body mass index Height and weight Clinical 
abstraction
Ethnicity Determined by country Patient-reported 
sourcesEducational level Level of schooling completed 
according to ISCEDb
Relationship status Relationship status
Baseline Clinical Factors




Comorbidities Modified SCQc Patient-reported 
sources
















Clinical documentation of 
IBD diagnosis
Baseline Tumor Factors






Presence of more than one 
primary tumord
Tumor location N/A




table 2 – Summary of case-mix factors and treatment approaches for the ICHOM Colorectal Cancer 
Standard Set (continued)
Patient Population Measure Details Data Sourcesa
Patients with rectal 
cancer receiving 
surgery/RTx
Location of rectum 
tumor




Tumor grade Histological grade of tumor
BRAF status Presence of BRAF mutation
RAS status Presence of RAS mutation
MSI/DNA mismatch 
repair
Presence of microsatellite 
instability (MSI) mutation
Patients with surgery Pathological stage Pathological stage per AJCC 
5th - 7th
Number of lymph 
nodes resected
N/A




Presence of lymphovascular 
invasion of tumor
Perineural invasion of 
tumor
Presence of perineural 
invasion in resected tumor
Completeness of 
surgical resection
Presence of residual disease 
after surgery according to 
TNM
Baseline Treatment Factors
Patients with surgery Urgency of procedure According to CEPOD scoree Clinical 
abstractionAll patients Perforation Presence of perforation 
of the bowel at site of the 
tumor
Treatment intent Curative or palliative 
treatment intent
Treatment approaches




Radiotherapy Type of radiotherapy
Chemotherapy Type of chemotherapy





An international, multidisciplinary WG convened during 8 months to develop a 
standardized and comprehensive patient-centered outcomes measurement set for 
patients with CRC. Through the use of extensive patient input, a literature review, 
and expert consensus, the WG defined a final standard set, which we propose will fa-
cilitate institutions and practices in adapting to a restructuring of health care delivery 
and reimbursement that focuses on value (outcomes relative to cost).
We recognize that this standard set is not inclusive of all out-comes that may matter 
to patients. To balance the aims of the WG with the development of a product that 
would be practical to implement in clinical practice, the WG sought to construct 
a parsimonious data set. Centers are encouraged to collect additional information 
outside of the standard set, if desired. ICHOM has appointed a steering committee, 
composed of members of this working group, to convene annually and update the 
N/A= not applicable; ISCED= International Standard Classification of Education; ECOG= Eastern 
Cooperative Oncology Group; WHO= World Health Organization; SCQ= Self-administered Co-
morbidity Questionnaire; RTx= radiotherapy; IBD= inflammatory bowel disease; AJCC= American 
Joint Committee on Cancer; APC= Adenomatous polyposis coli; MMR= mismatch repair; EPCAM= 
Epithelial cell adhesion molecule; TNM= Tumor, Node, Metastasis Staging System; CEPOD= Confi-
dential Enquiry into Perioperative Deaths
a The data source reflects the way outcomes are collected and was determined as clinical (e.g. physi-
cian report), patient-reported (e.g. EORTC QLQ C-30) or administrative (with a combination of 
ways in some cases).
b Level of schooling defined in each country according to the International Standard Classification 
of Education.
c Have you ever been told by a doctor that you have any of the following? I have no other disease, 
heart disease (eg, angina, heart attack, or heart failure), high blood pressure, leg pain when walking 
due to poor circulation, lung disease (eg, asthma, chronic bronchitis, or emphysema), diabetes, kid-
ney disease, liver disease, problems caused by stroke, disease of the nervous system (eg, Parkinson’s 
disease or multiple sclerosis), other cancer (within the last 5 yr), depression, arthritis (select all that 
apply).
d If yes, please collect information of the tumor with the highest TNM stage
e Elective: operating room at time that suit both surgeon and patient, scheduled: operating room <3wks, 
early surgery preferred, not life saving, urgent: operating room <24hrs, a.s.a.p. after resuscitation, Emer-




standard set based on feed-back from implementers and other developments in the 
field of CRC treatment.
The standard set is limited by its integration of multiple PROMs. While most of 
the PROMs (59 of 64 [92.2%]) are from 2 well-tested instruments (EORTC Qual-
ity of Life C30 and CR29), the use of a single question from the EORTC Quality 
of Life LM21 and the addition of a module from the Memorial Sloan Kettering 
Cancer Center Bowel Function dietary subscale have not been tested in this context. 
These additional questions were added to inform outcomes that were prioritized by 
patients but not collected within the EORTC measurement system. Each recom-
mended instrument or question has been individually validated, but further work 
is required to understand how to interpret these instruments within a single set 
of outcomes. The WG recognizes that 64 total questions represent a significant 
respondent burden; however, there is evidence that questions of strong salience to 
patients that are integrated into the clinical inter-action can outweigh increased 
respondent burden [38]. Experience collecting these outcomes in practice will in-
form whether any of these domains can be eliminated while retaining the standard 
set’s usefulness. We anticipate that respondent burden will also be reduced through 
future development of item banks and computer-adaptive testing, which allow for 
modular selection of outcome do-mains and more precise measurement within a 
given domain [39].
We recognize that this recommendation will stretch the capabilities of most institu-
tions. Routine collection of patient-reported outcomes is rare in most organizations, 
and much of the recommended clinical data are unstructured, making it difficult 
to extract for analysis. There are larger trends actively changing these capabilities. 
Major electronic medical record vendors and many third-party tools exist to support 
patient-reported data collection and integration into the electronic medical record 
[40,41]. These same vendors are also creating structured data fields within specialty-
specific templates [42]. These changes are being driven by demands from payers 
and government for structured, standardized data elements to facilitate reporting of 
outcomes directly or through quality registries.
121
Chapter 6
Collection of this data set could also be limited by the existing national infrastruc-
ture for following up patients. In some countries, through linkages made possible 
by national patient identifiers [43], cancer recurrence can be tracked over time. In 
other countries, this data collection is not possible, and in the absence of resources 
for manual tracking, follow-up will likely be limited to those patients who remain 
longitudinally at their initial treating institution.
In light of these challenges, we recommend that institutions take a stepwise approach 
to implementation (Figure 2), beginning with patient-reported outcomes. Evidence 
suggests that the use of patient-reported outcomes in cancer treatment can improve 
patient-physician communication, QOL, and survival while reducing emergency 
department visits and hospitalizations [44,45]. Incorporating patient-reported out-
comes into clinical practice is also typically simpler than collecting structured clini-
cal data, which requires specially trained medical record abstractors or redesign of 
clinical workflows. However, clinical data are necessary for quality improvement or 
value-based payment applications.
Alongside improvements in technical infrastructure, successful implementation of 
the standard set will require a significant change in clinical attitudes and workflow 
[46], starting with the desire to incorporate the patients’ perspective more systemati-
1. Patient-Reported Data 2. Structured Clinical Data 3. Linked Data
Patient-reported Outcome Measures 
(e.g., EORTC QLQ-C30, EORTC QLQ-
C29, EORTC QLQ-LM21, and MSKCC 
Bowel Function – Dietary Subscale)
Tablet-based PRO data collection 
software for use in clinic with real-time 
scoringa
Better monitoring of symptom burden, 
better communication between patients 







Case mix variables (e.g., baseline 
clinical, tumor, and treatment factors) 
and complications of treatment
Manual chart abstractors, scribes, or 
smart forms built into the hospital’s 
electronic medical  record system
Quality improvement, benchmarking,  
value-based payment programs
Survival and disease control (e.g., 
disease recurrence, overall survival, 
date of death, place of death, and 
cause of death)
Unique patient identifiers, privacy laws 
that support linkages, facilitated by 
interoperability standardsb
Comparative effectiveness research
Figure 2. Sample Institutional Implementation Plan for Colorectal Cancer Standard Set 
aIncreasingly available in standard Electronic Medical Record systems (EMRs)
bLinkage capabilities are often constrained by national health IT infrastructure and patient privacy policies; in their absence, insti tutions are encouraged 
to follow patients according to their best ability and resources
figure 2. Sample institutional implementation plan for the colorectal cancer standard set
EORTC = European Organisation for Research and Treatment of Cancer;
MSKCC = Memorial Sloan Kettering Cancer Center; PROMs = patient-reported outcomes measure-
ments.
aIncreasingly available in standard electronic medical record systems.
bLinkage capabilities are often constrained by national health information technology infrastructure 
and patient privacy policies; in their absence, institutions are encouraged to follow up patients ac-
cording to their best ability and resources.
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cally into the care process. To help guide organizations through this process, ICHOM 
has developed a framework that comprises 4 phases (eFigure 2). It was designed to 
engage the organization and enable change as well as sustain and build on results. 
This framework has been successfully used across a range of conditions and settings.
ICHOM’s near-term implementation goal for this standard set is to partner with 
select members of the WG to implement the set as a proof of concept, to inform 
revision by the steering commit-tee, and to pave the way for broader adoption and 
endorsement by national policy and regulatory bodies. This approach has been 
successfully used for the localized prostate cancer standard set, facilitated by the 
Movember Foundation [47].
The goal of this project was to develop a standardized set of patient-centered out-
come measures to inform value-based health care efforts in CRC care. This article 
describes the process by which a novel comprehensive standard set was developed 
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efigure 1. Summary of the development of the ICHOM Colorectal Cancer Standard Set. WG = 
Working Group, CRC = colorectal cancer, PROMs = patient-reported outcome measurements, ISO-
QOL = International Society for Quality of Life Research
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etable 1. Search Strategy Overall
Search terms Results
#1 ((((((((“Colorectal Neoplasms”[Mesh]) AND (“Quality of Life”[Mesh] OR 
“Outcome Assessment (Health Care)”[Mesh] OR “Outcome and Process 
Assessment (Health Care)” OR “Quality Indicators, Health Care”[Mesh])) 
NOT ((“Animals”[Mesh] NOT “Humans”[Mesh]))) NOT ((Comment[ptyp] 
OR Editorial[ptyp] OR Letter[ptyp] OR News[ptyp] OR Case Reports[ptyp]))) 
AND English[Language]) AND (“06/03/2005”[Date - Publication] : 
“3000”[Date - Publication])) AND medline[sb])) OR (((((((((colon[tw] OR 
rectal[tw] OR colorectal[tw] OR rectum[tw]))) AND ((quality of life[tw] OR 
outcome*[tw] OR patient reported[tw] OR metric*[tw] OR measure*[tw] OR 
indicator*[tw]))) AND ((cancer*[tw] OR neoplas*[tw] OR carcinom*[tw] OR 
tumor*[tw] OR tumour*[tw] OR malignan*[tw]))) NOT ((Comment[ptyp] 
OR Editorial[ptyp] OR Letter[ptyp] OR News[ptyp] OR Case Reports[ptyp]))) 
AND (“2005/06/03”[Date - Publication] : “3000”[Date - Publication])) 
AND English[Language]) NOT medline[sb]) AND article type limited to 
“randomized clinical trials” OR “guidelines
1042
#2 Remove studies not meeting criteria (732 excluded in total), based on 
following in- and exclusion criteria:
•	 Inclusion	criteria:
Randomized control trials or guidelines assessing quality of life and clinical 
outcomes among a general colorectal cancer patient population or colorectal 
cancer patients in survivorship phase OR studies assessing the validity of 
outcome measurement tools in colorectal cancer in randomized control 
trials or guidelines; studies of outcomes of population treated with usual 
systemic, surgical, intervention (eg stent), radiation therapy and patients with 
specific disease characteristics (eg metastatic, left sided cancer) that are broad 
classifications.
•	 Exclusion	criteria:
Studies focusing on colorectal cancer patients with specified co-morbidity 
(ie. obesity, DM, HTN, other) or demographic group; studies focusing on 
the outcomes based on specific disease characteristics (eg liver metastases, 
tumor biology including genetic markers) or based on imaging studies; studies 
that evaluate specific interventions (compare one intervention to another 
or study interventions that are not part of usual care) or patient behaviors 
and their impact on quality of life or clinical outcomes; studies that are not 
geographically generalizable (eg done in one US state); disparities, screening 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































etable 4. Description of colorectal cancer patients and survivors participating in the patient survey
Survey respondents
N = 276
Baseline characteristics N (%)
Age, years
=/< 35 years 19 (7)
36 - 55 years 132 (48)
56 - 75 years 116 (42)





North America 146 (53)
Australia 121 (44)
Europe 8 (3)
Colon cancer 166 (60)
Locoregional 99 (36)
Metastatic 66 (24)





< 2 years ago 99 (36)
2-10 years ago 155 (56)









Targeted therapy 44 (16)
No treatment 8 (3)
Other 19 (7)
Stoma
No stoma 146 (53)
Yes, reversed stoma 97 (35)
Yes, permanent stoma 30 (11)
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etable 5. Results of item scores by colorectal cancer patients and survivors participating in the pa-
tient survey.
Outcomes
% rating “very important”
(score 7-9) Mean score
Survival and Disease Control
Overall survival 97% 8.9
Progression-free survival 97% 8.8
Recurrence free survivald 94% 8.7
Quality of Life and Functioning
Physical functioning 91% 8.2
Bowel functioning 91% 8.2
Overall quality of life 88% 8.2
Mobility 84% 7.9
Ostomy functioning 80% 7.7
Emotional functioning 79% 7.7
Depression 68% 7.0
Sexual functioning 55% 6.3
Long-term side effects
Neuropathy 64% 6.8
Fecal leakage 64% 6.7
Stool frequency 57% 6.6
Diarrhea 55% 6.4
Fatigue 54% 6.5
GI symptoms 52% 6.4
Pain 51% 6.4
Vaginal symptoms 40% 5.4
Erectile dysfunction 30% 4.6
Other
Acute complications 72% 7.3
All outcomes were provided with supporting definitions and categorized into three types to make it 
more understandable for patients: 1) positive gains from treatment (e.g. reducing the risk of recur-
rence), corresponds with the tier survival and cancer control 2) negative impact from treatment (e.g. 
pain), corresponds with the tier degree of health - long-term side-effects and 3) impact on quality of 
life and other issues related to treatment (e.g. sexual functioning), corresponds with the tier degree 
of health - quality of life and functioning and the tier disutility of care
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etable 6. Additional outcomes reported by colorectal cancer patients and survivors participating in 
the patient survey.
Additional outcomes No of respondentsa:
No additional outcomes needed 229
Additional outcomes: 47
Decision-making process: Informing on QoL and side effects 15
Availability of peer groups/support teams 11
Dietary changes 9
support for family 5
Cognitive functioning 5
Ability to work 4
Skin rashes 3
Fear of recurrence 3





support of doctor/sympathy 1
Information on alternative therapies 1
Retrograde ejaculation 1
One contact person 1
Fear of having ostomy 1
Worry about future 1
Body image 1
Sleeping disturbance 1
Ability to care for children 1
Fertility 1
Abbreviations: QoL = quality of life, PTSD = post-traumatic stress disorder, GI= gastro-intestinal




















































































































































































































































































































































































































































































































































































































































































Abbreviations: EORTC QLQ-C30= European Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire - Core, FLIC = Functional Living Index for Cancer, EORTC QLQ-
CR38/CR29 = European Organization for Research and Treatment of Cancer Quality of Life Ques-
tionnaire - Colorectal Cancer Module FACT-C =Functional Assessment of Cancer Therapy-Colorec-
tal, LARS= Low anterior resection syndrome score, MSKCC Bowel Function= Memorial Sloan 
Kettering Cancer Center Bowel instrument QLCIP = Quality of Life Index for Colostomy Patients
a The psychometric quality of each PROM was evaluated, based on the International Society for 
Quality of Life Research (ISOQOL) criteria
b The FACT-C is an instrument which combines the FACT-General to assess cancer specific QoL and 
the Colorectal Cancer Subscale (CCS) to assess colorectal cancer specific QoL.
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etable 8. Overview of domain coverage of patient reported outcome measurements (PROMs)
Outcomes

















Overall well-being Yes Partially No Yes No Partially Yes
Physical 
functioning
Yes Partially Partially Yes No Partially Partially
Emotional 
functioning
Yes Partially No Yes No No Partially
Social functioning Yes Partially No Yes No No Partially
Mobility Yes Partially No Partially No No Partially
Depression Yes Yes No Partially No No Partially
Pain/discomfort Yes Partially Partially Yes No No Yes
Fatigue Yes No No Partially No No Partially
Sexual 
functioning
Partially No Partially Partially No No Partially
Bowel function Partially No Partially Partially Partially Yes No
Ostomy 
functioning
No No Yes Partially No No No
Dietary issues No No no no No yes No
Fecal leakage No No Yes Yes Yes Yes No
Stool frequency No No Yes No Yes Yes No
Diarrhea Yes No Partially Yes Partially Yes No
GI symptoms Partially No Partially Partially Partially Yes No
Erectile 
dysunction
No No Yes No No No No
Vaginal symptoms No No Partially No No No No
Neuropathy No No No No No No No
Yes = outcome covered by instrument
Partially = outcome partially covered by instrument
No = outcome not covered by instrument
Abbreviations: EORTC QLQ-C30= European Organization for Research and Treatment of Can-
cer Quality of Life Questionnaire - Core, FLIC = Functional Living Index for Cancer, EORTC 
QLQ-CR38/CR29 = European Organization for Research and Treatment of Cancer Quality of Life 
143
Chapter 6
Questionnaire - Colorectal Cancer Module FACT-C =Functional Assessment of Cancer Therapy-
Colorectal, LARS= Low anterior resection syndrome score, MSKCC Bowel Function= Memorial 
Sloan Kettering Cancer Center Bowel instrument QLCIP = Quality of Life Index for Colostomy 
Patients.
Partially: PROM incompletely encompasses outcome desired.
a The FACT-C is an instrument which combines the FACT-General to assess cancer specific QoL and 
the Colorectal Cancer Subscale (CCS) to assess colorectal cancer specific QoL.
etable 9. Results of item scores by respondents of feedback survey
Statements on Colorectal Cancer Standard Set





Part I. High level overview of Standard Set
The Colorectal Cancer Standard Set represents 
a comprehensive overview of the most essential 
outcomes for CRC patients.
68% 7.0
The in- and exclusion criteria cover the 
population sufficiently with treatment 
approaches that are considered standard of care.
75% 7.6
The outcomes are sufficiently parsimonious 
to be collected routinely by patients and 
clinicians.
57% 6.4
Number of PROMs 
and clinical data 
items could lead to 
compliance issues in 
daily practice.
Time points for measurement are feasible to 
follow up patients.
61% 6.7
Collecting 5 year 
follow-up for patients 
without on-term 
problems might be 
sufficient and more 
feasible.
The case-mix factors are appropriately 
comprehensive to enable risk-model 
development for provider performance 
comparison.
54% 6.5
Tumor distance from 
anal verge is crucial 
for patients with 
rectal cancer as it can 
influence functional 
status.





etable 9. Results of item scores by respondents of feedback survey (continued)
Statements on Colorectal Cancer Standard Set





Part II. Complete overview of Standard Set
Case-mix factors are defined properly, are 
comprehensive enough to enable risk-
adjustment and can be collected in clinical 
practice.
67% 7.1
Items of patient-reported form are 
comprehensive enough to cover PRO domains 
and can be collected by patients.
63% 6.6
It could be challenging 
to have patients 
complete all PROMs
Clinical outcomes and treatment approaches 
are defined properly and can be collected in 
routine clinical practice.
67% 6.8
Collecting all items 
would require good IT 
support and linkage to 
the EHR system.
The online feedback survey consisted of two parts: 1) high-level overview of the Set for review of a 
summary of the recommended outcomes, treatment approaches, case-mix factors and in- and exclu-
sion criteria. 2) Complete overview of the Standard Set with access to the complete Reference Guide 
in order to review each variable with corresponding definitions and response options. Respondents 
had to rate their confidence on a 9-point Likert scale (e.g. 7-9 was very confident)
a Total of 28 healthcare professionals completed the survey, including 10 surgeons, 5 statisticians and 
researchers, 4 medical oncologists, 4 gastroenterologists, 3 nurses, 2 consultants)
b Response option was binary (“yes/no”) instead of the 9-point Likert scale




efigure 2. Phases involved in implementation of the Standard Set
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A major challenge in value-based health care is the lack of standardized health out-
comes measurements, hindering optimal monitoring and comparison of the quality 
of health care across different settings globally. The International Consortium for 
Health Outcomes Measurement (ICHOM) assembled a multidisciplinary interna-
tional working group, comprised of 26 health care providers and patient advocates, 
to develop a standard set of value-based patient-centered outcomes for breast cancer 
(BC). The working group convened via 8 teleconferences and completed a follow-up 
survey after each meeting. A modified 2-round Delphi method was used to achieve 
consensus on the outcomes and case-mix variables to be included. Patient focus 
group meetings (8 early or metastatic BC patients) and online anonymized surveys of 
1225 multinational BC patients and survivors were also conducted to obtain patients’ 
input. The standard set encompasses survival and cancer control, and disutility of 
care (eg, acute treatment complications) outcomes, to be collected through admin-
istrative data and/or clinical records. A combination of multiple patient-reported 
outcomes measurement (PROM) tools is recommended to capture long-term degree 
of health outcomes. Selected case-mix factors were recommended to be collected at 
baseline. The ICHOM will endeavor to achieve wide buy-in of this set and facilitate 





Breast cancer (BC) is the most common cancer and the most common cause of 
cancer death in women worldwide [1]. BC management usually requires a multi-
modal approach, involving surgery, radiotherapy, chemotherapy, hormonal therapy 
and survivorship care [2, 3]. However, there is significant variation in BC treatment 
across institutions, geographical regions and countries [4-9]. Multiple randomized 
trials have shown equivalent survivals with different BC treatments [10], hence the 
treatment decision often comes down to the value each patient places on the poten-
tial gains/losses associated with each treatment option.
While achieving high value – defined as health outcomes per dollar spent – for 
patients is the overarching goal of healthcare delivery [11], often, defining and mea-
suring health outcomes can be difficult. Outcome measurements need to encompass 
overall disease control, treatment complications, and quality of life (QOL) during 
and following treatment. Recognizing the lack of consistent outcome measurements, 
which hampers the monitoring of routine clinical practice, as well as quality of care 
and outcome comparison in a systematic and meaningful manner, the International 
Consortium for Health Outcomes Measures (ICHOM), a nonprofit organization has 
initiated efforts to develop standard sets of patient-centered outcome measurements 
for various medical conditions such as back pain [12], coronary artery diseases [13], 
cataract [14] and cancers (e.g. prostate cancer [15, 16] and lung cancer [17]). Building 
on previous ICHOM experience and successes, an international multidisciplinary 
working group (WG) for BC was assembled to develop a minimal standard set of 
outcomes that matter most to BC patients. The set can: 1) enhance clinician-patient 
shared decision-making; 2) provide quality outcome information to providers and 
institutions to drive transparency and improvement; and 3) increase the opportunity 




ichom breast cancer working group
The development of the set was initiated by ICHOM (www.ichom.org), (eTable 1). 
The WG comprised 26 experts, including clinicians (breast/plastic surgeons, medi-
cal/radiation oncologists, pathologists, radiologists and palliative care physicians), 
nurses, epidemiologists, patient representatives and advocacy groups, from Europe, 
North America, Latin America, Australia and Asia. A smaller project team (PT) 
(W.L.O., M.S., A.V.B., C.S., and C.S.) guided the efforts of the larger WG.
development of breast cancer standard set
The WG convened via eight videoconferences (August 2015–April 2016), and worked 
through a similar process as previous ICHOM WG [15-17]. Development of the set 
involved several phases (Figure 1).
development of potential outcomes and case-mix list
The PT performed a structured PubMed literature review (January 1, 2005 to July 29, 
2015) (eTable 2 and eFigure 1) to identify relevant clinical and patient-reported QOL 
outcomes, treatment-related complications, survival measures and case-mix factors. 
The literature review retrieved 1360 randomized controlled trials, and a total of 
398 papers were included for review. Existing BC registries were also reviewed, and 
WG experts were asked to identify additional relevant sources. To ensure patients’ 
input in the outcomes selection, a focus group meeting with eight early/metastatic 
BC patients was conducted (guided by W.L.O., M.S. and A.V.B.), to explore patients’ 
perspective on the importance of different outcomes, and what affected them, or 
other patients, the most during their day-to-day lives.
modified 2-round delphi method
After each videoconference, a survey was circulated, requiring each working group 
member to vote on the proposed outcomes, case-mix variables and PROMs. A modi-
fied 2-round Delphi approach (eTables 3 and 4) was used to reach consensus. In brief, 
the proposed outcomes or variables needed to be voted as very important (ie, score 
of 7-9 on a 9-point Likert scale) in either voting rounds by more than 70% of the 




The final list of outcomes was validated in 1225 multinational BC patients and survi-
vors, recruited via several international patient organizations (eTable 5). Participants 
were asked to complete an anonymized survey, rating the importance of each out-
come on a 9-point Likert scale, with an option of including additional outcomes in 
text form (eTables 6 and 7).
Figure 1. Summary of the development of the ICHOM Breast Cancer Standard Set. 
Abbreviations: WG = Working Group, BC=breast cancer, PROMs = patient-reported outcome measurements, ISOQOL =  International Society
 for Quality of Life Research 
WG Process Literature and external input 
Call 7: Data dictionary and 
transition to implementation 
Call 6: Standard Set wrap-up  
Call 5: Case-mix definitions 
 
Call 4: Case-mix factors 
2-round Delphi method: 
21/27 case-mix factors 
prioritized  
 
Call 3: Outcome wrap-up 
4 (parts of) PROMs included 
 
Call 2: Outcome definitions 
PROMs "look& feel" assigment 
Call 1: Outcome domains 
2-round Delphi method: 





Literature review of outcomes 
and definitions: 
398 papers included for review  
LIterature review of case-mix 
factors and definitions 
398 papers included for review 
 
Patient Focus Group 
BC patients/survivors (N=8)  




healthcare professionals (N=35) 
PROMs reviewed via ISOQOL 
criteria 
11 instruments included for review  
Patient input 
figure 1. Summary of the development of the ICHOM Breast Cancer Standard Set





After finalizing the list of outcomes, the corresponding PROMs were identified. The 
PROMs were evaluated by the project team, based on psychometric quality accord-
ing to the International Society for Quality of Life Research (ISOQOL) criteria [18] 
(eTable 8) and the domain coverage (eTable 9). Prior to the voting, working group 
members were asked to complete the different PROMs, from a patient’s perspective.
external input
The final draft was presented to key stakeholders and others with an interest in out-
come measurement for review and to provide feedback via online survey. They were 
asked to rate their confidence on several elements of the set (eg, completeness of the 
outcome list, implementation feasibility) on a 9-point Likert scale, with an open field 
for comments.
results
condition and treatment scope
The set was designed for all pathologically confirmed American Joint Committee of 
Cancer (AJCC) patients with stages 0 to IV BC, including ductal carcinoma in situ 
(DCIS), in both men and women. Rare tumors such as Phyllodes tumors and lobular 
carcinoma in situ were excluded, given the difficulty in defining a standard of care 
for these tumor subtypes.
outcomes
After consolidating the findings of the literature review and focus group meeting, a 
proposed list of 43 outcomes was identified for vote (eTable 9), the working group 
recommended the use of a combination of multiple PROMs (Table 1). The working 
group recognized that selection and recommendation of PROMs for inclusion in 
the set can be contentious given that there are multiple available PROMs of high 
psychometric quality (eg, European Organization for Research and Treatment 
of Cancer Quality of Life [EORTC-QLQ] and Functional Assessment of Cancer 
Therapy [FACT] questionnaires) that are already being used in different institutions. 
The PROMs were evaluated based on the outcomes cover-age, psychometric quality, 
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table 1 – Summary of outcomes for the ICHOM Breast Cancer Standard Set
Patient Population Measure Data Sourcesa
Survival and Disease Control
All patients Overall survival Administrative
Death attributed to breast cancer
Patients with curative 
intent
Recurrence free survival (local, regional or distant) Clinical
Degree of Health






















Tracked via BREAST-Q- 
Satisfaction with Breasts 
domain
Arm symptoms Tracked via EORTC QLQ-
BR23Breast symptoms





Tracked via EORTC QLQ-
LMC21- one item




clinical interpretability, and feasibility of PROMs implementation in daily practice 
(eTables 8 and 9). After extensive discussions and a “look-and-feel” assignment, 
the use of EORTC-QLQ-Core (C30) [24] and EORTC-QLQ-Breast Cancer (BR23) 
[25] was eventually recommended by the working group to capture the core cancer-
specific and BC-specific outcomes. The working group also recommended additional 
questions from other PROMs to capture outcomes not encompassed by the EORTC 
questionnaires. These included the BREAST-Q [26] sub-scale for breast satisfaction, 
a single item from EORTC-QLQ-Liver Metastases (Colorectal) (LMC21) [27] for 
peripheral neuropathy, and 6 items from the FACT-Endocrine Subscale (ES) [28] 
for vaginal symptoms and arthralgia. The assessment of degree of health outcomes 
was recommended at baseline (ie, at diagnosis), 6 months after primary surgery, and 
annually thereafter (Figure 2). Follow-up was recommended up to 10 years in early 
BC patients to capture the period during which patients might still be on endocrine 
therapy.
case-mix variables
The working group identified a minimal set of demographic, clinical, and tumor-
related factors to be collected at baseline for meaningful outcome comparisons 
(Table 2). While socioeconomic status (SES) is an important demographic factor, 
accurate characterization of SES can be complex, involving multiple components 
table 1 – Summary of outcomes for the ICHOM Breast Cancer Standard Set (continued)
Patient Population Measure Data Sourcesa
Disutility of Care
Patients with surgery Reoperations due to involved margins Clinical/patient-
reported
All patients with 
treatment
Severity of acute complications based on the 
Clavien-Dindo and CTCAE
Clinical
Name of acute complication
EORTC QLQ= European Organization for Research and Treatment of Cancer Quality of Life Ques-
tionnaire, C= Core module BR= Breast Cancer module, LMC=Colorectal Liver Metastases, FACT 
=Functional Assessment of Cancer Therapy, ES= Endocrine Subscale, CTCAE= US National Cancer 
Institute Common Terminology Criteria for Adverse Events
a The data source reflects the way outcomes are collected and was determined as clinical (e.g. physi-
cian report), patient-reported (e.g. EORTC QLQ C-30) and administrative (e.g. Death registry), in 
some cases a combination.
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such as occupation and income. As with previous ICHOM working groups, the 
BC working group recommended the collection of education level based on the 
International Standard of Schooling Classification [29] because it is reported to be a 
good surrogate for SES, easy to obtain, and globally comparable [30]. Relationship 
figure 2. Sample timelines illustrating when particular outcomes and baseline factors should be col-
lected for patients with breast cancer.
These timelines are intended to represent the outcome data collection points for possible treatment 
paths a patient could take, and do not advocate a particular treatment approach. Of note, a majority 
of baseline factors should be collected at the time of initiation of the Breast Cancer Standard Set, 
although several (eg, pathologic stage) are collected after treatment. NAC indicates neoadjuvant che-
motherapy; PROMs, patient-reported outcome measurements.
aCollection of acute complications is recommended while the patient is undergoing treatment or 
within 90 days of treatment completion, except for complications of hormonal therapy which will be 
collected up to 1 year.
bAll PROMs will be collected at baseline, 6 months after treatment, and then annually, except for the 
BREAST-Q-Satisfaction with Breasts domain, which will only be collected at baseline,1 year, and 2 
years after treatment.
cDistinction for long-term follow-up: patients with local disease; follow-up up to 10 years, patients 
with advanced disease; follow-up annually for life
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table 2 – Summary of case-mix factorsa and treatment approaches for the ICHOM Breast Cancer 
Standard Set
Patient Population Measure Data Sourcesb
Demographic Factors
All patients Gender Patient-reported
Date of birth










All patients Date of histological diagnosis Clinical
Histological type
Mutation status predisposing BC
Tumor grade (invasive)
Tumor grade (DCIS)
Patients with NAC Clinical TNM stage (AJCC 7th)
Patients with surgery Pathological TNM stage (AJCC 7th)
Size of invasive component of tumor (in mm)
Number of lymph nodes resected













status is also included, because it is an indicator of available social support and is 
associated with survival and several functional outcomes [31]. Race and ethnicity 
did not meet the predefined voting criteria for inclusion in the set. However, because 
there is evidence suggesting its potential association with treatment decisions [32] 
and outcomes [33,34] for certain countries, it was decided to include this as optional.
Patients’ baseline health status is another important factor influencing treatment 
decision-making and eventual treatment out-comes. However, the Eastern Coopera-
tive Oncology Group (ECOG) performance status scoring is deemed to be an over-
simplified representation of patients’ health status, and is not commonly collected in 
patients with early stage BC. Likewise, collection of the Charlson Comorbidity Index 
(CCI) can be burdensome. Therefore, the working group recommended the use of 
the modified Self-administered Comorbidity Questionnaire (SCQ) to capture a list 
of relevant medical comorbidities [35], and baseline health status as measured by the 
EORTC-QLQ-C30/BR23 (Table 1). It has been shown that SCQ predicts functional 
outcomes as well as the CCI [36] Tumor factors to be collected are based on the 
AJCC TNM staging. Information on hormone and human epidermal growth factor 
receptor 2 status are recommended to be collected as a binary data (“yes” or “no”), 
recognizing variability in pathology reporting between institutions and countries.
SCQ = Self-administered comorbidity questionnaire, DCIS = ductal carcinoma in situ, BC = breast 
cancer, NAC= neo-adjuvant therapy, AJCC = American Joint Committee on Cancer, DCIS = ductal 
carcinoma in situ
a All case-mix factors include measures with corresponding patient populations, definitions or sup-
porting information, timing for collection and source of data.
b The data source reflects the way outcomes are collected and was determined as clinical (e.g. physi-
cian report), patient-reported (e.g. EORTC QLQ C-30) and administrative, in some cases a combi-
nation.
c Level of schooling defined in each country according to the International Standard Classification 
of Education.
d Have you ever been told by a doctor that you have any of the following? I have no other disease, heart 
disease (eg, angina, heart attack, or heart failure), high blood pressure, leg pain when walking due to 
poor circulation, lung disease (eg, asthma, chronic bronchitis, or emphysema), diabetes, kidney dis-
ease, liver disease, problems caused by stroke, disease of the nervous system (eg, Parkinson’s disease 




To provide a standardized terminology of treatment options over heterogeneous, 
international health care settings, the most commonly used treatment modalities in 
daily practice were included (Table 2). Patients should also be asked to report on 
their ongoing treatments during follow-up because clinical data may be inaccurate, 
especially with endocrine therapy adherence [37].
external input
A total of 35 health care professionals from different specialties completed the survey. 
The respondents were confident (mean score, 6.7 on 9-point Likert scale) of the 
comprehensiveness of the outcome list, case-mix variables, and feasibility of data 
collection in routine clinical practice (eTable 10). The main concerns raised were 
related to the lack of end-of-life (EOL) care outcomes, and the number of PROMs 
items, which could lead to noncompliance.
data collection and implementation
The next crucial step after finalizing the BC set is the adoption and implementation 
of the set. To minimize variability and inconsistency in data collection, a reference 
guide including sample questionnaire s and a data dictionary has been created by 
ICHOM (http://www.ichom.org /medical-conditions/breast-cancer/). This will 
cover the potential source of the data, including clinical records and patient-reported 
sources, as well as frequency for each data collection.
discussion
With rising health care costs, and the options of multiple treatment modalities and 
prolonged survival among patients with BC, the importance of value-based health-
care is increasingly being recognized [38]. However, a major challenge in value-based 
health care is the lack of standardization in outcome measurements meaningful to 
patients across different cultural and geographical settings [38]. The ICHOM has 
therefore convened an international multidisciplinary working group, from middle- 
to high-income countries, to develop a standard set of patient-centered outcomes 
that should be measured in all patients with BC.
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The aim was to develop a set, which can, and should be collected in routine clinical 
practice, even in resource-limited health systems. We acknowledge that randomized 
controlled trials remain the gold standard for treatment outcomes comparison; 
however, the measurement of outcomes in routine clinical practice will better reflect 
outcomes in a real life setting. Furthermore, the set can function as a core outcomes 
measurement to be collected in trial set-tings, and can be expanded to include ad-
ditional outcomes, based on individual trial requirements.
We are cognizant of the need to collect minimal data to limit bur-den to both health 
care providers and patients, but at the same time recognize the need to encompass 
important outcomes for meaningful comparisons. More than 80% of the multina-
tional survey respondents agreed with the set, providing support that the set captures 
the key outcomes relevant to patients with BC. The working group is aware that the 
recommendation of collecting (part of) multiple PROMs, ranging from 59 to 82 
questions, represents significant patient burden. However, patient representatives in 
the working group did not find the PROMs too cumbersome, because they are all 
salient questions. The EORTC is currently developing computerized adaptive testing 
(CAT) versions, which should reduce respondent burden [39]. In addition, there is 
evidence suggesting clinical benefits in symptom-monitoring with PROM during 
routine cancer treatment [40].
The primary PROMs recommended by the working group are based on the EORTC 
questionnaire. However, other PROMs, such as the FACT questionnaire, are also 
commonly used in many institutions. In fact there is no strong evidence to suggest 
that the psychometric properties of 1 PROMs are superior to the other [41]. However, 
the EORTC questionnaire was deemed to be less ambiguous by the working group 
(after having completed both EORTC and FACT questionnaires themselves), and has 
wider outcomes coverage, encompassing outcomes such as cognitive functioning and 
financial impact. The working group recognized that switching across to the EORTC 
questionnaire might cause disruption in longitudinal data collection in institutions 
not currently using it. Hence, future studies are definitely warranted in making com-
monly used PROMs comparable, to allow for transition into the implementation of 
the standardized measurement recommended by the working group.
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To our knowledge, this is the first international set incorporating outcomes of almost 
a full cycle of BC care, from diagnosis to completion of treatment and long-term 
survivorship, with an emphasis on patient-reported outcomes. Other entities cur-
rently measuring BC care outcomes have largely been monodisciplinary, focusing 
largely on surgical treatments [42,43], are more related to measuring and de-fining 
quality by processes and short-term outcomes of BC care [44-46], or have been set up 
for a short research period [47]. It is also important to acknowledge that the BC set 
does not include outcomes measurement on EOL care. While EOL care was raised 
during several video-conferences, the working group felt that EOL care is often not 
BC-specific, and ICHOM will consider assembling a palliative care working group to 
develop a standard set encompassing EOL care across various cancers and medical 
conditions.
To facilitate the implementation and for practicality, the working group has de-
veloped a measurement timeline in such a way that the PROMs collection runs in 
conjunction with patients’ follow-up visits, and so the data can be used as part of 
clinical consultation. Even so, ICHOM recognizes the challenges involved in imple-
mentation. Routine collection of this set in clinical settings will require investment in 
human resources and information technology, and will depend on the active involve-
ment of clinicians, who must see the value of having such data at the point of care, as 
well as for retrospective and comparative analyses.
Initially, ICHOM aims to facilitate the implementation process in a number of pilot 
institutions. The experience and lessons learned from these institutions will be docu-
mented, and feedback to a steering committee comprising a subgroup of the current 
working group members, to refine the set and to prepare it for widespread adoption. 
This approach has been successfully adopted for the localized prostate cancer set, 
facilitated by the Movember Foundation [48]. The implementation process will 
involve 4 phases: (1) to engage clinical champions and establish proper governance 
process; (2) to identify current measurement audit practices and gaps, and suggest 
practical strategies for collecting structured clinical data and administrating PROM 
assessment at the indicated time points; (3) to use pilot sites to trial strategies includ-
ing existing data sets collection; and (4) to establish how to feedback the data to the 




Through the use of literature review and extensive patient input, an international 
multidisciplinary team of BC experts has developed a minimal standard set of 
value-based patient-centered outcome measures, deemed to be most important to 
patients with BC, and generally applicable worldwide. It is recommended that the set 
is collected in routine clinical practice. This will allow for monitoring and meaning-
ful comparison of BC treatment outcomes within, and across, countries, and in the 
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etable 2. Search Strategy Overall
search terms results
#1 “breast neoplasms”[MeSH Terms] AND (((“randomized controlled trials as 
topic”[MeSH Terms] OR ((“randomized controlled trial”[Publication Type] OR 
“randomized controlled trials as topic”[MeSH Terms] OR “randomized controlled 
trial”[All Fields] OR “randomised controlled trial”[All Fields]) OR randomized 
controlled trial,[All Fields] OR (“randomized controlled trial”[Publication Type] 
OR “randomized controlled trials as topic”[MeSH Terms] OR “randomized 
controlled trials”[All Fields] OR “randomised controlled trials”[All Fields]))) OR 
((“randomized controlled trial”[Publication Type] OR “randomized controlled 
trials as topic”[MeSH Terms] OR “randomised controlled trial”[All Fields] 
OR “randomized controlled trial”[All Fields]) OR (“randomized controlled 
trial”[Publication Type] OR “randomized controlled trials as topic”[MeSH 
Terms] OR “randomised controlled trials”[All Fields] OR “randomized 
controlled trials”[All Fields]))) OR randomized controlled trial[Publication 
Type]) AND (((“Quality of Life”[Mesh] OR “Outcome Assessment (Health 
Care)”[Mesh]) OR “Outcome and Process Assessment (Health Care)”[All Fields]) 
OR “Quality Indicators, Health Care”[Mesh]) AND (“2005/01/01”[PDAT] : 
“2015/07/31”[PDAT]) AND Clinical Trial[ptyp]
1517
#2 #1 AND English[lang] 1483
#3 Remove duplicates 1359






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































etable 5. Description of breast cancer patients and survivors participating in the patient survey
Survey respondents
N = 1225
Baseline characteristics N (%)
Age, years
=/< 35 years 12 (1)
36 - 45 years 98 (8)
46 - 65 years 821 (67)
=/> 66 years 221 (18)
Continent




< 2 years ago 221 (18)
2-10 years ago 809 (66)










Breast-conserving therapy 515 (42)
Breast reconstruction therapy 306 (25)
Sentinel node biopsy 698 (57)




Hormonal therapy 821 (67)
Targeted therapy 172 (14)




etable 6. Results of item scores by breast cancer patients and survivors participating in the patient 
survey.
outcomes




survival and cancer control
Recurrence free survival 97% 8.8
Overall survival 96% 8.8
quality of life and functioning
Emotional functioning 90% 8.0
Physical functioning 90% 8.0
Overall QoL 88% 8.1
Cognitive functioning 85% 7.8
Ability to work 83% 7.7
Social functioning 81% 7.6
Body image 64% 6.8
Sexual functioning 58% 6.6






Vasomotor symptoms 48% 5.8
Arm symptoms 47% 5.7
Peripheral neuropathy 45% 5.5
Pain 39% 5.4
Breast symptoms 36% 5.3
Vaginal symptoms 33% 4.7
disutility of care
Acute complications 50% 5.3
All outcomes were provided with supporting definitions and categorized into three types to make it 
more understandable for patients: 1) positive gains from treatment (e.g. reducing the risk of recur-
rence), corresponds with the tier survival and cancer control 2) negative impact from treatment (e.g. 
pain), corresponds with the tier degree of health - long-term side-effects and 3) impact on quality of 
life and other issues related to treatment (e.g. sexual functioning), corresponds with the tier degree 
of health - quality of life and functioning and the tier disutility of care
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etable 7. Additional outcomes reported by breast cancer patients and survivors participating in the 
patient survey.
Additional outcomes no of respondentsa:
No additional outcomes needed 992
Additional outcomes: 233
Decision-making process: Informing on QoL and side effects 42
Financial impact 15
Availability of peer groups/support teams 12
Fear of recurrence 10
Impact on (relationship with) family/friends 10
Acceptance of new life 10




support for family/children 4
support from family/friends 4
Counseling partner/family 3
Information on alternative therapies 3




Loss of confidence 2
Fear of lymphoedema 2
Spiritual well-being 2
Ability to eat 2
Insomnia/sleep disturbance 2








Information on nutrition 1
Nausea and vomiting 1
Abbreviations: QoL = quality of life, PTSD = post-traumatic stress disorder










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































etable 10. Results of item scores by respondents of feedback survey
statements on Breast cancer standard 
set





Part I. High level overview of Standard Set
The Breast Cancer Standard Set represents 
a comprehensive overview of the most 
essential outcomes for patients with BC.
63% 7.0
No outcomes specific to end 
of life care are included.
The in- and exclusion criteria cover the 
population sufficiently with treatment 
approaches that are considered standard 
of care.
74% 7.5
The outcomes are sufficiently parsimonious 
to be collected routinely by patients and 
clinicians.
54% 6.5
Number of PROM items 
could lead to compliance 
issues in daily practice.
Disutility of care could be 
shortened as complications 
are relatively uncommon in 
BC care and might not be 
useful for benchmarking.
Time points for measurement are feasible 
to follow up patients.
57% 6.2
Collecting long-term 
outcomes would require 
good IT support
The case-mix factors are appropriately 
comprehensive to enable risk-model 
development for provider performance 
comparison.
57% 6.3
I agree with recommend tools, questions 
and methods.
71%b
Part II. Complete overview of Standard Set
Case-mix factors are defined properly, 
are comprehensive enough to enable risk-
adjustment and can be collected in clinical 
practice.
62% 6.6
Items of patient-reported form are 
comprehensive enough to cover PRO 
domains and can be collected by patients.
72% 6.7
It could be challenging to 




etable 10. Results of item scores by respondents of feedback survey (continued)
statements on Breast cancer standard 
set





Clinical outcomes and treatment 
approaches are defined properly and can be 
collected in routine clinical practice.
62% 6.5
Reoperation due to involved 
margins was considered 
a debatable measure for 
quality of care because it 
also relates to patient wishes 
and could create wrong 
incentives.
The online feedback survey consisted of two parts: 1) high-level overview of the Set for review of a 
summary of the recommended outcomes, treatment approaches, case-mix factors and in- and exclu-
sion criteria. 2) complete overview of the Standard Set with access to the complete Reference Guide 
in order to review each variable with corresponding definitions and response options. Respondent 
had to rate their confidence on a 9-point Likert scale (e.g. 7-9 was very confident)
a Total of 35 healthcare professionals completed the survey, including 16 surgeons, 8 statisticians and 
researchers, 4 medical oncologists, 2 nurses, 1 radiation oncologist, 1 radiologist, 1 plastic surgeon 
and 1 consultant)
b Response option was binary (“yes/no”) instead of the 9-point Likert scale
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etable 11. Types of treatment modalities and treatment-specific acute complications and long-term 
morbidity






severity of acute 
complication



























































a Collection of acute complications is recommended whilst the patient is undergoing treatment or 
within 90 days of treatment completion, except for complications of hormonal therapy which will be 
collected up to 1 year
b Tracked via patient-reported outcome measurements (PROMs) annually, up to 10 years
c Including surgical, radiological and endoscopic interventions






































In most western healthcare systems, over the last decade major efforts have been 
made to monitor and improve the quality and effectiveness of cancer care. Assuring 
quality via nationwide clinical audits has proved to be a powerful tool to gain insight 
in the quality of care and to facilitate quality improvement. In the context of the rapid 
advancements in new anticancer drugs, the trends in multidisciplinary cancer care 
and the focus towards patient-centred outcomes, assurance of quality needs to evolve 
constantly to anticipate to these changes. This thesis aims to investigate how quality 
could be assured facing these trends in cancer care.
part i: Assuring quality in multidisciplinary cancer care
Hospital variation in medical oncology
The majority of DICA audits have their focus on the quality of surgical treatment and 
short-term outcomes of care. Risk-adjusted outcomes like postoperative morbidity 
and mortality are often used to evaluate hospital performance and give an ultimate 
insight into the quality of surgical care [1] [2]. However, with a growing number of 
treatment modalities becoming available for many tumour types, auditing the non-
surgical component of multimodality therapy becomes increasingly important.
In gastric cancer treatment, Dutch guidelines recommend perioperative chemo(radio)
therapy for patients with resectable gastric cancer who are eligible in terms of physi-
cal condition and comorbidity [3]. We have observed considerable hospital variation 
in the use of adjuvant chemo(radio)therapy in gastric cancer patients, even after 
random variation and case-mix correction [this thesis]. This suggests that the varia-
tion is not merely a reflection of age or comorbidity burden, but it may also reflect 
other (hospital specific) factors.
However, as the DUCA has its focus on the quality of surgical treatment and short-
term outcomes of care, detailed information is missing on the adjuvant component 
and long-term outcome data is not registered. Moreover, hospital-specific quality 
data in relation to the national average is only fed back to the participating surgeons. 
Because the underlying cause of the variation could not be further investigated, an 
in-depth investigation in hospitals was performed with the aim of identifying orga-
nizational and process factors associated with the use of multimodality treatment 
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[4]. A multidisciplinary extension of the DUCA with medical oncologists, radiation 
oncologists, pathologists and gastroenterologists may offer a better understanding in 
the decisional process and quality of multimodal treatment from the audit itself and 
would facilitate such in-depth investigations. All disciplines would then be provided 
with benchmarked feedback, including oncologists and radiologists who play a ma-
jor role in the multimodal treatment of gastric cancer patients.
Fortunately, (surgical) DICA audits are slowly transforming to multidisciplinary condi-
tion focused audits. The DSCA is converted to the multidisciplinary Dutch ColoRectal 
Audt (DCRA) as radiotherapists, gastroenterologists, medical oncologist and radiolo-
gists joined the audit. In addition to data collection of patient undergoing resections 
for colorectal cancer, patients with a wait-and-see strategy after initial treatment with 
(chemo)radiotherapy, with or without surgery, for rectal cancer are now registered.
A true condition focused audit in which multiple treatment strategies are registered 
by the relevant disciplines has been created for lung cancer: the Dutch Lung Cancer 
Audit (DLCA), in which radiotherapist, surgeons and pulmonologists participate. In 
addition, linkage of data from the DUCA and DCRA with long-term survival data 
from Vektis, a database containing data from all Dutch healthcare insured Dutch 
citizens, is recently realized.
Although challenging with regards to linkage of databases, privacy issues and registra-
tion burden, only such multidisciplinary condition focused audits including survival 
data would create a better understanding on the quality of multimodal treatment in 
cancer patients and it’s impact on long-term survival. In future, with the increasing 
population of old and frail cancer patients it would be extremely valuable to track the 
outcomes of patients who receive palliative treatment or no treatment at all.
Multidisciplinary outcomes
Multidisciplinary tumour boards have become the hallmark for cancer care and have 
been rooted in everyday practice [5]. In the Netherlands, such multidisciplinary 
boards have developed evidence-based guidelines on the treatment of many tumour 
types [3]. In addition, the Dutch federation of oncological societies (SONCOS) has 
set up multiple multidisciplinary quality standards listing requirements a cancer cen-
tre must meet [6]. Although cancer care is increasingly becoming a multidisciplinary 
undertaking, benchmarked feedback via audits is mainly discussed monodisciplinary 
in Dutch hospitals. For instance, surgeons only discuss postoperative complications 
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with their peers. However, adverse outcomes can transcend disciplines [this thesis]. 
We showed that gastric cancer patients with severe postoperative complications 
had an increased likelihood of adjuvant chemotherapy omission. In hospitals with 
the lowest administration rate, adjuvant chemotherapy was three times more likely 
to be omitted compared to the national average. It is unlikely that the omission of 
chemotherapy can be fully attributed to postoperative complications or frailty of 
patients. Differences in the expertise of the medical team to recognize and adequately 
treat complications to ensure patients are fit enough for postoperative chemotherapy 
might also play a role. The considerable variation might also reflect differences in 
the culture or communication between surgical and medical departments. It would 
therefore be valuable to discuss such multidisciplinary quality measures in multi-
disciplinary team meetings within hospitals on a regular basis. This could stimulate 
shared accountability and ultimately enhance joint quality initiatives.
part ii: Assuring quality in precision medicine
Value of registries in medical oncology: appropriate drug use and safety surveillance
The treatment of metastatic melanoma has been revolutionized with the introduction 
of the BRAF inhibitor vemurafenib and immune checkpoint inhibitor ipilimumab 
[7]. Since the approval of ipilimumab in 2011 [8] and vemurafenib in 2012 [9] by the 
European Medicines Agency (EMA), more than seven new drugs are registered for 
the treatment of metastatic melanoma [10]. These developments indicate the speed 
with which changes in anticancer therapies are occurring.
The societal challenge is to combine the development and availability of promis-
ing new anticancer drugs with the sustainability of our healthcare system. Current 
checkpoint inhibitors have a list price near 60.000 Euro per year [10]. These promis-
ing drugs have also been approved for many other cancers, such as metastatic lung 
cancer, renal cell cancer, head and neck cancer, bladder cancer, Merkel cell carcinoma, 
various types of lymphomas, and others will follow soon. As a result of the rapidly 
evolving treatment landscape of oncologic care together with the aging population 
and growing number of cancer survivors, the sustainability of cancer services as part 
of national health systems has become a major challenge. In the Netherlands, the 
prediction is that around 23 billion euro will be spent on cancer treatment by 2040, 
over four times as much as in 2015 [11].
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In response to this, a special committee of the Dutch Cancer Society (KWF) in-
vestigated the accessibility and affordability of expensive anticancer drugs [12]. In 
their report, they advocate set-ups of registries like the DMTR as it gives insight 
into real-world cost-effectiveness of treatments and treatment-patterns. First results 
from the DMTR demonstrate that the new drugs for metastatic melanoma have been 
safely introduced in the Netherlands with comparable toxicity rates as reported in the 
pivotal trials [this thesis]. This may be attributed to the centralization of advanced 
melanoma care into fourteen specialized melanoma centres and the obligatory 
minimum volume standard of 20 melanoma patients yearly [13]. Registries like the 
DMTR are therefore important to inform policy makers whether interventions work 
in real world.
Bearing the high costs and potentially life-threatening side effects of the new drugs in 
mind, defining subgroups of patients who benefit most is of great importance.
This thesis demonstrated that metastatic melanoma patients with a baseline lactate 
dehydrogenase (LDH) of >2x the upper limit of normal (ULN) who respond to tar-
geted therapy with normalization of LDH have a good chance to get durable response 
on immunotherapy [this thesis]. If LDH remains elevated, immunotherapy does 
not stand a chance. After a median follow-up of 22 months, we demonstrated that 
median OS from start of immunotherapy was not reached in the former group while 
median OS was only 0.9 months in the latter group. This information can be used to 
determine the optimal sequencing of various drug types in a real-world setting, while 
the pivotal trials only report on the investigational drug. Although randomized trials 
are needed to assess the real benefit of sequential treatment strategies, results from 
the DMTR can be of added value while trial results are yet to be published.
Combining risk factors instead of assessing them separately as has been done in the 
pivotal trials could be helpful to stratify patients into favourable or poor prognosis 
groups. Almost 70% of metastatic melanoma patients treated with vemurafenib had 
multiple risk factors, such as an elevated LDH level, symptomatic brain metastases 
and poor performance status [this thesis]. We demonstrated that survival of BRAF-
mutated advanced melanoma patients treated with vemurafenib having >3 risk fac-
tors was only a third of the survival of patients without any risk factors (5.4 months 
vs 15.4 months). From a patient and doctor perspective, these data can help in shared 
195
Chapter 8
decision making and managing expectations. In patients with multiple risk factors, 
the drug has a low probability of benefitting the patient and may instead be physically 
and mentally harmful with wasted costs to the health system. This knowledge can 
nourish the debate on appropriate drug use.
In response to political and societal pressure, the FDA and EMA have introduced 
numerous fast-track approval and adaptive pathways for new anticancer drugs since 
the beginning of the 21st century [14]. Conditional approval may benefit patients by 
speeding up the availability of ‘promising’ drugs, but on the other hand are not based 
on profound evidence of a phase III randomized clinical trial. Such drugs may be 
studied with smaller patient numbers or in single-arm studies with no comparator 
[15]. In addition, cancer drug approvals based on surrogate outcomes (e.g. progres-
sion free survival) have become more common leading to faster drug access and 
lower trial costs, but are not always reliable surrogates for improved survival or QoL, 
in particular in non-curative settings [16]. Together with the fact that trial results are 
not generalizable to a more heterogeneous patient population in daily practice, great 
uncertainties regarding clinical benefit and safety remain at time of drug approval.
Real-world registries could complement findings from trials and could provide a 
better understanding of a drug’s real world value after (fast-track) approval [17]. 
Registry data can hence be helpful to detect approved drugs that fail to demonstrate 
clinical benefit or harm patients in real world which warrant further investigations 
or even requires withdrawal from the market.
DMTR: a blueprint for quality assurance in the era of expensive anticancer drugs?
First results of the DMTR showed the value and feasibility of nationwide registries 
with new anticancer therapies, as demonstrated by high quality data and nationwide 
coverage of all patients with metastatic melanoma in the registry within the first year 
[this thesis].
Downside of such a multipurpose registry like the DMTR is the financial and ad-
ministrative burden. Although detailed data for economic evaluation (informal care, 
productivity losses) are only collected in selected melanoma centres, the majority of 
data (clinical, economic, PROMs) are collected for all metastatic melanoma patients. 
This approach adds a lot to time and costs. One patient record requires 8 hours of 
registration, including data-entry, validation, data-analyses, reporting and training 
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of the data managers. Questions could be raised whether this set-up could serve as a 
blueprint for future registries. For instance, immunotherapies are now approved for 
lung cancer with over 10.000 eligible patients every year (in contrast to 800 eligible 
metastatic melanoma patients per year).
To minimize registration burden, a solution may be to use multiple datasets. A 
small dataset will be collected for all patients to track trivial quality data such as 
case-mix factors, treatment modality, QoL, mortality and morbidity, whereas ad-
ditional limited datasets will be collected in a subsample for other purposes like 
cost-effectiveness. For cost-effectiveness models, cost data of a very small subset can 
easily be extrapolated because only mean values of costs are required [18].
Second, it needs to be stimulated to evaluate all data items on its added value on a 
regular basis. Since the landscape of immunotherapy and targeted therapy is evolving 
rapidly, (detailed) data items of certain treatment modalities can soon be outdated.
Third, data-entry accounts for the majority of the time and costs of the DMTR 
because data managers manually enter the data by searching though the EHR. Initia-
tives such as data capture at the point of care (e.g. Registratie aan de Bron) allow 
registries to obtain (part of) their data directly from EHRs [19]. For instance, head 
and neck surgeons of Radboudumc have succeeded to reorganize their EHR in such 
a way that all 150 items required for quality indicators of the Dutch Head and Neck 
Audit are directly obtained from EHRs. Implementation of such EHR systems could 
further reduce financial and administrative burden.
Last, a large amount of the dataset of the DMTR is collected to facilitate reimburse-
ment research. In The Netherlands, new expensive drugs can be reimbursement 
conditionally in order to guarantee early access to promising drugs since 2016. In 
exchange, it is obliged to gather data on real-world cost-effectiveness. A reassessment 
of a drug’s real-world value after 4 years determines whether additional financing 
will continue [20]. During this period, a large amount of additional data has to be 
gathered through the patient registry (e.g. data on hospital resource, non-medical 
costs).
Assessment of the best time for definite reimbursement decision rather than setting a 
fixed 4-year period could avoid costly and time-consuming data gathering. Statistical 
methods have been proposed to calculate the optimal length of registry period based 
on patient numbers, costs and outcomes. A recent study showed that the observation 
period to make the definite reimbursement decision on the use of oxaliplatin for 
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colon cancer could have been stopped after a maximum of 2 years rather than the 
fixed 4 years [21].
It should also be noted that the costs of multi-purpose quality registries like the 
DMTR are a fraction of the total costs of the new drugs. The National Health Care 
institute calculated that less than 1% of the total amount of costs per treated advanced 
melanoma patient would be required for the set-up and maintenance of the DMTR. 
It will be important to all stakeholders involved to discuss whether securing a small 
percentage of the total treatment budget for obtaining quality information for future 
registries would be acceptable.
part iii: Assuring quality focusing on patient centred outcomes
VBHC auditing– the way forward?
Understanding the effect of treatment on how a patient survives, feels or functions is 
crucial [22]. Although anticancer treatment has brought major advances in patient 
survival rates, it is also associated with significant toxicity that can impair quality of 
life (QoL). The impact on QoL can only be understood by collecting information 
directly from patients about their physical functioning, adverse events or cancer-
related symptoms. Despite growing interest in patient reported outcome (PROs) 
measures in cancer care, drug developers and physicians do still not systematically 
collect PROs in pivotal trials or clinical practice [23]. The majority of pivotal trials 
publish PRO results in separate papers as if it is not important when balancing the 
risks and benefits of new drugs [24] [25]. This way, true shared decision-making 
between patients and oncologists is hampered by lack of reliable and acceptable PRO 
data.
This thesis illustrates the ‘blind spot’ of collecting merely clinical outcomes. We have 
demonstrated that benefit of vemurafenib was unlikely in frail advanced melanoma 
patients with a high disease load in terms of overall survival [this thesis]. Since 
vemurafenib could induce rapid symptom relief in this subgroup of patients [26], the 
emphasis lies however predominantly on improving quality of life (QoL). Without 
such information, we are left with an incomplete picture on the properties of this 
drug. Fortunately, the DMTR is currently collecting QoL data in order to assess the 
true benefit of the new anti-melanoma drugs in daily practice, which will eventually 
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lead to better shared decision-making. The importance of collecting PRO data has 
been acknowledged by other DICA audits of which eight are currently collecting 
PROMs.
Many tumour types can increasingly be seen as a chronic disease. In The Nether-
lands, the 5-year overall survival of cancer patients is almost doubled in the past 
50 years (Figure 1), where traditional outcome measures such progression-free and 
overall survival are less relevant, and quality of life and functional outcomes will 
be more valued. As a result of having had cancer and its treatment, cancer patients 
and survivors are affected by gastrointestinal problems, sexual dysfunction, pain, 
lymphedema, chronic fatigue, depression, and so on. A wider recognition of cancer 
care as a chronic disease is required in quality assessment programmes.
This has been acknowledged by the International Consortium for Health Outcomes 
Measurement (ICHOM) that recently launched a patient-centred outcomes set for 
patients with colorectal cancer and breast cancer [this thesis]. The ICHOM standard 
sets encompass the entire care spectrum, from diagnosis, treatment, short- and 
long-term outcomes to end-of-life care. Patient-reported outcomes are included in 
every standard set to capture symptom burden, functional status and health-related 
quality of life. The ICHOM breast and colorectal standard set comprises fourteen 
patient-centred outcomes of which the majority (70%) is patient-reported (Figure 2).
DICA has started to synchronize its datasets with the ICHOM standard sets, includ-
ing the incorporation of PROMs recommended by ICHOM. Such monitoring and 
comparison of patient-centered outcomes can identify opportunities for improve-
ment and ideally, lead to a sharing of best practices within the full range of cancer 
care. Moreover, international comparison with other (nationwide) registries can be 
achieved.
Although the VBHC principle has been embraced in multiple countries, there are 
also reasons to be cautious.
In contrast to existing surgical audits where short-term outcomes like anastomic 
leakage after colorectal surgery are clearly linked to interventions [1], patient-centred 
outcomes like fatigue or sexual functioning after breast cancer treatment are likely to 
be multifactorial. It is harder to accurately assess case-mix variables as these outcomes 
can also be influenced by other factors than patient- and tumour characteristics such 
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as societal and financial characteristic or supportive therapies such as psychological 
treatment.
Secondly, ICHOM standard sets only focus on outcomes, while process measures like 
waiting times or completeness of pathology report are not included. These measures 
are however important to identify the critical steps in a process that lead to a par-
ticular outcome (quality assessment). This way care providers accountable for these 
steps can be determined. In order to set-up quality improvement initiatives, negative 
outcomes as defined by the ICHOM standard set must be distilled to its essence by 
identifying these steps.
Moreover, patient-reported experience measures (PREMs), which capture a patient’s 
view of what happened during the care process, were not included in the ICHOM 
standard sets. Cancer care nowadays has become an integral part of the lives of most 
cancer patients and survivors, and experience measures such as autonomy, choice, 
communication and support (access to family and community support networks) 
are increasingly be seen as important measures of the effectiveness of healthcare 
[27]. This was also demonstrated by the results of the patient validation survey of the 
ICHOM breast and colorectal standard sets. In both sets, 20% of patients believed 
additional outcomes on experience measures had to be included [this thesis]. The 
ultimate model might be a hybrid model where the most important process mea-
sures (clinical and PREMs) and (long-term) patient-centred outcomes (clinical and 
PROMs) are collected.
Although PROMS data has proved to be highly wanted for assuring quality in cancer 
care [28], more research is needed on the feasibility of collecting PROMs in daily 
practice. For instance, since 2013 Santeon, a Dutch network of seven hospitals, col-
lects PROs systematically for prostate cancer and lung cancer but compliance rates of 
only 20-25% have been reported [29].
One explanation might be the significant patient burden of the questionnaires. The 
majority of existing questionnaires are primarily designed for clinical trials resulting 
in lengthy, static and old-fashioned surveys. For instance, the ICHOM dataset on 
breast cancer recommends the collection of (part of) multiple PROMS ranging from 
59-82 questions [this thesis], which could be discouraging. Multiple organizations 
focusing on PROM development are currently developing computerized adaptive 
testing (CAT) versions, which should reduce respondent burden [30]. On the 
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other hand, previous studies showed that the number of questions is not the primary 
reason for non-compliance [31]. Problem areas are more related to implementa-
tion practices, such as reminder issues or user-unfriendly PRO design. The use of 
modern technology for data capture may reduce the frequency of these issues, such 
as completion of electronic PROs (ePROs) via tablets, cell phones and computers 
including online reminders [32]. Moreover, staff commitment and education with 
regards to integration of PRO collection efficiently in daily practice is crucial for 
successful data collection.
Another issue might be that PROs are mostly used for scientific purpose and results 
are not fed back to the patients. If PROs are used to detect symptom worsening and 
would alert physicians during consultations, patients are more willing to complete 
the (lengthy) questionnaires [33]. A recent trial even found a survival benefit of 5 
months with symptom-monitoring via ePROs including feedback compared with 
usual care in patients with metastatic cancer [34].
future perspectives
Clinical auditing outside the traditional boundaries of medical specialties and hospitals
Although clinical auditing is increasingly shifting from monodisciplinary to multidis-
ciplinary and condition-focused audits, most audits are set-up within the boundaries 
of medical specialties. However, the role of nurse specialists and allied healthcare 
professionals such as psychologists, physiotherapists, and dietitians in cancer care 
has increased. These disciplines are likely to contribute to patient outcomes, in par-
ticular on QoL and functional aspects. For instance, the Dutch guideline on breast 
cancer recommends physiotherapeutic treatment in patients who have undergone 
axillary treatment as it could have beneficial effects on functional complaints and 
lymphedema [35]. Dietary issues and management by a dietician were considered 
highly important by colorectal cancer patients who were involved in the develop-
ment of the ICHOM colorectal cancer standard set [this thesis].
The Dutch Head and Neck Audit is the first DICA audit that gathers quality indicators 
from the perspective of allied health professionals in addition to the perspective of 
the medical specialties and patients. First results showed it is challenging but feasible 
to create quality indicators and collect data from allied health professionals [36].
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Complementing quality data of the standard medical therapies with data of support-
ing therapies will give us insight in the quality of all aspects of cancer care. This way, 
we could assess the impact of supporting therapies, learn from other disciplines and 
motivate collaboration even more.
The ICHOM breast and colorectal standard sets created a focus towards cancer sur-
vivorship with the inclusion of long-term clinical and PRO data. However, these data 
is solely collected during or in between outpatient visits within a hospital setting. 
In the Netherlands, substitution of (cancer) care is high on the political agenda in 
order to keep care affordable. One main goal is the transition of follow-up visits of 
cancer survivors that are not required at a high level of care, to primary care practices 
[37]. Transitioning care for low-risk cancer survivors from oncologists to primary 
care physicians is found to be safe and cost-effective in other countries [38]. This 
transition would be a major influence on the organization of cancer care and it would 
be important to track and understand the impact on patient outcomes, such as QoL, 
emergency visits, hospital admissions, recurrence and survival outcomes.
Quality measurement is not new for primary care in The Netherlands. Several qual-
ity indicators exist for patients with chronic illness, such as diabetes and COPD for 
internal and external use [39] [40]. One of the aims is to assess whether the coordina-
tion of diabetes and COPD care into coordinated multidisciplinary care groups in 
primary care has helped improving the quality and has lowered the costs [41].
Measuring quality of care in primary care practices could help justify such changes 
and transitions and could guide further improvement and collaboration between 
care providers in hospitals and primary care practices.
Big data technologies to assure quality
Several efforts have been made in order to enhance data quality and to reduce 
registration burden for physicians. Some hospitals have reorganized their EHRs in 
such a way that required data for clinical auditing could be automatically extracted. 
Moreover, existing databases are connected to clinical audits to obtain relevant data 
once, such as the linkage of PALGA, the national database of pathology results, with 
the DCRA so that pathology data can directly be entered into the DCRA. However, 
database linkage is not possible for all data items and different IT systems across hos-
pitals make it difficult to introduce automated data subtraction on a national level. 
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Furthermore, IT systems are primarily build to support daily practice and don’t have 
an (financial) incentive to make it as effective for quality purposes. These barriers 
could hinder expansion to condition-specific audits in the future.
Although uniform data collection for multiple purposes needs to be stimulated, 
rapid advances in health information technology (HIT) have created opportunities 
to collect, aggregate and analyze large amounts of real-world data in unconnected 
servers, unstructured notes in EHRs and other sources such as claims databases [42]. 
This could help overcome the wide variation that exists between EHR data stan-
dards. Rapid-learning systems could examine all available information on patient 
characteristics, genetics, treatments, outcomes and costs. It could serve a variety of 
purposes, ranging from quality improvement to data driven guidelines and clinical 
decision support tools based on a vast amount of observational data. Rapid-learning 
systems in different forms already exist within oncology, such as CancerLinQ created 
by ASCO [43]. Although the published literature on the practicality and results of 
such systems remain quite preliminary [44] and privacy and juridical issues have to 
be managed, the potential impact of big data in assuring quality is evident.
end conclusions
This thesis showed that the multi-purpose design of the DMTR could be used as a 
blueprint for future quality initiatives in the era of rapid advancements in immuno-
therapy and targeted therapy. It could complement findings from trials, as it provides 
information on long-term (functional) outcomes and optimal sequencing of drugs 
in a heterogeneous patient population that are normally excluded from trials. The 
new drugs are becoming a larger part in medical oncology as the number of immu-
notherapies and targeted therapies increases for a growing number of tumour types. 
Together with the rise of early access programmes of new expensive drugs, registries 
like the DMTR are highly needed for cost-effectiveness analyses and to accurately 
assess the safety and real-world benefit of these drugs.
Notwithstanding, efforts should be made to minimize registration and financial 
burden to such a level that the balance between practical feasibility and data quality 
and reliability is optimal.
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Furthermore, this thesis showed that important quality outcomes could transcend 
disciplines. The expansion from monodisciplinary to condition-focused audits is 
therefore a welcoming development and hopefully, this will stimulate discussions of 
benchmarked feedback in a multidisciplinary setting within hospitals and facilitate 
joint quality initiatives.
The breast and colorectal cancer standard sets of ICHOM incorporate outcomes of 
almost a full cycle of care, from diagnosis to treatment and long-term survivorship, 
with an emphasis on patient-reported outcomes. While these sets stretch the capabili-
ties of most hospitals, the integration of PROs in daily practice with direct feedback 
to the patient during outpatient visits may improve the experience, efficiency and 
outcomes of care. The sets are intended to facilitate international comparisons and 
research on quality of care outcomes. Monitoring and comparison of outcomes can 
identify opportunities for improvement and ideally, lead to a sharing of best practices 




figure 1. Overall survival of all tumour types in The Netherlands (1961-2015). Source: IKNL
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Surgery  |  Radiotherapy  |  Chemotherapy  |  Targeted therapy    





1  Complications will be recorded based on the type of therapy needed or action required to correct the complication as described          
     in the Clavien-Dindo Classification and CTCAE v4.0. 
2, 3, 4  Recommeded to track via the EORTC Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30).
5  Includes bowel functioning, fecal leakage, stool frequency, diarrhea and dietary issues. Recommeded to track via the dietary                                                        
    subscale of the Memorial Sloan-Kettering Cancer Center (MSKCC) Bowel Function. Recommeded to track via the EORTC Quality of  
    Life Questionnaire - Colorectal Cancer Module (EORTC QLQ-CR29).
6  Recommended to track via a single item from the EORTC Quality of Life Questionnaire - Liver Metastases Colorectal Module         
    (EORTC QLQ-LMC21).
7  Recommended to track via the EORTC Quality of Life Questionnaire - Colorectal Cancer Module (EORTC QLQ-CR29).
8  Includes erectile dysfunction and vaginal symptoms. Recommended to track via the EORTC Quality of Life Questionnaire -    
    Colorectal Cancer Module (EORTC QLQ-CR29).
9  Includes physical, emotional and social functioning and mobility and overall well-being. Recommended to track via the EORTC             
    Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30).
10 Includes overall and cause-specific survival.
11 Includes pathologic complete response, margin status and recurrence and progression free survival.
12 Includes place of death and preference for place of death according to the patient.
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figure 2. The ICHOM standard set outcomes wheels for colorectal cancer (a) and breast cancer (b), 
d tail g the outc me domains within the Standard Set.
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ICHOM Standard Set for
BREAST CANCER 
Treatment approach covered
Surgery  |  Radiotherapy  |  Chemotherapy  |  Reconstruction  |  Hormonal Therapy | Targeted Therapy | Best Supportive Care      




1  Complications will be recorded based on the type of therapy needed or action required to correct the complication as described in     
     the Clavien-Dindo Classification and CTCAE v4.0 
2  Includes depression and anxiety. 
3, 4  Recommended to track via the EORTC Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30). 
5  Includes body image and satisfaction with breast(s). Recommended to track via the EORTC Quality of Life Questionnaire - Breast     
    Cancer Specific Questionnaire (EORTC QLQ-BR23). Recommended to track via the BREAST-Q - Satisfaction with Breasts. 
6  Includes arm and breast symptoms. Recommended to track via the EORTC Quality of Life Questionnaire - Breast Cancer Specific  
    Questionnaire (EORTC QLQ-BR23).
7  Recommended to track via the EORTC Quality of Life Questionnaire - Breast Cancer Specific Questionnaire (EORTC QLQ-BR23).
8  Recommended to track via a single item from the EORTC Quality of Life Questionnaire - Liver Metastases Colorectal Module   
    (EORTC QLQ-LMC21).
9  Recommended to track via a subset of questions from the Functional Assessment of Cancer Therapy-Endocrine Symptoms   
    (FACT-ES). 
10 Recommended to track via the EORTC Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30).
11 Includes sexual functioning and vaginal symptoms. Recommended to track via the EORTC Quality of Life Questionnaire - Breast  
      Cancer Specific Questionnaire (EORTC QLQ-BR23). Recommended to track via a subset of questions from the Functional   
      Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES). 
12 Includes physical, emotional, cognitive and social functioning, ability to work and overall well-being. Recommeded to track via the
      EORTC Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30).
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een geïntegreerde kijk op kwAliteitsmeting vAn 
multimodAle therApie in de oncologische zorg
Er zijn grote ontwikkelingen gaande binnen de oncologische zorg. Kankerzorg is een 
steeds complexere medische discipline met een grote hoeveelheid aan specialismen 
en paramedici die betrokken zijn in het zorgproces.
Daarnaast hebben de opkomst van immunotherapie en doelgerichte therapie een 
ware revolutie teweeggebracht in de oncologie. Doelgerichte therapie blokkeert de 
groei en deling van kankercellen doordat ze de werking tegengaan van specifieke 
moleculen die de kankercellen nodig hebben voor hun groei en overleving. Immu-
notherapie verandert het eigen afweersysteem zodat het beter in staat is om kan-
kercellen te doden. Deze nieuwe behandelmethodes hebben de overlevingskansen 
van veel oncologische patiënten sterk verbeterd; de groep patiënten die kanker heeft 
overleefd groeit enorm.
Ten slotte neemt personalised medicine ofwel ‘therapie op maat’ een steeds belang-
rijke plaats in binnen de oncologie. Hierbij wordt de meest succesvolle behandeling 
voor een individuele patiënt bepaalt op basis van specifieke karakteristieken van de 
patiënt of tumor, zoals bepaalde mutaties van een tumor.
Al deze ontwikkelingen zorgen voor een nieuwe kijk op kwaliteitsmeting van onco-
logische zorg. Dit proefschrift beschrijft hoe kwaliteitsmeting kan worden verricht in 
dit nieuwe tijdperk.
deel 1. kwaliteitsmeting in multidisciplinaire kankerzorg
Al enkele jaren wordt het belang van professionele kwaliteitsmeting van de onco-
logische zorg in de vorm van clinical auditing in Nederland onderstreept. Clinical 
auditing heeft als doel het zorgproces en de uitkomsten van de zorg inzichtelijk te 
maken en continue te verbeteren. In 2009 is de Dutch Surgical Colorectal Audit 
(DSCA) opgericht om de kwaliteit van de darmkankerchirurgie inzichtelijk te 
maken. De DSCA bleek een krachtig kwaliteitsinstrument waarbij er binnen enkele 
jaren aanzienlijke verbeteringen zijn opgetreden in het zorgproces en in de uitkom-
sten van darmkanker patiënten. In navolging op het succes van de DSCA zijn er veel 




Clinical auditing werd jarenlang vooral gebruikt in de chirurgische oncologie. Echter, 
multimodale therapie, waarbij naast chirurgie ook andere therapievormen worden 
gebruikt zoals radiotherapie en chemotherapie, is de afgelopen jaren de hoeksteen 
geworden in de behandeling van veel tumorsoorten. In tegenstelling tot de grote 
hoeveelheid internationale literatuur over de kwaliteit en variatie van de chirurgische 
behandeling van oncologische patiënten, is er over de kwaliteit en variatie van de 
multimodale therapie betrekkelijk weinig bekend.
hoofdstuk 2 evalueert de ziekenhuisvariatie in het gebruik van chemotherapie na 
een operatie voor maagkanker. De multidisciplinaire richtlijn voor maagkanker 
adviseert perioperatieve chemo(radio)therapie voor alle patiënten met een operabel 
maagcarcinoom, mits de conditie van de patiënt dit toelaat. Voor dit onderzoek is 
gebruik gemaakt van gegevens afkomstig uit de Dutch Upper GI Audit (DUCA). De 
DUCA werd in 2011 opgericht door de Dutch Oesophageal Cancer Group (DOCG) 
en de Dutch Gastric Cancer Group (DGCG) met als doel het verkrijgen van inzicht 
in de kwaliteit van zorg van de chirurgische behandeling van slokdarm- en maagkan-
ker en het in gang zetten van verbetertrajecten.
Het onderzoek toont aan dat er een zeer grote spreiding bestaat tussen ziekenhuizen 
in het gebruik van postoperatieve chemotherapie bij geopereerde maagkanker pati-
enten die hiervoor in aanmerking komen. Omdat patiënt- en tumorkarakteristieken 
het gebruik van chemotherapie kunnen beïnvloeden (casemix), is hiervoor gecor-
rigeerd. In sommige ziekenhuizen was de kans op het krijgen van chemotherapie 
zeven keer zo groot ten opzichte van het landelijk gemiddelde. Dit onderzoek laat 
het belang zien van kwaliteitsmeting van niet-chirurgische behandelingen. Omdat 
de DUCA in opzet een chirurgische audit is, konden eventuele oorzaken die ten 
grondslag liggen aan deze ziekenhuisvariatie helaas niet verder worden onderzocht. 
Doordat multimodale therapie een steeds grotere plaats inneemt in de oncologische 
zorg, kunnen alleen multidisciplinaire, ziekte specifieke audits een complete kijk 
geven op de kwaliteit van zorg. Gelukkig zijn een aantal chirurgisch georiënteerde 
kwaliteitsregistraties van DICA uitgebreid tot multidisciplinaire registraties, waarbij 
ook andere behandelingen, zoals radiotherapie en chemotherapie, worden ge-
registreerd. Een goed voorbeeld hiervan is de Dutch Lung Cancer Audit, waarbij 




Multimodale therapie zorgt daarnaast voor een complexere vorm van kwaliteitsme-
ting omdat verschillende behandelingen elkaar kunnen beïnvloeden. hoofdstuk 2 
toont aan dat de kans op het krijgen van chemotherapie drie keer zo klein is voor 
geopereerde maagkanker patiënten met ernstige postoperatieve complicaties ten 
opzichte van patiënten zonder ernstige complicaties. Dit onderzoek laat zien dat 
postoperatieve complicaties niet alleen van invloed zijn op korte termijn uitkomsten, 
maar ook een negatief effect kunnen hebben op de lange termijn overleving doordat 
postoperatieve chemotherapie achterwege wordt gelaten. Het is onwaarschijnlijk dat 
dit geheel ten grondslag ligt aan de kwetsbaarheid van de patiënt. Er is immers gecor-
rigeerd voor casemix factoren. Waarschijnlijk spelen andere ziekenhuis gerelateerde 
factoren ook een rol, zoals de expertise van het medische team om een complicatie 
adequaat op te sporen en te behandelen zodat de conditie van de patiënt goed genoeg 
is voor chemotherapie. De aanzienlijke ziekenhuisvariatie kan ook een afspiegeling 
zijn van verschillen in communicatie tussen het chirurgische en oncologische team. 
Het zou daarom waardevol zijn om zulke discipline overstijgende uitkomsten te 
bespreken in multidisciplinaire teams met als doel er van te leren en gezamenlijke 
verbetertrajecten op te stellen.
deel 2. kwaliteitsmeting in personalised medicine
Voor een lange tijd was chemotherapie de belangrijkste behandelvorm in het 
therapeutische arsenaal van medisch oncologen. Het selecteren van patiënten, de 
behandelschema’s en de toxiciteit die de behandeling teweeg bracht, waren min of 
meer gelijk voor de verschillende tumorsoorten.
De introductie van immunotherapie met immuun-checkpoint-remmers en doelge-
richte therapie hebben hier verandering in gebracht.
De eerste ervaringen met immunotherapie werden opgedaan bij patiënten met een 
gemetastaseerd melanoom.
Vijf tot tien jaar geleden was DTIC, een vorm van chemotherapie, de enige beschik-
bare behandeling voor patiënten met een gemetastaseerd melanoom. Het melanoom 
reageerde echter nauwelijks op chemotherapie, waarbij slechts in 5% van de gevallen 
de groei van de tumor (vaak tijdelijk) tot stilstand kwam. Sinds de opkomst van de 
nieuwe oncolytica is de overleving van patiënten met een gemetastaseerd melanoom 
sterk verbeterd. Ipilimumab, een anti-CTLA-4 monoclonale antilichaam, is het eer-
ste immuuntherapeutisch medicijn wat op de markt is gebracht in 2011. De toelating 
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van BRAF-kinaseremmers vemurafenib en dabrafenib behorend tot de doelgerichte 
therapie volgde de jaren erna.
Ondanks de positieve overlevingsresultaten, hebben de nieuwe oncolytica ook 
gezorgd voor nieuwe uitdagingen. De nieuwe geneesmiddelen kunnen ongewone 
en potentieel ernstige bijwerkingen veroorzaken die expertise vereisen in de herken-
ning en behandeling hiervan. Verder draagt de opkomst van de dure oncolytica in 
toenemende mate bij aan de stijging van de zorgkosten. De kosten kunnen oplopen 
tot wel 60.000 euro per patiënt per jaar. Ook vereist de moleculaire analyse van het 
melanoom, de indicatiestelling en de sequentie van de verschillende behandeling 
expertise in de behandeling van het gemetastaseerd melanoom.
De minister van Volksgezondheid, Welzijn en Sport heeft daarom in 2012 enkele ei-
sen gesteld alvorens de nieuwe geneesmiddelen voor het gemetastaseerde melanoom 
te vergoeden. De systemische behandeling moest worden gecentraliseerd in veertien 
gespecialiseerde ziekenhuizen verspreid over Nederland, zogeheten melanoomcen-
tra, waarbij verplicht is gesteld dat elk centrum een minimum van twintig patiënten 
per jaar behandeld. Daarnaast kregen deze centra de verplichting om informatie van 
alle melanoompatiënten vast te leggen in een register: the Dutch Melanoma Treat-
ment Registry (DMTR).
Dit register, gefaciliteerd door DICA, is opgezet om het gebruik, de effectiviteit 
en de kosten van de nieuwe middelen in de dagelijkse praktijk te monitoren en te 
beoordelen.
In hoofdstuk 3 wordt de unieke opzet van de DMTR en worden de eerste resultaten 
beschreven. De DMTR heeft meerdere doelen:
•	 Clinical	auditing:	door	periodieke	online	terugkoppeling	van	de	kwaliteitsindi-
catoren aan de melanoomcentra in vergelijking met de andere melanoomcentra 
en het landelijk gemiddelde, kan de geleverde zorg in kaart gebracht worden en 
kunnen verbetercycli worden opgesteld;
•	 Transparantie	van	zorg:	de	kwaliteitsindicatoren	kunnen	worden	gebruikt	voor	
externe verantwoording en keuze informatie voor patiënten;
•	 Doelmatigheidsonderzoek:	de	beoordeling	van	het	effect	van	de	nieuwe	genees-
middelen in de dagelijkse praktijk, inclusief de gezondheidswinst en de kosten 




De studie laat zien dat het gelukt is om een nationale dekking te realiseren binnen 
één jaar. Daarnaast tonen de eerste resultaten aan dat het percentage ernstige bijwer-
kingen in de dagelijkse praktijk nagenoeg gelijk is aan hetgeen is gerapporteerd in de 
gerandomiseerde trials. Mogelijkerwijs heeft dit te maken met de centralisatie van 
de melanoomzorg in de veertien gespecialiseerde centra. Hierdoor kon uitgebreide 
ervaring worden opgedaan met de nieuwe middelen. Daarnaast kon de opgedane 
kennis beter worden besproken tussen de centra en konden nieuwe middelen sneller 
worden geïmplementeerd in de dagelijkse praktijk.
Ten slotte laten de eerste resultaten een significante verbetering van de overleving 
zien. De mediane overlevingsduur steeg van 10,1 maanden (95% BI 9,1-11,1) in het 
eerste registratiejaar naar 12,7 maanden (95% BI 11,6-13,7) in het tweede registra-
tiejaar.
Vele studies hebben aangetoond dat trial data niet zomaar te extrapoleren zijn naar 
de dagelijkse praktijk omdat trials alleen streng geselecteerde patiënten includeren. 
Het is dus erg waardevol om gegevens uit de klinische praktijk te gebruiken als aan-
vulling op de kennis afkomstig uit gerandomiseerde onderzoeken. Omdat de nieuwe 
oncolytica erg duur zijn en potentieel ernstige bijwerkingen kunnen hebben, is een 
goede selectie van patiënten die voordeel hebben van het medicijn in de dagelijkse 
praktijk onontbeerlijk. Doordat een kwaliteitsregister zoals de DMTR een grote hoe-
veelheid data van heterogene patiëntengroepen bevat, is het mogelijk om relevante 
subgroepen te evalueren.
hoofdstuk 4 analyseert subgroepen van melanoompatiënten met bepaalde risico-
factoren die behandeld zijn met de BRAF-remmer vemurafenib. Deze studie toont 
aan dat bepaalde risicofactoren een slechte prognose geven, waarbij niet alleen de 
klinische conditie van de patiënt (de ‘WHO performance status’) een belangrijke 
rol speelt maar ook een aantal tumorkenmerken, zoals het gehalte van het lactaat 
dehydrogenase (LDH) in het bloed, het totaal aantal metastasen en het hebben van 
hersenmetastasen. Deze studie laat verder zien dat de uitkomsten van een behande-
ling met vemurafenib bij patiënten met een gunstig risicoprofiel vergelijkbaar zijn 
met de resultaten gebaseerd op de klinische trials. De studie toont echter ook aan dat 
de mediane algehele overleving meer dan halveert voor patiënten met drie of meer 
risicofactoren in vergelijking met patiënten zonder risicofactoren (5,1 maanden vs 
15,4 maanden). Omdat het ‘real-world’ data betreft, kan deze informatie behulpzaam 
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zijn voor zowel dokters als patiënten bij het maken van een behandelkeuze. In de 
toekomst zal ook informatie afkomstig van de patiënt, de zogeheten patiënten ge-
rapporteerde uitkomsten (PROMs) gekoppeld worden aan de klinische informatie. 
Alleen dan kan een volledig beeld ontstaan van de zorguitkomsten in de dagelijkse 
praktijk.
De gerandomiseerde onderzoeken van de nieuwe melanoom medicijnen tonen de 
uitkomsten van één te testen behandeling ten opzichte van een controlebehandeling, 
meestal de geldende gouden standaard. We weten echter uit de dagelijkse praktijk 
dat verschillende nieuwe medicijnen vaak opeenvolgend worden voorgeschreven. In 
hoofdstuk 5 is onderzocht of melanoompatiënten met een agressieve ziekte baat heb-
ben bij een behandeling met doelgerichte therapie in de vorm van BRAF-remming, 
al dan niet in combinatie met MEK-remming, voorafgaand aan een behandeling met 
immunotherapie. De gedachte is dat er door de zeer krachtige antitumor effecten van 
BRAF- en MEK-remmers snel maar tijdelijk resultaat geboekt kan worden, zodat 
er meer tijd zou zijn om van de effecten van immunotherapie te kunnen profiteren. 
Agressieve ziekte wordt in deze studie gedefinieerd als het hebben van een >2 keer 
verhoogd LDH gehalte. Ook al zijn de aantallen klein, de studie laat zien dat pa-
tiënten waarbij het LDH gehalte normaliseert tijdens de behandeling met BRAF-/
MEK-remming een goede kans hebben op respons van immunotherapie. Daarnaast 
blijkt immunotherapie niet heilzaam bij patiënten waarbij het LDH gehalte verhoogd 
blijft. Ondanks het feit dat klinische trials nodig zijn om het effect van een bepaalde 
volgorde van behandelingen aan te tonen, kan deze informatie uit de DMTR van 
aanvullende waarde zijn.
De indicatie voor immunotherapie wordt nu uitgebreid naar andere vormen van 
kanker, zoals longkanker, nierkanker, hoofd-halstumoren, blaaskanker, Merkelcel-
carcinoom en verschillende vormen van lymfomen. Als we de indicatiestelling voor 
longkanker als voorbeeld nemen, dan gaat het jaarlijks niet meer om een groep van 
800 patiënten zoals bij het gemetastaseerd melanoom, maar om een groep van bijna 
10.000 geschikte patiënten. Of de DMTR als blauwdruk kan fungeren voor andere 
registraties valt te bezien. Aan de ene kant hebben de eerste resultaten van de DMTR 
laten zien dat het zeer waardevolle informatie oplevert ten aanzien van kwaliteitsme-
ting van melanoomzorg in de dagelijkse praktijk. Echter, omdat de DMTR meerdere 
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doelen dient, is de registratielast aanzienlijk en de kosten die ermee gepaard gaan 
relatief hoog. Om een toekomstig register op te zetten, zal er moeten worden gekeken 
hoe de registratielast zoveel mogelijk kan worden beperkt. Dit kan worden opgelost 
door meerdere datasets te creëren voor de verschillende doelen: één kleine dataset 
met de meest belangrijke kwaliteitsdata, zoals casemixfactoren, het type behandeling, 
morbiditeit en mortaliteit, bestemd voor alle patiënten. Naast deze kern dataset zul-
len er additionele datasets worden toegevoegd, bestemd voor een kleinere steekproef 
voor bijvoorbeeld doelmatigheidsonderzoek.
Verder zou extractie van gegevens uit het elektronisch patiëntendossier (EPD) 
kunnen zorgen voor een sterke vermindering van de registratielast. Projecten zoals 
‘Registratie aan de Bron’ hebben laten zien dat voor sommige DICA registraties alle 
items rechtstreeks uit het EPD kunnen worden gehaald.
Er moet wel gezegd worden dat de kosten voor de opzet en het onderhoud van een 
dergelijk kwaliteitsregister zoals de DMTR maar een fractie is van de totale kosten 
van de nieuwe geneesmiddelen. Het zorginstituut Nederland heeft uitgerekend dat 
er slechts 1% van de geneesmiddelenkosten per melanoom patiënt nodig zou zijn om 
de opzet en het onderhoud van de DMTR te kunnen bekostigen. Het is belangrijk dat 
de overheid, de zorgverzekeraars en de farmacotherapeutische bedrijven met elkaar 
in discussie gaan over de belangrijke vraag of het wenselijk is om een kleine bijdrage 
van het totale geneesmiddelenbudget uit te geven aan de kosten van toekomstige 
kwaliteitsregistraties.
deel 3: kwaliteitsmeting met behulp van patiëntgerichte uitkomsten
Doordat de overleving van kankerpatiënten stijgt, worden traditionele uitkomst-
maten zoals overleving en progressievrije ziekte, niet meer gezien als de enige uit-
komsten die er toe doen, maar is het meten van patiënt gerapporteerde uitkomsten 
(PROMs) tijdens en na de behandeling veel belangrijker geworden. Daarnaast willen 
steeds meer patiënten in samenspraak met hun arts beslissen over de behandeling 
(‘shared decision making’). Hiervoor is betrouwbare en voor de patiënt relevante 
uitkomstinformatie uit de dagelijkse praktijk essentieel. Ten slotte is het waardevol 




ICHOM is een internationaal consortium voor uitkomstmetingen in de zorg, opge-
richt in 2012 door de Harvard Business School, de Boston Consulting Group en het 
Karolinksa Instituut. De missie van ICHOM is om voor de meest belangrijke ziek-
tebeelden standaardsets van patiëntgerichte uitkomsten te definiëren die wereldwijd 
gebruikt kunnen worden.
hoofdstuk 6 en hoofdstuk 7 beschrijven het proces en het resultaat van twee werk-
groepen die een ICHOM standaard set voor borstkanker en darmkanker hebben 
ontwikkeld.
De ICHOM sets werden ontwikkeld door een internationale werkgroep waarbij 
zorgverleners en patiënten samenwerkten. Met behulp van een systematische review 
van de literatuur en middels een Delphi proces werd er in acht maanden tijd een set 
met de belangrijkste patiëntgerichte uitkomsten gedefinieerd. De uitkomsten werden 
gevalideerd middels een patiënten survey en een panel van externe experts.
Beide sets omvatten veertien patiëntgerichte uitkomsten waarvan de meerderheid 
(70%) patiënt gerapporteerd zijn. De klinische uitkomsten hebben betrekking op 
de (ziekte vrije) overleving en ernstige complicaties. De patiënt gerapporteerde 
uitkomsten worden door middel van een aantal gevalideerde PROMS vragenlijsten 
uitgevraagd en hebben betrekking op de kwaliteit van leven van de patiënt, waarbij 
domeinen zoals emotioneel en cognitief functioneren worden vastgelegd alsmede 
symptomen zoals pijn, moeheid en lymfoedeem. Ten slotte worden er een aantal 
casemixfactoren geadviseerd, zoals patiënt- en tumorkarakteristieken en het type 
behandeling, om een zo eerlijke vergelijking mogelijk te maken.
DICA heeft recentelijk een deel van de borstkanker en de darmkanker ICHOM set 
geïntegreerd in de DICA audits, te weten de NABON Breast Cancer Audit (NBCA) 
en de Dutch ColoRectal Audit (DCRA).
Het gebruik van PROMs vragenlijsten voor kwaliteitsmeting staat nog steeds in de 
kinderschoenen. De PROMs vragenlijsten zijn vaak lange, statische vragenlijsten 
omdat ze speciaal ontwikkeld zijn voor wetenschappelijk onderzoek. De komende 
jaren zal er gekeken moeten worden hoe de vragenlijsten kunnen worden ingekort 
zonder dat ze waarde verliezen. Verder is uit onderzoek gebleken dat het erg be-
langrijk is om de PROMs uitkomsten niet alleen te gebruiken voor wetenschappelijk 
onderzoek of clinical auditing, maar ook in de spreekkamer. Als bijvoorbeeld blijkt 
uit de PROMs vragenlijsten dat een patiënt erg veel pijn heeft of depressieve klachten 
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aan het ontwikkelen is, kan daar in de spreekkamer gericht naar worden gekeken. 
Indien nodig kan een patiënt doorverwezen worden naar een andere zorgverlener. 
Het is daarnaast van belang dat de zorgverleners goed duidelijk maken aan de patiënt 
wat de meerwaarde is van de PROMs vragenlijsten.
Er zijn enkele kanttekeningen te plaatsen bij de manier waarop ICHOM zijn standaard 
sets vormgeeft. Het advies van ICHOM is om enkel de uitkomsten te registreren, 
waardoor er geen inzicht wordt verkregen in de processen die eraan ten grondslag 
liggen. Met behulp van het meten van zowel uitkomst- als procesindicatoren kan er 
gerichter een verbetertraject worden opgesteld.
Ook worden er geen adviezen gegeven ten aanzien van Patient Reported Experience 
Measures (PREMs) vragenlijsten. Bij PREMs gaat het om de ervaring en beleving van 
de patiënt. De resultaten kunnen waardevol zijn om zorg(processen) te verbeteren. 
Uit de patiënten survey van de borst- en darmkankerset van ICHOM bleek dat 20% 
van de deelnemers vond dat er PREMs vragenlijsten toegevoegd moesten worden.
Het meest waardevolle model is wellicht een hybride model waarbij zowel de belang-
rijkste procesindicatoren (klinisch en PREMs) als ook de belangrijke patiëntgerichte 
uitkomsten (klinisch en PROMs) worden vastgelegd.
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tions and the opportunity to build long lasting relationships with patients and their 
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meetings out of your busy schedule, you’ve never skipped one.
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